Imidazolyl-cyclic acetals

ABSTRACT

Compounds of formula (I) are described in which R 1  is optionally substituted heteroaryl; R 2  is optionally substituted aryl or optionally substituted heteroaryl; R 3  is a group -L 1 -R 7  or -L 2 -R 8  [where L 1  is an optionally substituted alkylene linkage; R 7  is hydrogen, aryl, cyano, cycloalkyl, heteroaryl, heterocycloalkyl, nitro, —S(O) n R 9 , —NHSO 2 R 9 , —C(=Z)OR 10 , —C(=Z)R 10 , —OR 10 , —N(R 11 )—C(=Z)R 9 , —NY 1 Y 2 , —SO 2 —NY 1 Y 2 , —C(=Z)-NY 1 Y 2 , —N(R 11 )—C(=Z)-NY 1 Y 2 , —N(OR 10 )—C(=Z)-NY 1 Y 2 , —N(OR 10 )—C(=Z)R 10 , —C(=NOR 10 )R 10 , —C(=Z)NR 10 OR 12 , —N(R 11 )—C(═NR 13 )—NY 1 Y 2  or —N(R 11 )—C(=Z)OR 11 ; L 2  is a direct bond or a straight- or branched-carbon chain comprising from 2 to about 6 carbon atoms and contains a double or triple carbon-carbon bond; and R 8  is hydrogen, aryl, cycloalkenyl, cycloalkyl, heteroaryl or heterocycloalkyl]; R 4  is a group -L 3 -R 14  [where L 3  is a direct bond or an optionally substituted alkylene linkage and R 14  is hydrogen, alkyl, azido, hydroxy, alkoxy, aryl, arylalkyloxy, aryloxy, carboxy (or an acid bioisostere), cycloalkyloxy, heteroaryl, heteroarylalkyloxy, heteroaryloxy, heterocycloalkyl, heterocycloalkyloxy, nitro, —NY 4 Y 5 , —N(R 10 )—C(=Z)-R 15 ; —N(R 10 )—C(=Z)-L 4 -R 16 , —NH—C(=Z)-NH—R 15 , —NH—C(=Z)-NH-L 4 -R 16 , —N(R 10 )—SO 2 —R 15 , —N(R 10 )—SO 2 -L 4 -R 16 , —S(O) n R 9 , —C(=Z)-NY 4 Y 5  or —C(=Z)-OR 9 ]; R 5  is hydrogen, alkyl or hydroxyalkyl; or R 4  and R 5 , when attached to the same carbon atom, may form with the said carbon atom a cycloalkyl, cycloalkenyl or heterocycloalkyl ring or a group C═CH 2 ; R 6  is hydrogen or alkyl; and m is zero or an integer 1 or 2; and N-oxides thereof, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (I) and N-oxides thereof, and their prodrugs.  
     The compounds are TNF inhibitors and are useful as pharmaceuticals.

[0001] This application is a continuation of international applicationNo. PCT/GB98/0171 1, filed Jun. 12, 1998, which is acontinuation-in-part application of U.S. provisional application No.60/052,185, filed Jul. 10, 1997, now abandoned, and U.S. provisionalapplication No. 60/085,499, filed May 14, 1998, now abandoned.

[0002] This invention is directed to imidazolyl-cyclic acetals, theirpreparation, pharmaceutical compositions containing these compounds, andtheir pharmaceutical use in the treatment of disease states capable ofbeing modulated by the inhibition of TNF.

[0003] Tumour necrosis factor (TNF) is an important pro-inflammatorycytokine which causes hemorrhagic necrosis of tumors and possesses otherimportant biological activities. TNF is released by activatedmacrophages, activated T-lymphocytes, natural killer cells, mast cellsand basophils, fibroblasts, endothelial cells and brain astrocytes amongother cells.

[0004] The principal in vivo actions of TNF can be broadly classified asinflammatory and catabolic. It has been implicated as a mediator ofendotoxic shock, inflammation of joints and of the airways, immunedeficiency states, allograft rejection, and in the cachexia associatedwith malignant disease and some parasitic infections. In view of theassociation of high serum levels of TNF with poor prognosis in sepsis,graft versus host disease and adult respiratory distress syndrome, andits role in many other immunologic processes, this factor is regarded asan important mediator of general inflammation.

[0005] TNF primes or activates neutrophils, eosinophils, and endothelialcells to release tissue damaging mediators and increase the expressionof adhesion molecules. In fibroblasts, TNF stimulates the production ofcollagenase, an enzyme implicated in the joint destruction in rheumatoidarthritis. TNF also activates monocytes, macrophages and T-lymphocytesto cause the production of colony stimulating factors and otherpro-inflammatory cytokines such IL-1, IL-6, IL-8 and GM-CSF, which insome cases mediate the end effects of TNF. The ability of TNF toactivate T-lymphocytes, monocytes, macrophages and related cells hasbeen implicated in the progression of Human Immunodeficiency Virus (HIV)infection. In order for these cells to become infected with HIV and forHIV replication to take place the cells must be maintained in anactivated state. Cytokines such as TNF have been shown to activate HIVreplication in monocytes and macrophages. Features of endotoxic shocksuch as fever, metabolic acidosis, hypotension and intravascularcoagulation are thought to be mediated through the actions of TNF. Thecachexia associated with certain disease states is mediated throughindirect effects on protein catabolism. TNF also promotes boneresorption and acute phase protein synthesis.

[0006] TNF-alpha inhibits surfactant protein C gene transcription, whichmay contribute to abnormalities of surfactant homeostasis associatedwith pulmonary injury and infection, induces mucin hypersecretion andmediates the recruitment of neutrophils and eosinophils during airwayinflammation. Although TNF-alpha inhibits collagen synthesis infibroblasts, a number of studies point to it being pro-fibrotic in vivo.Thus, by inhibiting TNF-alpha production, the compounds of the inventionhave potential in suppressing the inflammation and airways remodellingthat occurs in asthma.

[0007] TNF-alpha inhibits the ability of insulin to stimulate glucoseuptake in adipose tissue. In obesity the overproduction of TNF isthought to cause an insulin-resistant state. Thus, by blocking TNFrelease the compounds of the invention have anti-diabetic potential.

[0008] TNF-alpha can induce angiogenesis in normally avascular tissue,possibly through upregulation of other pro-inflammatory cytokines,upregulation of adhesion molecules, stimulation of matrixmettalloproteinase expression and increased prostaglandin production.Thus, inhibition of TNF-alpha release by compounds of the invention willhave benefit in angiogenesis dependent diseases including arthritis,diabetic retinopathies and ischemia induced diseases (myocardialinfarction) and cancer.

[0009] The discussion herein relates to disease states associated withTNF including those disease states related to the production of TNFitself, and disease states associated with other cytokines, such as, butnot limited to IL-1 or IL-6, that are modulated by association with TNF.For example, a IL-1 associated disease state, where IL-1 production oraction is exacerbated or secreted in response to TNF, would therefore beconsidered a disease state associated with TNF. TNF-alpha and TNF-betaare also herein referred to collectively as “TNF” unless specificallydelineated otherwise, since there is a close structural homology betweenTNF-alpha (cachectin) and TNF-beta (lymphotoxin) and each of them has acapacity to induce similar biological responses and bind to the samecellular receptor.

[0010] We have now found a novel group of imidazolyl-cyclic acetalswhich have valuable pharmaceutical properties, in particular the abilityto regulate proteins that mediate cellular activity, for example TNF.

[0011] Thus, in one aspect, the present invention is directed tocompounds of general formula (I):—

[0012] wherein:—

[0013] R¹ is optionally substituted heteroaryl;

[0014] R² is optionally substituted aryl or optionally substitutedheteroaryl;

[0015] R³ represents a group -L¹-R⁷ or -L²-R⁸

[0016] [where L¹ represents a straight- or branched-chain alkylenelinkage containing from 1 to about 6 carbon atoms optionally substitutedby halogen or oxo; R⁷ is hydrogen, aryl, cyano, cycloalkyl, heteroaryl,heterocycloalkyl, nitro, —S(O)_(n)R⁹, (where R⁹ is alkyl, aryl,arylalkyl, cycloalkyl, heteroaryl, heteroarylalkyl, or heterocycloalkyland n is zero or an integer 1 or 2), —NHSO₂R⁹, —C(=Z)OR¹⁰ (where Z is anoxygen or sulphur atom and R¹⁰ is hydrogen or R⁹), —C(=Z)R¹⁰, —OR¹⁰,—N(R¹¹)—C(=Z)R⁹ (where R¹¹ is hydrogen or alkyl), —NY¹Y² {where Y¹ andY² are independently hydrogen, alkenyl, alkyl, alkynyl, aryl, arylalkyl,cycloalkenyl, cycloalkyl, heteroaryl or heteroarylalkyl, or the group—NY¹Y² may form a 5-7 membered cyclic amine which may optionally containa further heteroatom selected from O, S, or NY³ (where Y³ is hydrogen,alkyl, aryl, arylalkyl, —CHO, —C(=Z)R⁹ or —SO₂R⁹), or which may also befused to additional aryl, heteroaryl, heterocycloalkyl or cycloalkylrings to form a bicyclic or tricyclic ring system}, —SO₂NY¹Y²,—C(=Z)-NY¹Y², —N(R¹¹)—C(=Z)-NY¹Y², —N(OR¹⁰)—C(=Z)-NY¹Y²,—N(OR¹⁰)—C(=Z)R¹⁰, —C(═NOR¹⁰)R¹⁰, —C(=Z)NR¹⁰OR¹² (where R¹² is hydrogen,alkyl, aryl or arylalkyl), —N(R¹¹)—C(═NR¹³)—NY¹Y² (where R¹³ ishydrogen, cyano, alkyl, cycloalkyl or aryl), or —N(R¹¹)—C(=Z)OR¹¹; L²represents a direct bond or a straight- or branched-carbon chaincomprising from 2 to about 6 carbon atoms and contains a double ortriple carbon-carbon bond; and R⁸ is hydrogen, aryl, cycloalkenyl,cycloalkyl, heteroaryl or heterocycloalkyl];

[0017] R⁴ represents a group -L³-R¹⁴

[0018] [where L³ represents a direct bond or a straight- orbranched-chain alkylene linkage containing from 1 to about 6 carbonatoms (optionally substituted by halogen, hydroxy, alkoxy or oxo); and

[0019] R¹⁴ is hydrogen, alkyl, azido, hydroxy, alkoxy, aryl,arylalkyloxy, aryloxy, carboxy (or an acid bioisostere), cycloalkyloxy,heteroaryl, heteroarylalkyloxy, heteroaryloxy, heterocycloalkyl,heterocycloalkyloxy, nitro, —NY⁴Y⁵, {where Y⁴ and Y⁵ are independentlyhydrogen, aryl, cycloalkyl, heterocycloalkyl, heteroaryl or alkyloptionally substituted by alkoxy, aryl, cyano, cycloalkyl, heteroaryl,heterocycloalkyl, hydroxy, oxo, —CO₂R¹⁰, —CONY¹Y² or —NY¹Y², or thegroup —NY⁴Y⁵ may form a 5-7 membered cyclic amine which (i) may beoptionally substituted with one or more substituents selected fromalkoxy, carboxamido, carboxy, hydroxy, oxo (or a 5, 6,or 7 memberedcyclic acetal derivative thereof), R⁹ or alkyl substituted by carboxy,carboxamido or hydroxy (ii) may also contain a further heteroatomselected from O, S, SO₂ or NY⁶ (where Y⁶ is hydrogen, alkyl, aryl,arylalkyl, —C(=Z)R⁹, —C(=Z)OR⁹ or —SO₂R⁹) and (iii) may also be fused toadditional aryl, heteroaryl, heterocycloalkyl or cycloalkyl rings toform a bicyclic or tricyclic ring system}, —N(R¹⁰)—C(=Z)-R¹⁵ (where R¹⁵is alkyl, alkoxy, aryl, arylalkyloxy, cycloalkyl, heteroaryl,heteroarylalkoxy or heterocycloalkyl); —N(R¹⁰)—C(=Z)-L⁴-R¹⁶ (where R¹⁶is alkoxy, aryl, arylalkyloxy, arylalkyloxyvcarbonylamino, carboxy (oran acid bioisostere), cycloalkyl, cyano, halo, heteroaryl,heteroarylalkoxy, heterocycloalkyl, hydroxy or —NY¹Y², and L⁴ is astraight- or branched-chain alkylene linkage containing from 1 to about6 carbon atoms), —NH—C(=Z)-NH—R¹⁵, —NH—C(=Z)-NH-L⁴-R¹⁶, —N(R¹⁰)—SO₂—R¹⁵,—N(R¹⁰)—SO₂-L⁴-R¹⁶, —S(O)_(n)R⁹, —C(=Z)-NY⁴Y⁵ or —C(=Z)-OR⁹];

[0020] R⁵ represents hydrogen, alkyl or hydroxyalkyl; or

[0021] R⁴ and R⁵, when attached to the same carbon atom, may form withthe said carbon atom a cycloalkyl, cycloalkenyl or heterocycloalkyl ringor a group C═CH₂;

[0022] R⁶ represents hydrogen or alkyl; and

[0023] m is zero or an integer 1 or 2;

[0024] and N-oxides thereof, and their prodrugs; and pharmaceuticallyacceptable salts and solvates (e.g. hydrates) of compounds of formula(I) and N-oxides thereof, and their prodrugs.

[0025] In the present specification, the term “compounds of theinvention”, and equivalent expressions, are meant to embrace compoundsof general formula (I) as hereinbefore described, which expressionincludes the N-oxides, the prodrugs, the pharmaceutically acceptablesalts, and the solvates, e.g. hydrates, where the context so permits.Similarly, reference to intermediates, whether or not they themselvesare claimed, is meant to embrace their N-oxides, salts, and solvates,where the context so permits. For the sake of clarity, particularinstances when the context so permits are sometimes indicated in thetext, but these instances are purely illustrative and it is not intendedto exclude other instances when the context so permits.

[0026] It will be appreciated that when m is zero the cyclic acetalsystem in formula (I) represents a 1,3-dioxolane ring; when m is 1 thecyclic acetal system in formula (I) represents a 1,3-dioxane; and when mis 2 the cyclic acetal system in formula (I) represents a 1,3-dioxepane.

[0027] As used above, and throughout the description of the invention,the following terms, unless otherwise indicated, shall be understood tohave the following meanings:—

[0028] “Patient” includes both human and other mammals.

[0029] “Acid bioisostere” means a group which has chemical and physicalsimilarities producing broadly similar biological properties to acarboxy group (see Lipinski, Annual Reports in Medicinal Chemistry,1986, 21, page 283 “Bioisosterism In Drug Design”; Yun, Hwahak Sekye,1993, 33, pages 576-579 “Application Of Bioisosterism To New DrugDesign”; Zhao, Huaxue Tongbao, 1995, pages 34-38 “BioisostericReplacement And Development Of Lead Compounds In Drug Design”; Graham,Theochem, 1995, 343, pages 105-109 “Theoretical Studies Applied To DrugDesign:ab initio Electronic Distributions In Bioisosteres”). Examples ofsuitable acid bioisosteres include: —C(═O)—NHOH, —C(═O)—CH₂OH,—C(═O)—CH₂SH, —C(═O)—NH—CN, sulpho, phosphono, alkylsulphonylcarbamoyl,tetrazolyl, arylsulphonylcarbamoyl, heteroarylsulphonylcarbamoyl,N-methoxycarbamoyl, 3-hydroxy-3-cyclobutene-1,2-dione,3,5-dioxo-1,2,4-oxadiazolidinyl or heterocyclic phenols such as3-hydroxyisoxazolyl and 3-hydoxy-1-methylpyrazolyl.

[0030] “Acyl” means an H—CO— or alkyl-CO— group in which the alkyl groupis as described herein.

[0031] “Acylamino” is an acyl-NH— group wherein acyl is as definedherein.

[0032] “Alkenyl” means an aliphatic hydrocarbon group containing acarbon-carbon double bond and which may be straight or branched havingabout 2 to about 15 carbon atoms in the chain. Preferred alkenyl groupshave 2 to about 12 carbon atoms in the chain; and more preferably about2 to about 4 carbon atoms in the chain. “Branched”, as used herein andthroughout the text, means that one or more lower alkyl groups such asmethyl, ethyl or propyl are attached to a linear chain; here a linearalkenyl chain. “Lower alkenyl” means about 2 to about 4 carbon atoms inthe chain which may be straight or branched. Exemplary alkenyl groupsinclude ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl,n-pentenyl, heptenyl, octenyl, cyclohexylbutenyl and decenyl.

[0033] “Alkoxy” means an alkyl-O— group in which the alkyl group is asdescribed herein. Exemplary alkoxy groups include methoxy, ethoxy,n-propoxy, i-propoxy, n-butoxy and heptoxy.

[0034] “Alkoxymethyl” means an alkyl-O—CH₂— group in which the alkylgroup is as described herein. Exemplary alkoxymethyl groups includemethoxymethyl and ethoxymethyl.

[0035] “Alkoxycarbonyl” means an alkyl-O—CO— group in which the alkylgroup is as described herein. Exemplary alkoxycarbonyl groups includemethoxy- and ethoxycarbonyl.

[0036] “Alkyl” means, unless otherwise specified, an aliphatichydrocarbon group which may be straight or branched having about 1 toabout 15 carbon atoms in the chain, optionally substituted by one ormore halogen atoms. Particular alkyl groups have from 1 to about 6carbon atoms. Exemplary alkyl groups for R⁵, R⁶ and within R⁴ includeC₁₋₄alkyl groups such as methyl, ethyl, n-propyl and i-propyl.

[0037] “Alkylene” means a straight or branched bivalent hydrocarbonchain having from 1 to about 15 carbon atoms. Particular alkylene groupsare the lower alkylene groups having from 1 to about 6 carbon atoms.Exemplary groups include methylene and ethylene.

[0038] “Alkylsulphinyl” means an alkyl-SO— group in which the alkylgroup is as previously described. Preferred groups are those in whichthe alkyl group is C₁₋₄alkyl.

[0039] “Alkylsulphonyl” means an alkyl-SO₂— group in which the alkylgroup is as previously described. Preferred groups are those in whichthe alkyl group is C₁₋₄alkyl.

[0040] “Alkylsulphonylcarbamoyl” means an alkyl-SO₂—NH—C(═O)— group inwhich the alkyl group is as previously described. Preferredalkylsulphonylcarbamoyl groups are those in which the alkyl group isC₁₋₄alkyl.

[0041] “Alkylthio” means an alkyl-S— group in which the alkyl group isas previously described. Exemplary alkylthio groups include methylthio,ethylthio, isopropylthio and heptylthio.

[0042] “Alkynyl” means an aliphatic hydrocarbon group containing acarbon-carbon triple bond and which may be straight or branched havingabout 2 to about 15 carbon atoms in the chain. Preferred alkynyl groupshave 2 to about 12 carbon atoms in the chain; and more preferably about2 to about 4 carbon atoms in the chain. Exemplary alkynyl groups includeethynyl, propynyl, n-butynyl, i-butynyl, 3-methylbut-2-ynyl, andn-pentynyl.

[0043] “Aroyl” means an aryl-CO— group in which the aryl group is asdescribed herein. Exemplary groups include benzoyl and 1- and2-naphthoyl.

[0044] “Aroylamino” is an aroyl-NH— group wherein aroyl is as previouslydefined.

[0045] “Aryl” as a group or part of a group denotes: (i) an optionallysubstituted monocyclic or multicyclic aromatic carbocyclic moiety ofabout 6 to about 14 carbon atoms, such as phenyl or naphthyl; or (ii) anoptionally substituted partially saturated multicyclic aromaticcarbocyclic moiety in which an aryl and a cycloalkyl or cycloalkenylgroup are fused together to form a cyclic structure, such as atetrahydronaphthyl, indenyl or indanyl ring. Aryl groups may besubstituted with one or more aryl group substituents which may be thesame or different, where “aryl group substituent” includes, for example,acyl, acylamino, alkoxy, alkoxycarbonyl, alkylenedioxy, alkylsulphinyl,alkylsulphonyl, alkylthio, aroyl, aroylamino, aryl, arylalkyloxy,arylalkyloxycarbonyl, arylalkylthio, aryloxy, aryloxycarbonyl,arylsulphinyl, arylsulphonyl, arylthio, carboxy, cyano, halo,heteroaroyl, heteroaryl, heteroarylalkyloxy, heteroaroylamino,heteroaryloxy, hydroxy, nitro, trifluoromethyl, Y⁷Y⁸N—, Y⁷Y⁸NCO—,Y⁷Y⁸NSO₂—(where Y⁷ and Y⁸ are independently hydrogen, alkyl, aryl,arylalkyl, heteroaryl and heteroarylalkyl), Y⁷Y⁸N—C₂₋₆alkylene-Z²-(whereZ² is O, NR⁵ or S(O)_(n)), alkylC(═O)—Y⁷N—, akylSO₂—Y⁷N— or alkyloptionally substituted with aryl, heteroaryl, hydroxy, or Y⁷Y⁸N—.Preferred aryl group substituents within R² include halogen, alkoxy,trifluoromethyl, alkylthio, alkylsulphinyl, Y⁷Y⁸N—, alkylC(═O)—Y⁷N— oralkylSO₂—Y⁷N—, more preferably fluoro.

[0046] “Arylalkyl” means an aryl-alkyl-group in which the aryl and alkylmoieties are as previously described. Preferred arylalkyl groups containa C₁₋₄alkyl moiety. Exemplary arylalkyl groups include benzyl,2-phenethyl and naphthlenemethyl.

[0047] “Arylalkyloxy” means an arylalkyl-O— group in which the arylalkylgroups is as previously described. Exemplary arylalkyloxy groups includebenzyloxy and 1- or 2-naphthalenemethoxy.

[0048] “Arylalkyloxycarbonyl” means an arylalkyl-O—CO— group in whichthe arylalkyl groups is as previously described. An exemplaryarylalkyloxycarbonyl group is benzyloxycarbonyl.

[0049] “Arylalkylthio” means an arylalkyl-S— group in which thearylalkyl group is as previously described. An exemplary arylalkylthiogroup is benzylthio.

[0050] “Aryloxy” means an aryl-O— group in which the aryl group is aspreviously described. Exemplary aryloxy groups include optionallysubstituted phenoxy and naphthoxy.

[0051] “Aryloxycarbonyl” means an aryl-O—CO— group in which the arylgroup is as previously described. Exemplary aryloxycarbonyl groupsinclude phenoxycarbonyl and naphthoxycarbonyl.

[0052] “Arylsulphinyl” means an aryl-SO— group in which the aryl groupis as previously described.

[0053] “Arylsulphonyl” means an aryl-SO₂— group in which the aryl groupis as previously described.

[0054] “Arylsulphonylcarbamoyl” means an aryl-SO₂—NH—C(═O)— group inwhich the aryl group is as previously described.

[0055] “Arylthio” means an aryl-S— group in which the aryl group is aspreviously described. Exemplary arylthio groups include phenylthio andnaphthylthio.

[0056] “Azaheteroaryl” means an aromatic carbocyclic moiety of about 5to about 10 ring members in which one of the ring members is nitrogenand the other ring members are chosen from carbon, oxygen, sulphur, ornitrogen. Examples of optionally substituted azaheteroaryl groupsinclude pyridyl, pyrimidinyl, quinolinyl, isoquinolinyl, quinazolinyl,imidazolyl, and benzimidazolyl, optionally substituted with one or more“heteroaryl group substituents”. Preferred azaheteroaryl groups withinR¹ include optionally substituted pyridyl and pyrimidinyl. Preferredheteroaryl group substituents when R¹ is pyrimidinyl includeR¹⁷Z³-[where R¹⁷ is alkyl, aryl, cycloalkyl, heteroaryl,heterocycloalkyl, or alkyl substituted by alkoxy, aryl, cyano,cycloalkyl, heteroaryl, heterocycloalkyl, hydroxy, oxo, —CO₂R¹⁰,—CONY¹Y² or —NY⁴Y⁵ and Z³ is O or S(O)_(n)] and Y⁴Y⁵N—.

[0057] “Cycloalkenyl” means an optionally substituted non-aromaticmonocyclic or multicyclic ring system containing at least onecarbon-carbon double bond and having about 5 to about 10 carbon atoms.Exemplary monocyclic cycloalkenyl rings include cyclopentenyl,cyclohexenyl and cyclopentenyl. Exemplary multicyclic cycloalkenyl ringinclude norbornenyl. The cycloalkenyl group may be substituted by one ormore substituents chosen from, for example, halo, or alkyl.

[0058] “Cycloalkoxymethyl” means a cycloalkyl-O—CH₂-group in which thecycloalkyl group is as described hereinafter. Exemplarycycloalkoxymethyl groups include cyclopropyloxymethyl andcyclopentyloxymethyl.

[0059] “Cycloalkyl” means an optionally substituted non-aromaticmonocyclic or multicyclic ring system of about 3 to about 10 carbonatoms. Exemplary monocyclic cycloalkyl rings include cyclopropyl,cyclopentyl, cyclohexyl and cycloheptyl. Exemplary multicycliccycloalkyl rings include perhydronaphthyl, adamant-(1- or 2-)yl andnorbornyl and spirocyclic groups e.g. spiro[4,4]non-2yl. When R³ is, orcontains, a cycloalkyl ring this may particularly represent a 3 to 7membered monocyclic ring, especially cyclohexyl. The cycloalkyl groupmay be substituted by one or more (e.g. 1, 2, or 3) substituents chosenfrom, for example, alkyl, aryl, arylalkyl, halo, halo substituted alkyl(such as trifluoromethyl), hydroxyalkyl, hydroxy, alkoxy,-S(O)_(n)-alkyl, —NY¹Y² or —CO₂R¹².

[0060] “Cycloalkylalkyl” means a cycloalkyl-alkyl-group in which thecycloalkyl and alkyl moieties are as previously described. Exemplarymonocyclic cycloalkylalkyl groups include cyclopropylmethyl,cyclopentylmethyl, cyclohexylmethyl and cycloheptylmethyl.

[0061] “Cycloalkyloxy” means a cycloalkyl-O— group in which thecycloalkyl group is as described herein. Exemplary cycloalkyloxy groupsinclude cyclopropyloxy, cyclopentyloxy, cyclohexyloxy andcycloheptyloxy.

[0062] “Halo” or “halogen” means fluoro, chloro, bromo, or iodo.Preferred are fluoro or chloro.

[0063] “Heteroaroyl” means a heteroaryl-CO— group in which theheteroaryl group is as described herein. Exemplary groups includepyridylcarbonyl.

[0064] “Heteroaroylamino” means a heteroaroyl-NH— group in which theheteroaroyl moiety is as previously described.

[0065] “Heteroaryl” as a group or part of a group denotes an optionallysubstituted aromatic monocyclic or multicyclic organic moiety of about 5to about 10 ring members in which one or more of the ring members is/areelement(s) other than carbon, for example nitrogen, oxygen or sulphur.Examples of suitable optionally substituted heteroaryl groups includebenzimidazolyl, furyl, imidazolyl, isoxazolyl, isoquinolinyl,isothiazolyl, oxadiazolyl, pyrazinyl, pyridazinyl, pyrazolyl, pyridyl,pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, 1,3,4-thiadiazolyl,thiazolyl, thienyl and triazolyl groups. When R¹ is an optionallysubstituted heteroaryl group this may particularly represent anoptionally substituted “azaheteroaryl” group. Heteroaryl groups may besubstituted with one or more heteroaryl group substituents which may bethe same or different, where “heteroaryl group substituent” includes,for example acyl, acylamino, alkoxycarbonyl, alkylenedioxy, aroyl,aroylamino, aryl, arylalkyloxycarbonyl, aryloxycarbonyl, carboxy, cyano,halo, heteroaroyl, heteroaryl, heteroaroylamino, hydroxy, nitro,trifluoromethyl, R¹⁷Z³-, Y⁴Y⁵N—, Y⁴Y⁵N—CO—, Y⁴Y⁵NSO₂—, alkylSO₂—Y⁴N— oralkyl optionally substituted with aryl, heteroaryl, hydroxy, oxo,—CO₂R¹⁰, —CONY¹Y² or Y⁴Y⁵N—.

[0066] “Heteroarylalkyl” means a heteroaryl-alkyl-group in which theheteroaryl and alkyl moieties are as previously described. Preferredheteroarylalkyl groups contain a C₁₋₄alkyl moiety. Exemplaryheteroarylalkyl groups include pyridylmethyl.

[0067] “Heteroarylalkyloxy” means an heteroarylalkyl-O— group in whichthe heteroarylalkyl group is as previously described. Exemplaryheteroaryloxy groups include optionally substituted pyridylmethoxy.

[0068] “Heteroaryloxy” means an heteroaryl-O— group in which theheteroaryl group is as previously described. Exemplary heteroaryloxygroups include optionally substituted pyridyloxy.

[0069] “Heteroarylsulphonylcarbamoyl” means a heteroaryl-SO₂—NH—C(═O)—group in which the heteroaryl group is as previously described.

[0070] “Heterocycloalkyl” means a cycloalkyl group of about 3 to 7 ringmembers which contains one or more heteroatoms selected from O, S orNY³. Exemplary heterocycloalkyl groups include 5-7 membered cyclicethers such as tetrahydrofuran and perhydropyran.

[0071] “Heterocycloalkylalkyl” means a heterocycloalkyl-alkyl-group inwhich the heterocycloalkyl and alkyl moieties are as previouslydescribed.

[0072] “Heterocycloalkyloxy” means a heterocycloalkyl-O— group in whichthe heterocycloalkyl is as previously defined.

[0073] “Hydroxyalkyl” means a HO-alkyl-group in which alkyl is aspreviously defined. Preferred hydroxyalkyl groups contain C₁₋₄alkyl.Exemplary hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.

[0074] “Y⁷Y⁸N—” means a substituted or unsubstituted amino group,wherein Y⁷ and Y⁸ are as previously described. Exemplary groups includeamino (H₂N—), methylamino, ethylmethylamino, dimethylamino anddiethylamino.

[0075] “Y⁷Y⁸NCO—” means a substituted or unsubstituted carbamoyl group,wherein Y⁷ and Y⁸ are as previously described. Exemplary groups arecarbamoyl (H₂NCO—) and dimethylcarbamoyl (Me₂NCO—).

[0076] “Y⁷Y⁸NSO₂—” means a substituted or unsubstituted sulphamoylgroup, wherein Y⁷ and Y⁸ are as previously described. Exemplary groupsare sulphamoyl (H₂NSO₂—) and dimethylsulphamoyl (Me₂NSO₂—).

[0077] “Prodrug” means a compound which is convertible in vivo bymetabolic means (e.g. by hydrolysis) to a compound of formula (I),including N-oxides thereof. For example an ester of a compound offormula (I) containing a hydroxy group may be convertible by hydrolysisin vivo to the parent molecule. Alternatively an ester of a compound offormula (I) containing a carboxy group may be convertible by hydrolysisin vivo to the parent molecule.

[0078] “Solvate” means a physical association of a compound of thisinvention with one or more solvent molecules. This physical associationincludes hydrogen bonding. In certain instances the solvate will becapable of isolation, for example when one or more solvent molecules areincorporated in the crystal lattice of the crystalline solid. “Solvate”encompasses both solution-phase and isolable solvates. Representativesolvates include hydrates, ethanolates, methanolates, and the like.

[0079] Suitable esters of compounds of formula (I) containing a hydroxygroup, are for example acetates, citrates, lactates, tartrates,malonates, oxalates, salicylates, propionates, succinates, fumarates,maleates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates,di-p-toluoyltartrates, methanesulphonates, ethanesulphonates,benzenesulphonates, p-toluenesulphonates, cyclohexylsulphamates andquinates.

[0080] Suitable esters of compounds of formula (I) containing a carboxygroup, are for example those described by F. J. Leinweber, Drug Metab.Res., 1987, 18, page 379.

[0081] An especially useful class of esters of compounds of formula (I)containing a hydroxy group, may be formed from acid moieties selectedfrom those described by Bundgaard et. al., J. Med. Chem., 1989, 32, page2503-2507, and include substituted (aminomethyl)-benzoates, for exampledialkylamino-methylbenzoates in which the two alkyl groups may be joinedtogether and/or interrupted by an oxygen atom or by an optionallysubstituted nitrogen atom, e.g. an alkylated nitrogen atom, moreespecially (morpholino-methyl)benzoates, e.g. 3- or4-(morpholinomethyl)-benzoates, and (4-alkylpiperazin-1-yl)benzoates,e.g. 3- or 4-(4-alkylpiperazin-1-yl)benzoates.

[0082] Some of the compounds of the present invention are basic, andsuch compounds are useful in the form of the free base or in the form ofa pharmaceutically acceptable acid addition salt thereof.

[0083] Acid addition salts are a more convenient form for use; and inpractice, use of the salt form inherently amounts to use of the freebase form. The acids which can be used to prepare the acid additionsalts include preferably those which produce, when combined with thefree base, pharmaceutically acceptable salts, that is, salts whoseanions are non-toxic to the patient in pharmaceutical doses of thesalts, so that the beneficial inhibitory effects inherent in the freebase are not vitiated by side effects ascribable to the anions. Althoughpharmaceutically acceptable salts of said basic compounds are preferred,all acid addition salts are useful as sources of the free base form evenif the particular salt, per se, is desired only as an intermediateproduct as, for example, when the salt is formed only for purposes ofpurification, and identification, or when it is used as intermediate inpreparing a pharmaceutically acceptable salt by ion exchange procedures.Pharmaceutically acceptable salts within the scope of the inventioninclude those derived from mineral acids and organic acids, and includehydrohalides, e.g. hydrochlorides and hydrobromides, sulphates,phosphates, nitrates, sulphamates, acetates, citrates, lactates,tartrates, malonates, oxalates, salicylates, propionates, succinates,fumarates, maleates, methylene-bis-b-hydroxynaphthoates, gentisates,isethionates, di-p-toluoyltartrates, methane-sulphonates,ethanesulphonates, benzenesulphonates, p-toluenesulphonates,cyclohexylsulphamates and quinates.

[0084] Where the compound of the invention is substituted with an acidicmoiety, base addition salts may be formed and are simply a moreconvenient form for use; and in practice, use of the salt forminherently amounts to use of the free acid form. The bases which can beused to prepare the base addition salts include preferably those whichproduce, when combined with the free acid, pharmaceutically acceptablesalts, that is, salts whose cations are non-toxic to the patient inpharmaceutical doses of the salts, so that the beneficial inhibitoryeffects inherent in the free base are not vitiated by side effectsascribable to the cations. Pharmaceutically acceptable salts, includingthose derived from alkali and alkaline earth metal salts, within thescope of the invention include those derived from the following bases:sodium hydride, sodium hydroxide, potassium hydroxide, calciumhydroxide, aluminium hydroxide, lithium hydroxide, magnesium hydroxide,zinc hydroxide, ammonia, ethylenediamine, N-methyl-glucamine, lysine,arginine, ornithine, choline, N,N′-dibenzylethylenediamine,chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine,diethylamine, piperazine, tris(hydroxymethyl)aminomethane,tetramethylammonium hydroxide, and the like.

[0085] As well as being useful in themselves as active compounds, saltsof compounds of the invention are useful for the purposes ofpurification of the compounds, for example by exploitation of thesolubility differences between the salts and the parent compounds, sideproducts and/or starting materials by techniques well known to thoseskilled in the art.

[0086] With reference to formula (I) above, the following are particularand preferred groupings:

[0087] R¹ may particularly represent optionally substitutedazaheteroaryl such as optionally substituted pyridyl, pyrimidinyl,quinolinyl, isoquinolinyl, quinazolinyl, imidazolyl or benzimidazolyl(for example optionally substituted 4-pyridyl, 4-pyrimidinyl,4-quinolinyl, 6-isoquinolinyl, 4-quinazolinyl, 1-imidazolyl or1-benzimidazolyl). R¹ is preferably optionally substituted 4-pyridyl or4-pyrimidinyl, especially unsubstituted 4-pyridyl or 2-substituted4-pyrimidinyl. Preferred substituents include C₁₋₄alkyl, especiallymethyl, —NY⁴Y⁵ (especially where at least one of Y⁴ and Y⁵ is hydrogen)or —OR¹⁷(especially where R¹⁷ is cycloalkyl).

[0088] R² is preferably optionally substituted phenyl, particularly whensubstituted by halogen, especially fluoro and chloro, or an alkylthio oralkylsulphinyl group, especially methylthio or methysulphinyl, or atrifluoromethyl group. R² is more preferably phenyl substituted by ahalogen (e.g. fluorine) atom, especially in the 4-position.

[0089] R³ may particularly represent hydrogen or C₁₋₄alkyl, preferablyhydrogen.

[0090] R⁴ may particularly represent a group -L³-R¹⁴ where L³ is adirect bond and R¹⁴ is —NY⁴Y⁵, where Y⁴ and Y⁵ are as definedhereinbefore, especially where Y⁴ and Y⁵ are hydrogen.

[0091] R⁴ may also particularly represent a group -L³-R¹⁴ where L³is adirect bond and R¹⁴ is —N(R¹⁰)—C(=Z)-R¹⁵, in which Z, R¹⁰ and R¹⁵ are asdefined hereinbefore, especially where Z is oxygen, R¹⁰ is hydrogen andR¹⁵ is alkyl (especially methyl), aryl (e.g. substituted or morepreferably, unsubstituted phenyl) or heteroaryl.

[0092] R⁴ may also particularly represent a group -L³-R¹⁴ where L³ is adirect bond and R¹⁴ is —N(R¹⁰)—C(=Z)-L⁴-R¹⁶, in which Z, L⁴, R¹⁰ and R¹⁶are as defined hereinbefore, especially where Z is oxygen, L⁴ ismethylene, R¹⁰ is hydrogen, and R¹⁶ is aryl (e.g. substituted or morepreferably, unsubstituted phenyl) or heteroaryl.

[0093] R⁴ may also particularly represent a group -L³-R¹⁴ where L³ is adirect bond and R¹⁴ is —C(=Z)-NY⁴Y⁵, in which Z is as definedhereinbefore, especially oxygen, and Y⁴ and Y⁵ are as definedhereinbefore, especially where Y⁴ and Y⁵ are hydrogen or where Y⁴ ishydrogen and Y⁵is aryl, arylalkyl, heteroaryl or heteroarylalkyl.

[0094] R⁴ may also particularly represent a group -L³-R¹⁴ where L³ is adirect bond and R¹⁴ is —C(=Z)-NY⁴Y⁵, in which Z is as definedhereinbefore, especially oxygen, and the group —NY⁴Y⁵ forms a 5-7membered cyclic amine [which may optionally contain a further heteroatomselected from O, S or NY⁶ (where Y⁶ is as defined hereinbefore)],preferably a 5-7 membered cyclic amine optionally containing oxygen,especially a morpholine ring.

[0095] R⁴ may also particularly represent a group -L³-R¹⁴ where L³ is adirect bond and R¹⁴ is —C(=Z)-OR⁹, in which Z and R⁹ are as definedhereinbefore, especially where Z is oxygen and R⁹ is C₁₋₄alkyl,preferably methyl.

[0096] R⁴ may also particularly represent a group -L³-R¹⁴ where L³ is adirect bond, especially methylene or ethylene, and R¹⁴ is alkyl,especially methyl.

[0097] R⁴ may also particularly represent a group -L³-R¹⁴ where L³ isC₁₋₆alkylene, especially methylene, and R¹⁴ is hydroxy.

[0098] R⁴ may also particularly represent a group -L³-R¹⁴ where L³ isC₁₋₆alkylene, especially methylene, and R¹⁴ is —N(R¹⁰)—C(=Z)-R¹⁵, inwhich Z, R¹⁰ and R¹⁵ are as defined hereinbefore, especially where Z isoxygen, R¹⁰ is hydrogen and R¹⁵ is alkyl, aryl or heteroaryl.

[0099] R⁴ may also particularly represent a group -L³-R¹⁴ where L³ isC₁₋₆alkylene, especially methylene, and R¹⁴ is —N(R¹⁰)—C(=Z)-L⁴-R¹⁶, inwhich Z, L⁴, R¹⁰ and R¹⁵ are as defined hereinbefore, especially where Zis oxygen, L⁴ is C₁₋₆alkylene, especially methylene, R¹⁰ is hydrogen andR¹⁶ is aryl or heteroaryl.

[0100] R⁴ may also particularly represent a group -L³-R¹⁴ where L³isC₁₋₆alkylene, especially methylene, and R¹⁴ is —NHC(=Z)-NH—R¹⁵, in whichZ and R¹⁵ are as defined hereinbefore, especially where R¹⁵ is alkyl,aryl or heteroaryl.

[0101] R⁴ may also particularly represent a group -L³-R¹⁴ where L³ isC₁₋₆alkylene, especially methylene, and R¹⁴ is —NH—C(=Z)-NH-L⁴-R¹⁶, inwhich Z, L⁴ and R¹⁶ are as defined hereinbefore, especially where L⁴ ismethylene and R¹⁵ is aryl or heteroaryl.

[0102] R⁴ may also particularly represent a group -L³-R¹⁴ where L³ isC₁₋₆alkylene, especially C₁₋₃alkylene, preferably methylene, and R¹⁴ is—NY⁴Y⁵, where Y⁴ and Y⁵ are as defined hereinbefore, especially where Y⁴and Y⁵ are hydrogen.

[0103] R⁴ may also particularly represent a group -L³-R¹⁴ where L³isC₁₋₆alkylene, especially methylene or ethylene, and R¹⁴ is aryl orheteroaryl.

[0104] R⁴ may also particularly represent a group -L³-R¹⁴ where L³ isC₁₋₆alkylene, especially methylene, and R¹⁴ is —N(R¹⁰)—SO₂—R¹⁵, in whichR¹⁰ and R¹⁵ are as defined hereinbefore, especially where R¹⁰ ishydrogen and R¹⁵ is alkyl, aryl or heteroaryl.

[0105] R⁴ may also particularly represent a group -L³-R¹⁴ where L³ isC₁₋₆alkylene, especially methylene, and R¹⁴ is —N(R¹⁰)—SO₂-L⁴-R¹⁵, inwhich L⁴, R¹⁰ and R¹⁵ are as defined hereinbefore, especially where L⁴is methylene R¹⁰ is hydrogen and R¹⁵ is alkyl or heteroaryl

[0106] R⁵ may particularly represent hydrogen or C₁₋₄alkyl, especiallymethyl.

[0107] R⁵ may also particularly represent hydroxyalkyl, especiallyhydroxymethyl.

[0108] R⁴ and R⁵ together with the carbon atom to which they areattached may particularly represent a group C═CH₂ or a 5-7 memberedcyclic ether such as tetrahydrofuran-2-yl or perhydropyran-2-yl.

[0109] R⁶ may particularly represent hydrogen or C₁₋₄alkyl, especiallyhydrogen.

[0110] m is preferably an integer 1.

[0111] It is to be understood that this invention covers all appropriatecombinations of the particular and preferred groupings referred toherein.

[0112] A particular group of compounds of the invention are compounds offormula (Ia):—

[0113] in which R⁴ and R⁵ are as hereinbefore defined, and N-oxidesthereof, and their prodrugs; and pharmaceutically acceptable salts andsolvates (e.g. hydrates) of compounds of formula (Ia) and N-oxidesthereof, and their prodrugs.

[0114] Compounds of formula (Ia) in which R⁴ represents a group -L³-R¹⁴where L³ is a direct bond and R¹⁴ is —NY⁴Y⁵, where Y⁴ and Y⁵ are asdefined hereinbefore, especially where Y⁴ and Y⁵ are hydrogen, arepreferred.

[0115] Compounds of formula (Ia) in which R⁴ represents a group -L³-R¹⁴where L³ is a direct bond and R¹⁴ is —N(R¹⁰)—C(=Z)-R¹⁵, in which Z, R¹⁰and R¹⁵ are as defined hereinbefore, especially where Z is oxygen, R¹⁰is hydrogen and R¹⁵ is alkyl (especially methyl), aryl (e.g. substitutedor more preferably, unsubstituted phenyl) or heteroaryl, are alsopreferred.

[0116] Compounds of formula (Ia) in which R⁴ represents a group -L³-R¹⁴where L³ is a direct bond and R¹⁴ is —N(R¹⁰)—C(=Z)-L⁴-R¹⁶, in which Z,L⁴, R¹⁰ and R¹⁶ are as defined hereinbefore, especially where Z isoxygen, L⁴ is methylene, R¹⁰ is hydrogen, and R¹⁶ is aryl (e.g.substituted or more preferably, unsubstituted phenyl) or heteroaryl, arealso preferred.

[0117] Compounds of formula (Ia) in which R⁴ represents a group -L³-R¹⁴where L³ is a direct bond and R¹⁴ is —C(=Z)-NY⁴Y⁵, in which Z is asdefined hereinbefore, especially oxygen, and Y⁴ and Y⁵ are as definedhereinbefore, especially where Y⁴ and Y⁵ are hydrogen or where Y⁴ ishydrogen and Y⁵is aryl, heteroaryl or heteroarylalkyl, are alsopreferred.

[0118] Compounds of formula (Ia) in which R⁴ represents a group -L³-R¹⁴where L³ is a direct bond and R¹⁴is —C(=Z)-NY⁴Y⁵, in which Z is asdefined hereinbefore, especially oxygen, and the group —NY⁴Y⁵ forms a5-7 membered cyclic amine [which may optionally contain a furtherheteroatom selected from O, S or NY⁶ (where Y⁶ is as definedhereinbefore)], preferably a 5-7 membered cyclic amine optionallycontaining oxygen, especially a morpholine ring, are also preferred.

[0119] Compounds of formula (Ia) in which R⁴ represents a group -L³-R¹⁴where L³ is a direct bond and R¹⁴ is —C(=Z)-OR⁹, in which Z and R⁹ areas defined hereinbefore, especially where Z is oxygen and R⁹ isC₁₋₄alkyl, preferably methyl, are also preferred.

[0120] Compounds of formula (Ia) in which R⁴ represents a group -L³-R¹⁴where L³ is a direct bond, especially methylene or ethylene, and R¹⁴ isalkyl, especially methyl, are also preferred.

[0121] Compounds of formula (Ia) in which R⁴ represents a group -L³-R¹⁴where L³ is C₁₋₆alkylene, especially methylene, and R¹⁴ is hydroxy, arealso preferred.

[0122] Compounds of formula (Ia) in which R⁴ represents a group -L³-R¹⁴where L³ is C₁₋₆alkylene, especially methylene, and R¹⁴ is—N(R¹⁰)—C(=Z)-R¹⁵, in which Z, R¹⁰ and R¹⁵ are as defined hereinbefore,especially where Z is oxygen, R¹⁰ is hydrogen and R¹⁵ is alkyl, aryl orheteroaryl, are also preferred.

[0123] Compounds of formula (Ia) in which R⁴ represents a group -L³-R¹⁴where L³is C₁₋₆alkylene, especially methylene, and R¹⁴ is—N(R¹⁰)—C(=Z)-L⁴-R¹⁶, in which Z, L⁴,R¹⁰ and R¹⁵ are as definedhereinbefore, especially where Z is oxygen, L⁴ is C₁₋₆alkylene,especially methylene, R¹⁰ is hydrogen and R¹⁶ is aryl or heteroaryl, arealso preferred.

[0124] Compounds of formula (Ia) in which R⁴ represents a group -L³-R¹⁴where L³is C₁₋₆alkylene, especially methylene, and R¹⁴ is—NH—C(=Z)-NH—R¹⁵, in which Z and R¹⁵ are as defined hereinbefore,especially where R¹⁵ is alkyl, aryl or heteroaryl, are also preferred.

[0125] Compounds of formula (Ia) in which R⁴ represents a group -L³-R¹⁴where L³ is C₁₋₆alkylene, especially methylene, and R¹⁴ is—NH—C(=Z)-NH-L⁴-R¹⁶, in which Z, L⁴ and R¹⁶ are as defined hereinbefore,especially where L⁴ is methylene and R¹⁵ is aryl or heteroaryl, are alsopreferred.

[0126] Compounds of formula (Ia) in which R⁴ represents a group -L³-R¹⁴where L³ is C₁₋₆alkylene, especially C₁₋₃alkylene, preferably methylene,and R¹⁴ is NY⁴Y⁵, where Y⁴ and Y⁵ are as defined hereinbefore,especially where Y⁴ and Y⁵ are hydrogen, are also preferred.

[0127] Compounds of formula (Ia) in which R⁴ represents a group -L³-R¹⁴where L³ is C₁₋₆alkylene, especially methylene or ethylene, and R¹⁴ isaryl or heteroaryl, are also preferred.

[0128] Compounds of formula (Ia) in which R⁴ represents a group -L³-R¹⁴where L³is C₁₋₆alkylene, especially methylene, and R¹⁴ is —N(R¹⁰)—SO₂—R⁵, in which R¹⁰ and R¹⁵ are as defined hereinbefore, especially whereR¹⁰ is hydrogen and R¹⁵ is alkyl, aryl or heteroaryl, are alsopreferred.

[0129] Compounds of formula (Ia) in which R⁴ represents a group -L³-R¹⁴where L³ is C₁₋₆alkylene, especially methylene and R¹⁴ is—N(R¹⁰)—SO₂-L⁴-R¹⁵ in which L⁴-R¹⁰ and R¹⁵ are as defined hereinbefore,especially where L⁴ is methylene, R¹⁰ is hydrogen and R¹⁵ is alkyl, arylor heteroaryl, are also preferred.

[0130] Compounds of formula (Ia) in which R⁵ represents hydrogen,C₁₋₄alkyl (e.g. methyl) or hydroxyC₁₋₄alkyl (e.g. hydroxymethyl),especially methyl, are preferred.

[0131] Compounds of formula (Ia) in which R⁴ and R⁵ together with thecarbon atom to which they are attached represent a group C═CH₂ or a 5-7membered cyclic ether such as tetrahydrofuran-2-yl or perhydropyran-2-ylare also preferred.

[0132] A preferred group of compounds of the invention are compounds offormula (Ia) in which R⁴ is a group -L³-R¹⁴ {where L³ is a direct bondand R¹⁴ is (i) —NY⁴Y⁵, preferably —NH₂; (ii) —N(R¹⁰)—C(=Z)-R¹⁵,preferably —NH—C(═O)-alkyl, —NH—C(═O)-aryl or —NH—C(═O)-heteroaryl,especially —NH—C(═O)-aryl, particularly where aryl is substituted, ormore preferably, unsubstituted phenyl; (iii) —N(R¹⁰)—C(=Z)-L⁴-R¹⁶,preferably —NH—C(═O)—CH₂-aryl or —NH—C(═O)—CH₂-heteroaryl, particularlywhere aryl is substituted, or more preferably, unsubstituted phenyl;(iv) —C(=Z)-NY⁴Y⁵, preferably —C(═O)—NH₂; (v) —C(=Z)-NY⁴Y⁵, preferably—C(═O)—NY⁴Y⁵ where the group —NY⁴Y⁵ forms a 5-7membered cyclic amine[which may optionally contain a further heteroatom selected from O, S orNY⁶ (where Y⁶ is as defined hereinbefore), preferably a 5-7 memberedcyclic amine optionally containing oxygen, especially a morpholinering]; (vi) —C(=Z)OR⁹, particularly —CO₂Me; or (vii) alkyl, especiallymethyl}

[0133] and R⁵ represents hydrogen, C₁₋₄alkyl (e.g. methyl) or hydroxyC1₄alkyl (e.g. hydroxymethyl), especially methyl; and N-oxides thereof,and their prodrugs; and pharmaceutically acceptable salts and solvates(e.g. hydrates) of compounds of formula (Ia) herein and N-oxidesthereof, and their prodrugs.

[0134] A further preferred group of compounds of formula (Ia) arecompounds in which R⁴ is a group -L³-R¹⁴ {where L³ is a methylenelinkage and R¹⁴ is (i) hydroxy; (ii) —N(R¹⁰)—C(=Z)-R¹⁵, preferably—NH—C(═O)-alkyl, —NH—C(═O)-aryl or —NH—C(═O)-heteroaryl; (iii)—N(R¹⁰)—C(=Z)-L⁴-R¹⁶, preferably —NH—C(═O)—CH₂-aryl or—NH—C(═O)—CH₂-heteroaryl; (iv) —NH—C(=Z)-NH—R¹⁵ preferably—NH—C(═O)—NH-alkyl, —NH—C(═O)—NH-aryl or —NH—C(═O)—NH-heteroaryl ;(v)NH—C(=Z)-NH-L⁴-R¹⁶ preferably —NH—C(═O)—NH—CH₂-alkyl,—NH—C(═O)—NH—CH₂-aryl or —NH—C(═O)—NH—CH₂-heteroaryl; (vi) —NY⁴Y⁵,preferably —NH₂; (vii) aryl; (viii) heteroaryl; (ix) —N(R¹⁰)—SO₂—R¹⁵,preferably —NH—SO₂-alkyl, NH—SO₂-aryl or —NH—SO₂-heteroaryl} and R⁵represents hydrogen, C₁₋₄alkyl (e.g. methyl) or hydroxyC₁₋₄alkyl (e.g.hydroxymethyl), especially methyl; and N-oxides thereof, and theirprodrugs; and pharmaceutically acceptable salts and solvates (e.g.hydrates) of compounds of formula (Ia) herein and N-oxides thereof, andtheir prodrugs.

[0135] A further particular group of compounds of the invention arecompounds of formula (Ib):—

[0136] in which R⁴ and R⁵ are as hereinbefore defined, and R¹⁸ is R¹⁷Z³-or Y⁴Y⁵N— (in which R¹⁷, Y⁴, Y⁵ and Z³ are as hereinbefore defined), andN-oxides thereof, and their prodrugs; and pharmaceutically acceptablesalts and solvates (e.g. hydrates) of compounds of formula (Ib) andN-oxides thereof, and their prodrugs.

[0137] Compounds of formula (Ib) in which R⁴ represents a group -L³-R¹⁴where L³ is a direct bond and R¹⁴ is —NY⁴Y⁵, where Y⁴ and Y⁵ are asdefined hereinbefore, especially where Y⁴ and Y⁵ are hydrogen, arepreferred.

[0138] Compounds of formula (Ib) in which R⁴ represents a group -L³-R¹⁴where L³ is a direct bond and R¹⁴ is —N(R¹⁰)—C(=Z)-R¹⁵, in which Z, R¹⁰and R¹⁵ are as defined hereinbefore, especially where Z is oxygen, R¹⁰is hydrogen and R¹⁵ is alkyl (especially methyl), aryl (e.g. substitutedor more preferably, unsubstituted phenyl) or heteroaryl, are alsopreferred.

[0139] Compounds of formula (Ib) in which R⁴ represents a group -L³-R¹⁴where L³ is a direct bond and R¹⁴ is —N(R¹⁰)—C(=Z)-L⁴-R¹⁶, in which Z,L⁴, R¹⁰ and R¹⁶ are as defined hereinbefore, especially where Z isoxygen, L⁴ is methylene, R¹⁰ is hydrogen, and R¹⁶ is aryl (e.g.substituted or more preferably, unsubstituted phenyl) or heteroaryl, arealso preferred.

[0140] Compounds of formula (Ib) in which R⁴ represents a group -L³-R¹⁴where L³ is a direct bond and R¹⁴ is —C(=Z)-NY⁴Y⁵, in which Z is asdefined hereinbefore, especially oxygen, and Y⁴ and Y⁵ are as definedhereinbefore, especially where Y⁴ and Y⁵ are hydrogen or where Y⁴ ishydrogen and Y⁵ is aryl, heteroaryl or heteroarylalkyl, are alsopreferred.

[0141] Compounds of formula (Ib) in which R⁴ represents a group -L³-R¹⁴where L³ is a direct bond and R¹⁴ is —C(=Z)-NY⁴Y⁵, in which Z is asdefined hereinbefore, especially oxygen, and the group —NY⁴Y⁵ forms a5-7 membered cyclic amine [which may optionally contain a furtherheteroatom selected from O, S or NY⁶ (where Y⁶ is as definedhereinbefore)], preferably a 5-7 membered cyclic amine optionallycontaining oxygen, especially a morpholine ring, are also preferred.

[0142] Compounds of formula (Ib) in which R⁴ represents a group -L³-R¹⁴where L³ is a direct bond and R¹⁴ is —C(=Z)-OR⁹, in which Z and R⁹ areas defined hereinbefore, especially where Z is oxygen and R⁹ isC₁₋₄alkyl, preferably methyl, are also preferred.

[0143] Compounds of formula (Ib) in which R⁴ represents a group -L³-R¹⁴where L³ is a direct bond, especially methylene or ethylene, and R¹⁴ isalkyl, especially methyl, are also preferred.

[0144] Compounds of formula (Ib) in which R⁴ represents a group -L³-R¹⁴where L³ is C₁₋₆alkylene, especially methylene, and R¹⁴ is hydroxy, arealso preferred.

[0145] Compounds of formula (Ib) in which R⁴ represents a group -L³-R¹⁴where L³ is C₁₋₆alkylene, especially methylene, and R¹⁴ is—N(R¹⁰)—C(=Z)-R¹⁵, in which Z, R¹⁰ and R¹⁵ are as defined hereinbefore,especially where Z is oxygen, R¹⁰ is hydrogen and R¹⁵ is alkyl, aryl orheteroaryl, are also preferred.

[0146] Compounds of formula (Ib) in which R⁴ represents a group -L³-R¹⁴where L³ is C₁ I₆alkylene, especially methylene, and R¹⁴ is—N(R¹⁰)—C(=Z)-L⁴-R¹⁶, in which Z, L⁴, R¹⁰ and R¹⁵ are as definedhereinbefore, especially where Z is oxygen, L⁴ is C₁₋₆alkylene,especially methylene, R¹⁰ is hydrogen and R¹⁶ is aryl or heteroaryl, arealso preferred.

[0147] Compounds of formula (Ib) in which R⁴ represents a group -L³-R¹⁴where L³ is C₁₋₆alkylene, especially methylene, and R¹⁴ is—NH—C(=Z)-NH—R¹⁵, in which Z and R¹⁵ are as defined hereinbefore,especially where R¹⁵ is alkyl, aryl or heteroaryl, are also preferred.

[0148] Compounds of formula (Ib) in which R⁴ represents a group -L³-R¹⁴where L³ is C₁₋₆alkylene, especially methylene, and R¹⁴ is—NH—C(=Z)-NH-L⁴-R¹⁶, in which Z, L⁴ and R¹⁶ are as defined hereinbefore,especially where L⁴ is methylene and R¹⁵ is aryl or heteroaryl, are alsopreferred.

[0149] Compounds of formula (Ib) in which R⁴ represents a group -L³-R¹⁴where L³ is C₁₋₆alkylene, especially C₁₋₃alkylene, preferably methylene,and R¹⁴ is —NY⁴Y⁵, where Y⁴ and Y⁵ are as defined hereinbefore,especially where Y⁴ and Y⁵ are hydrogen, are also preferred.

[0150] Compounds of formula (Ib) in which R⁴ represents a group -L³-R¹⁴where L³is C₁₋₆alkylene, especially methylene or ethylene, and R¹⁴ isaryl or heteroaryl, are also preferred.

[0151] Compounds of formula (Ib) in which R⁴ represents a group -L³-R¹⁴where L³is C₁₋₆alkylene, especially methylene, and R¹⁴ is—N(R¹⁰)—SO₂-R¹⁵, in which R¹⁰ and R¹⁵ are as defined hereinbefore,especially where R¹⁰ is hydrogen and R¹⁵ is alkyl, aryl or heteroaryl,are also preferred.

[0152] Compounds of formula (Ib) in which R⁴ represents a group -L³-R¹⁴where L³is C₁₋₆alkylene, especially methylene, and R¹⁴ is—N(R¹⁰)—SO₂-L⁴-R¹⁵, in which L⁴, R¹⁰ and R¹⁵ are as definedhereinbefore, especially where L⁴ is methylene, R¹⁰ is hydrogen and R¹⁵is alkyl, aryl or heteroaryl, are also preferred.

[0153] Compounds of formula (Ib) in which R⁵ represents hydrogen,C₁₋₄alkyl (e.g. methyl) or hydroxyC₁₋₄alkyl (.eg. hydroxymethyl)especially methyl are preferred.

[0154] Compounds of formula (Ib) in which R⁴ and R⁵ together with thecarbon atom to which they are attached represent a group C═CH₂ or a 5-7membered cyclic ether such as tetrahydrofuran-2-yl or perhydropyran-2-ylare also preferred.

[0155] Compounds of formula (Ib) in which R¹⁸ is —NY⁴Y⁵, where Y⁴ and Y⁵are as hereinbefore defined, especially where Y⁴ is hydrogen and Y⁵ is(i) arylalkyl, particularly optionally substituted benzyl or optionallysubstituted α-methylbenzyl (in which the phenyl group may be optionallysubstituted by one or more aryl group substituents, especially halo,methoxy, trifluoromethyl, methyl and methylenedioxy); (ii)heteroarylalkyl, particularly azaheteroaryl-alkyl, more particularlyazaheteroaryl-CH₂—; (iii) C₂₋₆alkyl substituted by alkoxy, particularlyC₂₋₆alkyl substituted by methoxy; (iv) C₂₋₆alkyl substituted by —NY¹Y²,particularly C₂₋₆alkyl substituted by —NMe₂; (v) C₂₋₆alkyl substitutedby hydroxy; (vi) cycloalkyl or (vii) aryl, especially phenyl optionallysubstituted by one or more aryl group substituents, especially halo,methoxy, trifluoromethyl, methyl or methylenedioxy; are preferred.

[0156] Compounds of formula (Ib) in which R¹⁸ is —OR¹⁷, where R¹⁷ is ashereinbefore defined, especially where R¹⁷ is alkyl, aryl (especiallyphenyl optionally substituted by one or more aryl group substituents,especially halo, methoxy, trifluoromethyl, methyl or methylenedioxy) orcycloalkyl, are also preferred.

[0157] A preferred group of compounds of the invention are compounds offormula (Ib) in which R⁴ is a group -L³-R¹⁴ {where L³ is a direct bondand R¹⁴ is (i) —NY⁴Y⁵, preferably —NH₂; (ii) —N(R¹⁰)—C(=Z)-R¹⁵,preferably —NH—C(═O)-alkyl, —NH—C(═O)-aryl or —NH—C(═O)-heteroaryl,especially —NH—C(═O)-aryl, particularly where aryl is substituted, ormore preferably, unsubstituted phenyl; (iii) —N(R ¹⁰)—C(=Z)-L⁴-R¹⁶,preferably —NH—C(═O)—CH₂-aryl or —NH—C(O)—CH₂-heteroaryl, particularlywhere aryl is substituted, or more preferably, unsubstituted phenyl;(iv) —C(=Z)-NY⁴Y⁵, preferably —C(═O)—NH₂; (v) —C(=Z)-NY⁴Y⁵, preferably—C(═O)—NY⁴Y⁵ where the group —NY⁴Y⁵ forms a 5-7 membered cyclic amine[which may optionally contain a further heteroatom selected from O, S orNY⁶ (where Y⁶ is as defined hereinbefore), preferably a 5-7 memberedcyclic amine optionally containing oxygen, especially a morpholinering]; (vi) -C(=Z)OR⁹, particularly —CO₂Me; or (vii) alkyl, especiallymethyl}.

[0158] R⁵ represents hydrogen, C₁₋₄alkyl (e.g. methyl) orhydroxyC₁₋₄alkyl (e.g. hydroxymethyl), especially methyl and R¹⁸represents —NY⁴Y⁵ {where Y⁴ and Y⁵ are as hereinbefore defined,especially where Y⁴ is hydrogen and Y⁵ is (i) arylalkyl, particularlybenzyl or cc-methylbenzyl; (ii) heteroarylalkyl, particularlyazaheteroaryl-alkyl, more particularly azaheteroaryl-CH₂—; (iii)C₂₋₆alkyl substituted by alkoxy, particularly C₂₋₆alkyl substituted bymethoxy; (iv) C₂₋₆alkyl substituted by —NY¹Y², particularly C₂₋₆alkylsubstituted by —NMe₂; (v) C₂₋₆alkyl substituted by hydroxy; (vi)cycloalkyl or (vii) aryl, especially phenyl optionally substituted byone or more aryl group substituents, especially halo, methoxy,trifluoromethyl, methyl or methylenedioxy} or —OR¹⁷, where R¹⁷ is alkylor cycloalkyl; and N-oxides thereof, and their prodrugs; andpharmaceutically acceptable salts and solvates (e.g. hydrates) ofcompounds of formula (Ia) herein and N-oxides thereof, and theirprodrugs.

[0159] A further preferred group of compounds of formula (Ib) arecompounds in which R⁴ is a group -L³-R¹⁴ {where L³ is a methylenelinkage and R¹⁴ is (i) hydroxy; (ii) —N(R¹⁰)—C(=Z)-R¹⁵, preferably—NH—C(═O)-alkyl, —NH—C(═O)-aryl or —NH—C(═O)-heteroaryl; (iii)—N(R¹⁰)—C(=Z)-L⁴-R¹⁶, preferably —NH—C(═O)—CH₂-aryl or—NH—C(═O)—CH₂-heteroaryl; (iv) —NH—C(=Z)-NH—R¹⁵ preferably—NH—C(═O)—NH-alkyl, —NH—C(═O)—NH-aryl or —NH—C(═O)—NH-heteroaryl;(v)NH—C(=Z)-NH-L⁴-R¹⁶ preferably —NH—C(═O)—NH—CH₂-alkyl,—NH—C(═O)—NH—CH₂-aryl or —NH—C(═O)—NH—CH₂-heteroaryl; (vi) —NY⁴Y⁵,preferably —NH₂; (vii) aryl; (viii) heteroaryl; (ix) —N(R¹⁰)—SO₂—R¹⁵,preferably —NH—SO₂-alkyl, NH—SO₂-aryl or —NH—SO₂-heteroaryl} and R⁵represents hydrogen, C₁₋₄alkyl (e.g. methyl) or hydroxyC₁₋₄alkyl (e.g.hydroxymethyl), especially methyl and R¹⁸ represents —NY⁴Y⁵ {where Y⁴and Y⁵ are as hereinbefore defined, especially where Y⁴ is hydrogen andY⁵ is (i) arylalkyl, particularly benzyl or α-methylbenzyl; (ii)heteroarylalkyl, particularly azaheteroarylalkyl, more particularlyazaheteroaryl-CH₂—; (iii) C₂₋₆alkyl substituted by alkoxy, particularlyC₂₋₆alkyl substituted by methoxy; (iv) C₂₋₆alkyl substituted by —NY¹Y²,particularly C₂₋₆alkyl substituted by —NMe₂; (v) C₂₋₆alkyl substitutedby hydroxy; or (vi) cycloalkyl} or —OR¹⁷, where R¹⁷ is alkyl orcycloalkyl; and N-oxides thereof, and their prodrugs; andpharmaceutically acceptable salts and solvates (e.g. hydrates) ofcompounds of formula (Ia) herein and N-oxides thereof, and theirprodrugs.

[0160] A particular group of compounds of the invention are thoseselected from the following:

[0161]{2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,cis-isomer, (Compound A);

[0162]{2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound B);

[0163]4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-1H-imidazol4-yl]-pyridine,(Compound C);

[0164]C-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5yl]-methylamine,cis- and trans-isomers, (Compound D);

[0165]2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-yl]acetamide,cis- and trans-isomers, (Compound E);

[0166]2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-yl]-acetamide,cis-isomer, (Compound F);

[0167]2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-yl]-acetamide,trans-isomer, (Compound G);

[0168]4-[2-(5-azidomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-pyridine,cis- and trans-isomers, (Compound H);

[0169]4-[2-(5-benzyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-pyridine,cis- and trans-isomers, (Compound I);

[0170]2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methyl ester, cis- and trans-isomers, (Compound J);

[0171]4-[5-(4-fluoro-phenyl)-2-(1,8,10-trioxa-spiro[5.5]undec-9-yl)-1H-imidazol-4-yl]-pyridine,(Compound K);

[0172]4-[5-(4-fluoro-phenyl)-2-(1,7,9-trioxa-spiro[4.5]dec-8-yl)-1H-imidazol-4-yl]-pyridine,(Compound L);

[0173]4-[2-(5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyridine,(Compound M);

[0174]4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyridine,(Compound N);

[0175]4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyridine,(Compound O);

[0176]4-[5-(4-fluoro-phenyl)-2-(4-methyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyridine,(R/S)(R/S) isomers, (Compound P);

[0177]4-[2-(4,6-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyridine,(R/S)(R/S)(R/S) isomers, (Compound Q);

[0178]4-[2-(5-benzyloxy-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyridine,cis- and trans-isomers, (Compound R);

[0179]4-[5-(4-fluoro-phenyl)-2-(5-phenyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyridine,cis- and trans-isomers, (Compound S);

[0180]4-[5-(4-fluoro-phenyl)-2-(4-isopropyl-5,5-dimethyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyridine,(R/S)(R/S) isomers, (Compound T);

[0181]4-[2-(5,5-diethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyridine,(Compound U);

[0182]4-[2-(2,4-dioxa-spiro[5.5]undec-8-en-3-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyridine,cis- and trans-isomers, (Compound V);

[0183]N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3dioxan-5-yl}-benzamide,cis- and trans-isomers, (Compound W);

[0184]1-(4-fluoro-phenyl)-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-thiourea,cis- and trans-isomers, (Compound X);

[0185]1-(2,6-dimethyl-phenyl)-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-thiourea,cis- and trans-isomers, (Compound Y);

[0186]4-[5-(4-fluoro-phenyl)-2-(5-methyl-5-pyrrol-1-yl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyridine,cis- and trans-isomer, (Compound Z);

[0187]C-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-yl]-methylamine,trans-isomer, (Compound AA);

[0188]C-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-yl]-methylamine,cis-isomer, (Compound AB);

[0189]2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylmethyl]-acetamide,trans-isomer, (Compound AC);

[0190]2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylmethyl]-acetamide,cis-isomer, (Compound AD);

[0191]5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylamine,cis-isomer, (Compound AE);

[0192]5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylamine,trans-isomer, (Compound AF);

[0193]5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylamine,cis- and trans-isomers, (Compound AG);

[0194]2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid, trans-isomer, (Compound AH);

[0195]2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid, cis-isomer, (Compound AI);

[0196]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, cis-isomer, (Compound AJ);

[0197]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound AK);

[0198]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)amide, trans-isomer, (Compound AL);

[0199]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound AM);

[0200]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound AN);

[0201]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (pyridin-2-ylmethyl)-amide, trans-isomer, (Compound AO);

[0202]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (pyridin-3-ylmethyl)-amide, trans-isomer, (Compound AP);

[0203] 2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylic acid(pyridin-4-ylmethyl)-amide, trans-isomer, (Compound AQ);

[0204]{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound AR);

[0205]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound AS);

[0206]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid [2-(1H-indol-3-yl)-ethyl]-amide, trans-isomer, (Compound AT);

[0207]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound AU);

[0208]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound AV);

[0209]{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound AW);

[0210]{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-pyrrolidin-1-yl-methanone, trans-isomer, (Compound AX);

[0211]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid butylamide, trans-isomer, (Compound AY);

[0212]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dipropylamide, trans-isomer, (Compound AZ);

[0213]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound BA);

[0214]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenethyl-amide, trans-isomer, (Compound BB);

[0215]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-pyridin-2-yl-ethyl)-amide, trans-isomer, (Compound BC);

[0216]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (furan-2-ylmethyl)-amide, trans-isomer, (Compound BD);

[0217]{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound BE);

[0218]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound BF);

[0219]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound BG);

[0220]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound BH);

[0221]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopentylamide, trans-isomer, Compound BI);

[0222]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound BJ);

[0223]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, cis-isomer, (Compound BK);

[0224]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, cis-isomer, (Compound BL);

[0225]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, cis-isomer, (Compound BM);

[0226]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (pyridin-2-ylmethyl)-amide, cis-isomer, (Compound BN);

[0227]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (pyridin-3-ylmethyl)-amide, cis-isomer, (Compound BO);

[0228]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (pyridin-4-ylmethyl)-amide, cis-isomer, (Compound BP);

[0229]{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,cis-isomer, (Compound BQ);

[0230]{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,cis-isomer, (Compound BR);

[0231]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, cis-isomer, (Compound BS);

[0232]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid [2-(1H-indol-3-yl)-ethyl]-amide, cis-isomer, (Compound BT);

[0233]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, cis-isomer, (Compound BU);

[0234]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenethyl-amide, cis-isomer, (Compound BV);

[0235]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, cis-isomer, (Compound BW);

[0236]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-pyridin-2-yl-ethyl)-amide, cis-isomer, (Compound BX);

[0237]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (furan-2-ylmethyl)-amide, cis-isomer, (Compound BY);

[0238]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, cis-isomer, (Compound BZ);

[0239]{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-pyrrolidin-1-yl-methanone,cis-isomer, (Compound CA);

[0240]{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,cis-isomer, (Compound CB);

[0241]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, cis-isomer, (Compound CC);

[0242]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid butylamide, cis-isomer, (Compound CD);

[0243]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, cis-isomer, (Compound CE);

[0244]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopentylamide, cis-isomer, (Compound CF);

[0245]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, cis-isomer, (Compound CG);

[0246]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, cis-isomer, (Compound CH);

[0247]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, cis-isomer, (Compound CI);

[0248]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, cis-isomer, (Compound CJ);

[0249]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dipropylamide, cis-isomer, (Compound CK);

[0250]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid ethylamide, cis-isomer, (Compound CL);

[0251]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound CM);

[0252]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound CN);

[0253]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid ethylamide, trans-isomer, (Compound CO);

[0254]1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-3-phenyl-urea,cis-isomer, (Compound CP);

[0255]1-ethyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3-dioxan-5-yl}-urea,cis-isomer, (Compound CQ);

[0256]1-(3,5-dimethyl-isoxazol-4-yl)-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-urea,cis-isomer, (Compound CR);

[0257]1-benzyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-urea,cis-isomer, (Compound CS);

[0258]1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-3-(2-thiophen-2-yl-ethyl)-urea,cis-isomer, (Compound CT);

[0259]1-(3-acetyl-phenyl)-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-urea,cis-isomer, (Compound CU);

[0260]1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-3-phenyl-urea,trans-isomer, (Compound CV);

[0261]3-(3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-ureido)-benzoicacid, trans-isomer, (Compound CW);

[0262]1-benzyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3-dioxan-5-yl}-urea,trans-isomer, (Compound CX);

[0263]1-ethyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-urea,trans-isomer, (Compound CY);

[0264]1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-3-(2-thiophen-2-yl-ethyl)-urea,trans-isomer, (Compound CZ);

[0265]1-benzyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-urea,cis-isomer, (Compound DA);

[0266]1-ethyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5ylmethyl}-urea,cis-isomer, (Compound DB);

[0267]1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3dioxan-5-ylmethyl}-3-phenyl-urea,cis-isomer, (Compound DC);

[0268]1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3dioxan-5-ylmethyl}-3-phenyl-urea,trans-isomer, (Compound DD);

[0269]1-benzyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-urea,trans-isomer, (Compound DE);

[0270]1-ethyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-urea,trans-isomer, (Compound DF);

[0271]1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-3-(2-morpholin-4-yl-ethyl)-thiourea,cis-isomer, (Compound DG);

[0272]1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-3-furan-3-ylmethyl-thiourea,cis-isomer, (Compound DH);

[0273]1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5yl}-3-pyridin-3-yl-thiourea,cis-isomer, (Compound DI);

[0274]1-benzo[1,3]dioxol-5-yl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-thiourea,cis-isomer, (Compound DJ);

[0275]1-benzo[1,3]dioxol-5-ylmethyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-thiourea,cis-isomer, (Compound DK);

[0276]1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-3-pyridin-3-yl-thiourea,trans-isomer, (Compound DL);

[0277]1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-3-(2-morpholin-4-yl-ethyl)-thiourea,trans-isomer, (Compound DM);

[0278]1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-3-furan-2-ylmethyl-thiourea,trans-isomer, (Compound DN);

[0279]1-benzo[1,3]dioxol-5-ylmethyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-thiourea,trans-isomer, (Compound DO);

[0280]1-benzo[1,3]dioxol-5-yl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-thiourea,cis-isomer, (Compound DP);

[0281]1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-3-furan-2-ylmethyl-thiourea,cis-isomer, (Compound DQ);

[0282]3-(3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-thioureido)-benzoicacid, cis-isomer, (Compound DR);

[0283]1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-3-pyridin-3-yl-thiourea,cis-isomer, (Compound DS);

[0284]1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-3-(2-morpholin-4-yl-ethyl)-thiourea,cis-isomer, (Compound DT);

[0285]1-benzo[1,3]dioxol-5-ylmethyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-thiourea,cis-isomer, (Compound DU);

[0286]N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-acetamide,cis-isomer, (Compound DV);

[0287]N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-2-phenyl-acetamide,cis-isomer, (Compound DW);

[0288] cyclohexanecarboxylic acid{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-amide,cis-isomer, (Compound DX);

[0289]2-benzyloxy-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-acetamide,trans-isomer, (Compound DY);

[0290]2-benzyloxy-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-acetamide,cis-isomer, (Compound DZ);

[0291]N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-acetamide,trans-isomer, (Compound EA);

[0292]N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-2-phenyl-acetamide,trans-isomer, (Compound EB);

[0293] cyclohexanecarboxylic acid{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-amide,trans-isomer, (Compound EC);

[0294]N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-2-phenyl-acetamide,cis-isomer, (Compound ED);

[0295]2-benzyloxy-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound EE);

[0296]N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound EF);

[0297]N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound EG);

[0298]N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound EH);

[0299] cyclohexanecarboxylic acid{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-amide,cis-isomer, (Compound EI);

[0300]N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,trans-isomer, (Compound EJ);

[0301]N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,trans-isomer, (Compound EK);

[0302] cyclohexanecarboxylic acid{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-amide,trans-isomer, (Compound EL);

[0303]N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,trans-isomer, (Compound EM);

[0304]4-{2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}-butyricacid, cis-isomer, (Compound EN);

[0305]4-({2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-carbamoyl)-butyricacid, cis-isomer, (Compound EO);

[0306]4-{2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}-propionicacid, cis-isomer, (Compound EP);

[0307]4-({2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-carbamoyl)-propionicacid, cis-isomer, (Compound EQ);

[0308]4-({2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-carbamoyl)-propionicacid, trans-isomer, (Compound ER);

[0309]N-{2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanesulphonamide,cis-isomer, (Compound ES);

[0310]N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulphonamide,cis-isomer, (Compound ET);

[0311]N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzenesulphonamide,cis-isomer, (Compound EU);

[0312]N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-C-phenyl-methanesulphonamide,cis-isomer, (Compound EV);

[0313] thiophene-2-sulphonic acid{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-amide,cis-isomer, (Compound EW);

[0314] 3,5-dimethyl-isoxazole-4-sulphonic acid{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-amide,cis-isomer, (Compound EX);

[0315]N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulphonamide,trans-isomer, (Compound EY);

[0316]N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzenesulphonamide,trans-isomer, (Compound EZ);

[0317] thiophene-2-sulphonic acid{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-amide,trans-isomer, (Compound FA);

[0318] 3,5-dimethyl-isoxazole-4-sulphonic acid{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-amide,trans-isomer, (Compound FB);

[0319]3-amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-propionamide,trans-isomer, (Compound FC);

[0320]3-amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-propionamide,cis-isomer, (Compound FD);

[0321]4-amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-butyramide,trans-isomer, (Compound FE);

[0322]4-amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-butyramide,cis-isomer, (Compound FF);

[0323]2-amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-acetamide,trans-isomer, (Compound FG);

[0324]2-amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-acetamide,cis-isomer, (Compound FH);

[0325](3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}-ethyl)-carbamicacid benzyl ester, trans-isomer, (Compound FI);

[0326](3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}-ethyl)-carbamicacid benzyl ester, cis-isomer, (Compound FJ);

[0327](3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}-propyl)-carbamicacid benzyl ester, trans-isomer, (Compound FK);

[0328](3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}-propyl)-carbamicacid benzyl ester, cis-isomer, (Compound FL);

[0329](3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}-methyl)-carbamicacid benzyl ester, trans-isomer, (Compound FM);

[0330](3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}-methyl)-carbamicacid benzyl ester, cis-isomer, (Compound FN);

[0331]4-dimethylamino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-butyramide,cis- and trans-isomers, (Compound FO);

[0332]N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-benzamide,trans-isomer, (Compound FR);

[0333]{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-hydroxy-piperidin-1-yl)-methanone,trans isomer, (Compound FS);

[0334](1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanone,trans isomer, (Compound FT);

[0335]1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carbonyl}-piperidine-4-carboxylicacid ethyl ester, trans isomer, (Compound FU);

[0336]1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carbonyl}-piperidine-4-carboxylicacid, trans isomer, (Compound FV);

[0337]{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-thiomorpholin-4-yl-methanone,trans isomer, (Compound FW);

[0338](1,1-dioxothiomorpholin-4-yl)-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanone,trans isomer, (Compound FX);

[0339]{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxymethyl-piperidin-1-yl)-methanone,trans isomer, (Compound FY);

[0340]{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-piperidin-1-yl)-methanone,trans isomer, (Compound FZ);

[0341](2,6-dimethyl-morpholin-4-yl)-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanone,trans isomer, (Compound GA);

[0342]{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans isomer, (Compound GB);

[0343]{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methoxy-piperidin-1-yl)-methanone,trans isomer, (Compound GC);

[0344]{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-[4-(2-hydroxy-ethyl)-piperidin-1-yl]-methanone,trans isomer, (Compound GD);

[0345]{5-Amino-2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,cis isomer, (Compound LE);

[0346]{5-Amino-2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans isomer, (Compound LF);

[0347]{2-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-nitro-[1,3]dioxan-5-yl}-methanol,cis isomer, (Compound LG);

[0348]{2-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-nitro-[1,3]dioxan-5-yl}-methanol,trans isomer,(Compound LH);

[0349]C-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5,5-dimethyl-[1,3]dioxan-4-yl}-methylamine(Compound LI);

[0350]4-[2-(5,5-dimethyl-4-nitromethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyridine(Compound LJ); and the corresponding N-oxides, and their prodrugs; andpharmaceutically acceptable salts and solvates (e.g. hydrates) of suchcompounds and their N-oxides and prodrugs.

[0351] A further particular group of compounds of the invention arethose selected from the following:

[0352]{2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl-}-morpholin-4-yl-methanone,trans isomer, (Compound GE);

[0353]2-[5-(2-Amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound GI);

[0354]{2-[5-(2-Dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl-}-morpholin-4-yl-methanone,trans-isomer, (Compound GJ);

[0355](2-{4-(4-Fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone, trans-isomer, (Compound GK);

[0356](2-{4-(4-Fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound GL);

[0357]{2-[4-(4-Fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound GM);

[0358](2-{4-(4-Fluoro-phenyl)-5-[2-(1-ethoxycarbonylpiperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin4-yl-methanone,trans-isomer, (Compound GN);

[0359]{2-[5-(2-Cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound GO);

[0360](2-{4-(4-Fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound GP);

[0361]{2-[5-[2-(2-Amino-ethylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound GQ);

[0362][2-(4-(4-Fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone,trans-isomer, (Compound GR);

[0363](2-{4-(4-Fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin4-yl-methanone,trans-isomer, (Compound GS);

[0364]2-[5-(2-Benzylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound GT);

[0365](2-{4-(4-Fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,R isomer, trans-isomer, (Compound GU);

[0366](2-{4-(4-Fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,S isomer, trans-isomer, (Compound GV);

[0367]{2-[4-(4-Fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound GW);

[0368]{2-[4-(4-Fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound GX);

[0369][2-(4-(4-Fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-morpholin4-yl-methanone,trans-isomer, (Compound GY);

[0370][2-(4-(4-Fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone,trans-isomer, (Compound GZ);

[0371][2-(4-(4-Fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone,trans-isomer, (Compound HA);

[0372][2-(4-(4-Fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone,trans-isomer, (Compound HB);

[0373][2-(4-(4-Fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone,trans-isomer, (Compound HC);

[0374][2-(4-(4-Fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone,trans-isomer, (Compound HD);

[0375](2-{4-(4-Fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound HE);

[0376]{2-[4-(4-Fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin4-yl-methanone,trans-isomer, (Compound HF);

[0377](2-{4-(4-Fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin4-yl-methanone,trans-isomer, (Compound FG);

[0378]{2-[5-[2-(3-Dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin4-yl-methanone,trans-isomer, (Compound HH);

[0379]{2-[5-[2-(2-Dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin4-yl-methanone,trans-isomer, (Compound HI);

[0380](4-{5-(4-Fluoro-phenyl)-2-[5-methyl-5-(morpholine4-carbonyl)-[1,3]dioxan-2-yl]-3H-imidazol-4yl}-pyrimidin-2-ylamino)-aceticacid, trans-isomer, (Compound HJ);

[0381]3-(4-{5-(4-Fluoro-phenyl)-2-[5-methyl-5-(morpholine4-carbonyl)-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-propionicacid, trans-isomer, (Compound HK);

[0382]4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamine,(Compound HL);

[0383]{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-pyrimidin-2yl}-methyl-amine,(Compound HM);

[0384]{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-dimethyl-amine,(Compound HN);

[0385]cyclopropyl-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-amine,(Compound HO);

[0386]cyclohexyl-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-amine,(Compound HQ);

[0387]2-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-ethanol,(Compound HR);

[0388]N1-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-ethane-1,2-diamine,(Compound HS);

[0389]{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-pyrimidin-2-yl}-[3-(5H-imidazol-1-yl)-propyl]-amine,(Compound HT);

[0390]{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(3-morpholin-4-yl-propyl)-amine,(Compound HU);

[0391]3-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propan-1-ol,(Compound HV);

[0392]benzyl-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-amine,(Compound HW);

[0393]{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(1-phenyl-ethyl)-amine,R-isomer, (Compound HX);

[0394]{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(1-phenyl-ethyl)-amine,S-isomer, (Compound HY);

[0395]{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-phenyl-amine,(Compound HZ);

[0396]4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-2-piperidin-1-yl-pyrimidine,(Compound IA);

[0397]{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-pyridin-4-ylmethyl-amine,(Compound IB);

[0398]{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-pyridin-2-ylmethyl-amine,(Compound IC);

[0399]{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-pyridin-3-ylmethyl-amine,(Compound ID);

[0400]{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(furan-2-ylmethyl)-amine,(Compound IE);

[0401]{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2yl}-(thiophen-2-ylmethyl)-amine,(Compound IF);

[0402]{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(tetrahydro-furan-2-ylmethyl)-amine,(Compound IG);

[0403]4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-2-(4-methyl-piperazin-1-yl-pyrimidine,(Compound IH);

[0404]4-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-morpholine,(Compound IJ);

[0405]{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(3-methoxy-propyl)-amine,(Compound IK);

[0406]{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(2-methoxy-ethyl)-amine,(Compound IL);

[0407]N-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-N′,N′-dimethyl-propane-1,3-diamine,(Compound IM);

[0408]N-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-N′,N′-dimethyl-ethane-1,2-diamine,(Compound IN);

[0409]{2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound IO)

[0410]{2-[4-(4-Fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound IP);

[0411]{2-[5-(2-Benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound IQ);

[0412]{2-[4-(4-Fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound IR);

[0413](2-{4-(4-Fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound IS);

[0414]{2-[5-[2-(2-Dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound IT);

[0415](2-[5-(2-Cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-y}-morpholin-4-yl-methanone,trans-isomer, (Compound IU);

[0416]{2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound IW);

[0417]4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-2-methoxy-pyrimidine,(Compound IY);

[0418]2-benzyloxy-4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidine,(Compound IZ);

[0419]4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-2-phenoxy-pyrimidine,(Compound JA);

[0420]4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-2-(2-methoxy-ethoxy)-pyrimidine,(Compound JB);

[0421](2-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-pyrimidin-2-yloxy}-ethyl)-dimethyl-amine,(Compound JC);

[0422]2-cyclohexyloxy-4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidine,(Compound JD);

[0423]2-isopropoxy4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidine,(Compound JE);

[0424]4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-pyrimidin-2-ylamine,cis-isomer, (Compound JF);

[0425]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-methyl-amine,cis-isomer, (Compound JG);

[0426]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-dimethyl-amine,cis-isomer, (Compound JH);

[0427]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-cyclopropyl-amine,cis-isomer, (Compound JI);

[0428]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-piperidin-4-yl-amine,cis-isomer, (Compound JJ);

[0429]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-cyclohexyl-amine,cis-isomer, (Compound JK);

[0430]2-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-ethanol,cis-isomer, (Compound JL);

[0431]N1-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-ethane-1,2-diamine,cis-isomer, (Compound JM);

[0432]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-[3-(5H-imidazol-1-yl)-propyl]-amine,cis-isomer, (Compound JN);

[0433]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(3-morpholin-4-yl-propyl)-amine,cis-isomer, (Compound JO);

[0434]3-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propan-1-ol,cis-isomer, (Compound JP);

[0435]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-benzyl-amine,cis-isomer, (Compound JQ);

[0436]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(1-phenyl-ethyl)-amine,R isomer, cis-isomer, (Compound JR);

[0437]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(1-phenyl-ethyl)-amine,S isomer, cis-isomer, (Compound JS);

[0438]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-phenyl-amine,cis-isomer, (Compound JT);

[0439]2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylamine,cis-isomer, (Compound JU);

[0440]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-pyridin-4-ylmethyl-amine,cis-isomer, (Compound JV);

[0441]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-pyridin-2-ylmethyl-amine,cis-isomer, (Compound JW);

[0442]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2yl}-pyridin-3-ylmethyl-amine,cis-isomer, (Compound JX);

[0443]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(furan-2-ylmethyl)-amine,cis-isomer, (Compound JY);

[0444]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(thiophen-2-ylmethyl)-amine,cis-isomer, (Compound JZ);

[0445]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(tetrahydro-furan-2-ylmethyl)-amine,cis-isomer, (Compound KA);

[0446]2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylamine,cis-isomer, (Compound KB);

[0447]2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylamine,cis-isomer, (Compound KC);

[0448]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(3-methoxy-propyl)-amine,cis-isomer, (Compound KD);

[0449]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(2-methoxy-ethyl)-amine,cis-isomer, (Compound KE);

[0450]N-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-N′,N′-dimethyl-propane-1,3-diamine,cis-isomer, (Compound KF);

[0451]N-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-N′,N′-dimethyl-ethane-1,2-diamine,cis-isomer, (Compound KG);

[0452]{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans isomer, (Compound KH);

[0453]2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonylpyrimidin-4-yl)-1H-imidazol-2-yl]-5,5-dimethyl-[1,3]dioxane(Compound KI);

[0454]{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer (Compound KJ);

[0455]{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,cis-isomer (Compound KK);

[0456]2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methylene-[1,3]dioxane(Compound KL).

[0457]4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-2-methylsulphonyl-pyrimidine(Compound KM);

[0458]{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer (Compound KN);

[0459]{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,cis-isomer (Compound KO);

[0460]2,2,2-trifluoro-N-[2-{4-(4-fluoro-phenyl)-5-(2-methanesulphonylpyrimidin-4-yl)-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl]acetamide,cis-isomer (Compound KP);

[0461]{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans isomer, (Compound KQ);

[0462]2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanylpyrimidin-4-yl)-1H-imidazol-2-yl]-5,5-dimethyl-[1,3]dioxane(Compound KR);

[0463]2,2,2-trifluoro-N-[2-{4-(4-fluoro-phenyl)-5-(2-methylsulphanyl-pyrimidin-4-yl)-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl]acetamide,cis-isomer, (Compound KS);

[0464]{2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,cis isomer (Compound KT);

[0465]{2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans isomer (Compound KU);

[0466]4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-2-methylsulfanyl-pyrimidine(Compound KV);

[0467]4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-2-methylsulphanyl-pyrimidine(Compound KW);

[0468]{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer (Compound KX);

[0469]{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,cis-isomer (Compound KY);

[0470]C-{2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methylamine,cis isomer (Compound KZ);

[0471]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, cis isomer Compound LA);

[0472]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid, cis isomer (Compound LB);

[0473]2-[4-(4-fluorophenyl)-5-(2-methylsulphanylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-carboxylicacid methyl ester, trans isomer, (Compound LC);

[0474]2-[4-(4-fluorophenyl)-5-(2-methylsulphanylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-carboxylicacid methyl ester, cis isomer, (Compound LD);

[0475]2,2,2-trifluoro-N-{2-[5-(2-methylsulphonyl-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis isomer, (Compound LK);

[0476]2,2,2-trifluoro-N-{2-[5-(2-methylsulphonyl-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,trans isomer,(Compound LL);

[0477]2-[4-(4-fluorophenyl)-5-(2-methylsulphonylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-carboxylicacid methyl ester, trans isomer, (Compound LM);

[0478] 2-[4-(4-fluorophenyl)-5-(2-methylenesulphonylpyrimidin-4-yl)-H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-carboxylic acid methyl ester,cis isomer (Compound LN); and the corresponding N-oxides, and theirprodrugs; and pharmaceutically acceptable salts and solvates (e.g.hydrates) of such compounds and their N-oxides and prodrugs.

[0479] Preferred compounds of the invention include:

[0480]{2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,cis-isomer, (Compound A);

[0481]C-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-yl]-methylamine,cis- and trans-isomers, (Compound D);

[0482]4-[5-(4-fluoro-phenyl)-2-(4-isopropyl-5,5-dimethyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyridine,(R/S)(R/S) isomers, (Compound T);

[0483]C-[5-methyl-2-(5-phenyl-4-pyridin-4-yl-1H-imidazol-2-yl)-[1,3]dioxan-5-yl]-methylamine,trans-isomer, (Compound AA);

[0484]C-[5-methyl-2-(5-phenyl-4-pyridin-4-yl-1H-imidazol-2-yl)-[1,3]dioxan-5-yl]-methylamine,cis-isomer, (Compound AB);

[0485]5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylamine,cis-isomer, (Compound AE);

[0486]5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylamine,trans-isomer, (Compound AF);

[0487]5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylamine,cis- and trans-isomers, (Compound AG);

[0488]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound AN);

[0489]{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound AW);

[0490]2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, cis-isomer, (Compound BM);

[0491]amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-acetamide,trans-isomer, (Compound FC);

[0492]amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-acetamide,cis-isomer, (Compound FD);

[0493]N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-benzamide,trans-isomer, (Compound FR); and the corresponding N-oxides, and theirprodrugs; and pharmaceutically acceptable salts and solvates (e.g.hydrates) of such compounds and their N-oxides and prodrugs.

[0494] Further preferred compounds of the invention include:

[0495]{2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans isomer, (Compound GE);

[0496](2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans isomer, (Compound GI);

[0497]2-{4-(4-fluoro-phenyl)-5-[2-(1-ethoxycarbonylpiperdin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans isomer, (Compound GK);

[0498]{2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans isomer, (Compound GL);

[0499] and the corresponding N-oxides, and their prodrugs; andpharmaceutically acceptable salts and solvates (e.g. hydrates) of suchcompounds and their N-oxides and prodrugs.

[0500] A particularly preferred compound of the invention is{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound AW);

[0501] and the corresponding N-oxide, and its prodrugs; andpharmaceutically acceptable salts and solvates (e.g. hydrates) of thiscompound and its N-oxide and prodrugs, especially its methane sulphonicacid salt as depicted by Compound FP.

[0502] The compounds of the invention exhibit useful pharmacologicalactivity and accordingly are incorporated into pharmaceuticalcompositions and used in the treatment of patients suffering fromcertain medical disorders. The present invention thus provides,according to a further aspect, compounds of the invention andcompositions containing compounds of the invention for use in therapy.

[0503] Compounds within the scope of the present invention areinhibitors of the generation of tumour necrosis factor (TNF), especiallyTNF-alpha, according to tests described in the literature and describedin vitro and in vivo procedures hereinafter, and which tests results arebelieved to correlate to pharmacological activity in humans and othermammals. Thus, in a further embodiment, the present invention providescompounds of the invention and compositions containing compounds of theinvention for use in the treatment of a patient suffering from, orsubject to, conditions which can be ameliorated by the administration ofan inhibitor of TNF, especially of TNF-alpha. For example, compounds ofthe present invention are useful in the treatment of joint inflammation,including arthritis, rheumatoid arthritis and other arthritic conditionssuch as rheumatoid spondylitis, gouty arthritis, traumatic arthritis,rubella arthritis, psoriatic arthritis and osteoarthritis. Additionally,the compounds are useful in the treatment of acute synovitis,tuberculosis, atherosclerosis, muscle degeneration, cachexia, Reiter'ssyndrome, endotoxaemia, sepsis, septic shock, endotoxic shock, gramnegative sepsis, gout, toxic shock syndrome, chronic pulmonaryinflammatory diseases including asthma and adult respiratory distresssyndrome, silicosis, pulmonary sarcoidosis, bone resorption diseases,osteoporosis, restenosis, heart failure and myocardial ischaemicsyndromes, cardiac and renal reperfusion injury, thrombosis,glomerularnephritis, graft vs. host reaction, allograft rejection andleprosy. Furthermore, the compounds are useful in the treatment ofinfections such as viral infections, for example HIV, cytomegalovirus(CMV), influenza, adenovirus and the Herpes group of viruses, parasiticinfections, for example malaria such as cerebral malaria, and yeast andfungal infections, for example fungal meningitis; fever and myalgias dueto infection; AIDS; AIDS related complex (ARC); cachexia secondary toinfection or malignancy; cachexia secondary to acquired immunedeficiency syndrome (AIDS) or to cancer; keloid and scar tissueformation; pyresis; diabetes; inflammatory bowel diseases such asCrohn's disease and ulcerative colitis; eczema; contact dermititis;psoriasis; sunburn and conjunctivitis.

[0504] Compounds of the invention are also useful in the treatment ofdiseases of, or injury to, the brain in which over-production ofTNF-alpha has been implicated, such as multiple sclerosis, Alzheimersdisease, trauma, stroke and other ischaemic conditions.

[0505] Compounds of the invention may also be useful in inhibitingdiseases associated with over-production of other pro-inflammatorycytokines, IL-1, IL-6 and IL-8.

[0506] A special embodiment of the therapeutic methods of the presentinvention is the treating of asthma.

[0507] Another special embodiment of the therapeutic methods of thepresent invention is the treating of joint inflammation.

[0508] According to a further feature of the invention there is provideda method for the treatment of a human or animal patient suffering from,or subject to, conditions which can be ameliorated by the administrationof an inhibitor of TNF, especially TNF-alpha, for example conditions ashereinbefore described, which comprises the administration to thepatient of an effective amount of compound of the invention or acomposition containing a compound of the invention. “Effective amount”is meant to describe an amount of compound of the present inventioneffective in inhibiting TNF and thus producing the desired therapeuticeffect.

[0509] References herein to treatment should be understood to includeprophylactic therapy as well as treatment of established conditions.

[0510] The present invention also includes within its scopepharmaceutical compositions comprising at least one of the compounds ofthe invention in association with a pharmaceutically acceptable carrieror excipient.

[0511] Compounds of the invention may be administered by any suitablemeans. In practice compounds of the present invention may generally beadministered parenterally, topically, rectally, orally or by inhalation,especially by the oral route.

[0512] Compositions according to the invention may be prepared accordingto the customary methods, using one or more pharmaceutically acceptableadjuvants or excipients. The adjuvants comprise, inter alia, diluents,sterile aqueous media and the various non-toxic organic solvents. Thecompositions may be presented in the form of tablets, pills, granules,powders, aqueous solutions or suspensions, injectable solutions, elixirsor syrups, and can contain one or more agents chosen from the groupcomprising sweeteners, flavorings, colorings, or stabilizers in order toobtain pharmaceutically acceptable preparations. The choice of vehicleand the content of active substance in the vehicle are generallydetermined in accordance with the solubility and chemical properties ofthe active compound, the particular mode of administration and theprovisions to be observed in pharmaceutical practice. For example,excipients such as lactose, sodium citrate, calcium carbonate, dicalciumphosphate and disintegrating agents such as starch, alginic acids andcertain complex silicates combined with lubricants such as magnesiumstearate, sodium lauryl sulphate and talc may be used for preparingtablets. To prepare a capsule, it is advantageous to use lactose andhigh molecular weight polyethylene glycols. When aqueous suspensions areused they can contain emulsifying agents or agents which facilitatesuspension. Diluents such as sucrose, ethanol, polyethylene glycol,propylene glycol, glycerol and chloroform or mixtures thereof may alsobe used.

[0513] For parenteral administration, emulsions, suspensions orsolutions of the products according to the invention in vegetable oil,for example sesame oil, groundnut oil or olive oil, or aqueous-organicsolutions such as water and propylene glycol, injectable organic esterssuch as ethyl oleate, as well as sterile aqueous solutions of thepharmaceutically acceptable salts, are used. The solutions of the saltsof the products according to the invention are especially useful foradministration by intramuscular or subcutaneous injection. The aqueoussolutions, also comprising solutions of the salts in pure distilledwater, may be used for intravenous administration with the proviso thattheir pH is suitably adjusted, that they are judiciously buffered andrendered isotonic with a sufficient quantity of glucose or sodiumchloride and that they are sterilized by heating, irradiation ormicrofiltration.

[0514] For topical administration, gels (water or alcohol based), creamsor ointments containing compounds of the invention may be used.Compounds of the invention may also be incorporated in a gel or matrixbase for application in a patch, which would allow a controlled releaseof compound through the transdermal barrier.

[0515] For administration by inhalation compounds of the invention maybe dissolved or suspended in a suitable carrier for use in a nebulizeror a suspension or solution aerosol, or may be absorbed or adsorbed ontoa suitable solid carrier for use in a dry powder inhaler.

[0516] Solid compositions for rectal administration includesuppositories formulated in accordance with known methods and containingat least one compound of the invention.

[0517] The percentage of active ingredient in the compositions of theinvention may be varied, it being necessary that it should constitute aproportion such that a suitable dosage shall be obtained.

[0518] Obviously, several unit dosage forms may be administered at aboutthe same time. The dose employed will be determined by the physician,and depends upon the desired therapeutic effect, the route ofadministration and the duration of the treatment, and the condition ofthe patient. In the adult, the doses are generally from about 0.001 toabout 50, preferably about 0.001 to about 5, mg/kg body weight per dayby inhalation, from about 0.01 to about 100, preferably 0.1 to 70, moreespecially 0.5 to 10, mg/kg body weight per day by oral administration,and from about 0.001 to about 10, preferably 0.01 to 1, mg/kg bodyweight per day by intravenous administration. In each particular case,the doses will be determined in accordance with the factors distinctiveto the subject to be treated, such as age, weight, general state ofhealth and other characteristics which can influence the efficacy of themedicinal product.

[0519] The compounds according to the invention may be administered asfrequently as necessary in order to obtain the desired therapeuticeffect. Some patients may respond rapidly to a higher or lower dose andmay find much weaker maintenance doses adequate. For other patients, itmay be necessary to have long-term treatments at the rate of 1 to 4doses per day, in accordance with the physiological requirements of eachparticular patient. Generally, the active product may be administeredorally 1 to 4 times per day. Of course, for some patients, it will benecessary to prescribe not more than one or two doses per day.

[0520] Compounds of the invention may be prepared by the application oradaptation of known methods, by which is meant methods used heretoforeor described in the literature.

[0521] Compounds of the invention may be prepared by methods similar tothose described in EP424195 and EP506437.

[0522] In the reactions described hereinafter it may be necessary toprotect reactive functional groups, for example hydroxy, amino, imino,thio or carboxy groups, where these are desired in the final product, toavoid their unwanted participation in the reactions. Conventionalprotecting groups may be used in accordance with standard practice, forexamples see T. W. Greene and P. G. M. Wuts in “Protective Groups inOrganic Chemistry” John Wiley and Sons, 1991.

[0523] Compounds of this invention may be represented by the formula(Ic):—

[0524] wherein R⁴, R⁵, R⁶ and m are as hereinbefore defined and T¹represents a group of the formula:—

[0525] wherein R¹, R² and R³ are as hereinbefore defined.

[0526] In a process (A), compounds of formula (I), wherein R¹, R², R⁴,R⁵, R⁶ and m are as hereinbefore defined and R³ is hydrogen, may beprepared by reaction of compounds of formula (II):—

[0527] wherein R¹ and R² are as hereinbefore defined, R¹⁹ is hydrogen ora suitable protecting group, such as 2-trimethylsilanyl-ethoxymethyl,which is subsequently removed under the acidic reaction conditions andR²⁰ is —CHO or —CH(OMe)₂, with compounds of formula (III):—

[0528] wherein R⁴, R⁵, R⁶ and m are as hereinbefore defined. Thereaction may conveniently be carried out in the presence of an acidcatalyst, such as pyridinium 4-toluene sulphonate or 4-toluene sulphonicacid, in an inert solvent, such as toluene, at reflux temperature, withazeotropic removal of the water formed in the reaction.

[0529] Compounds of formula (I), wherein R¹, R², R⁴, R⁵, R⁶ and m are ashereinbefore defined and R³ represents a group -L¹-R⁷ (where L¹ and R⁷are as hereinbefore defined) or -L²-R⁸ (where L² is as hereinbeforedefined and R⁸ is aryl, cycloalkenyl, cycloalkyl, heteroaryl,heterocycloalkyl) may be similarly prepared by reaction of compounds offormula (II), wherein R¹, R² are as hereinbefore defined, R¹⁹ representsa group -L¹-R⁷ (where L¹ and R⁷ are as hereinbefore defined) or -L²-R⁸(where L² is as hereinbefore defined and R⁸ is aryl, cycloalkenyl,cycloalkyl, heteroaryl, heterocycloalkyl) and R²⁰ is —CHO or —CH(OMe)₂,with compounds of formula (III) wherein R⁴, R⁵, R⁶ and m are ashereinbefore defined.

[0530] In a process B, compounds of formula (I), wherein R², R³, R⁴, R⁵,R⁶ and m are as hereinbefore defined, and R¹ represents a group (IV):—

[0531] wherein R¹⁸ is Y⁴Y⁵N— (in which Y⁴ and Y⁵ are as hereinbeforedefined), may be prepared by:—

[0532] (i) treating Merrifield resin (chloromethylpolystyrene resin)with potassium thioacetate in an inert solvent, such asdimethylformamide, at a temperature at about room temperature, to giveResin A;

[0533] (ii) reaction of Resin A with lithium borohydride in an inertsolvent, such as tetrahydrofuran, and at a temperature at about roomtemperature, to give Resin B;

[0534] (iii) reaction of Resin B with an alkali metal hydride, such assodium hydride, in an inert solvent, such as dimethylformamide, at atemperature at about room temperature, followed by treatment withcompounds of formula (V);

[0535] wherein R², R³, R⁴, R⁵, R⁶ and m are as hereinbefore defined, ata temperature from about room temperature to about 80° C., to give ResinC;

[0536] in which R², R³, R⁴, R⁵, R⁶ and m are as hereinbefore defined;followed by appropriate functional group interconversions, for examplethose described hereinafter.

[0537] (iv) reaction of Resin C, in which R², R³, R⁴, R⁵, R⁶ and m areas hereinbefore defined, with m-chloroperoxybenzoic acid, in an inertsolvent or preferably in a mixture of inert solvents, such as a mixtureof dichloromethane and methanol, to give resin D, in which R², R³, R⁴,R⁵, R⁶ and m are as hereinbefore defined;

[0538] (v) reaction of Resin D, wherein R², R³, R⁴, R⁵, R⁶ and m are ashereinbefore defined, with amines of formula HNY⁴Y⁵, wherein Y⁴ and Y⁵are as hereinbefore defined, in an inert solvent, such asdimethoxyethane, and at a temperature at about 70° C.

[0539] Compounds of formula (I), wherein R², R³, R⁴, R⁵, R⁶ and m are ashereinbefore defined and R¹ represents a group (IV), wherein R¹⁸ is a—OR¹⁷ or —SR¹⁷ group (in which R¹⁷ is as hereinbefore defined), may beprepared by reaction of Resin D wherein R², R³, R⁴, R⁵, R⁶ and m are ashereinbefore defined, with compounds of formula R¹⁷OH or R¹⁷SH (in whichR¹⁷ is as hereinbefore defined), in the presence of an alkali metalhydride, such as sodium hydride, in an inert solvent, such asdimethylformamide, and at a temperature from about room temperature toabout 80° C.

[0540] According to a further feature of the present invention,compounds of the invention may be prepared by interconversion of othercompounds of the invention.

[0541] For example compounds of formula (I), wherein R¹, R², R⁴, R⁵, R⁶and m are as hereinbefore defined and R³is a group -L¹-R⁷ (in which L¹represents a straight- or branched-chain alkylene linkage containingfrom 1 to about 6 carbon atoms and R⁷ is as hereinbefore defined), maybe prepared by alkylation of compounds of formula (I) wherein R¹, R²,R⁴, R⁵,R⁶ and m are as hereinbefore defined and R³ is hydrogen, with analkyl halide of formula (IV):—

X¹-L¹-R⁷   (IV)

[0542] wherein L¹ and R⁷ are as hereinbefore defined immediately aboveand X¹ is a halogen atom, preferably a bromine atom. The alkylation mayfor example be carried out in the presence of a base, such as an alkalimetal hydride, e.g. sodium hydride, in dimethylformamide, or dimethylsulphoxide, at a temperature from about 0° C. to about 100° C.

[0543] As another example of the interconversion process, compounds offormula (I), wherein R¹, R², R⁴, R⁵, R⁶ and m are as hereinbeforedefined and R³is a group -L²-R⁸ (in which L² represents a straight- orbranched-carbon chain comprising from 2 to about 6 carbon atoms andcontains a double or triple carbon-carbon bond, and R⁸ is aryl,cycloalkenyl, cycloalkyl, heteroaryl, heterocycloalkyl), may besimilarly prepared by alkylation of compounds of formula (1), whereinR¹, R², R⁴, R⁵, R⁶ and m are as hereinbefore defined and R³ is hydrogen,with compounds of formula (V):—

X¹-L²-R⁸   (V)

[0544] wherein L² and R⁸ are as hereinbefore defined immediately aboveand X¹ is a halogen atom, preferably a bromine atom.

[0545] As another example of the interconversion process, compounds offormula (Ic), wherein T¹, R⁵,R⁶ and m are as hereinbefore defined and R⁴contains a —NH₂ group, may be prepared by reaction of compounds offormula (Ic) wherein T¹, R⁵, R⁶ and m are as hereinbefore defined, andR⁴ contains a —NHC(═O)CF₃ group, with a base such as potassium orammonium carbonate in methanol, or a mixture of methanol and water, at atemperature at about reflux temperature.

[0546] As another example of the interconversion process, compounds offormula (Ic), wherein T¹, R⁵, R⁶ and m are as hereinbefore defined andR⁴ contains a —N(R¹⁰)—C(═O)—R¹⁵ or —N(R¹⁰)—C(═O)-L⁴-R¹⁶ group (in whichR¹⁰, R¹⁵, R¹⁶ and L⁴ are as hereinbefore defined), may be prepared byreaction of compounds of formula (Ic) wherein T¹, R⁵, R⁶ and m are ashereinbefore defined, and R⁴ contains a —NHR¹⁰ group (in which R¹⁰ is ashereinbefore defined), with the appropriately substituted acid chlorideCl—C(═O)—R¹⁵ or Cl—C(═O)-L⁴-R¹⁶ (in which R¹⁵, R¹⁶ and L⁴ are ashereinbefore defined) in the presence of triethylamine in an inertsolvent such as tetrahydrofuran and at a temperature at about roomtemperature.

[0547] As another example of the interconversion process, compounds offormula (Ic), wherein T¹, R⁵, R⁶ and m are as hereinbefore defined, andR⁴ contains a —NH—C(═O)—R¹⁵ or —NH—C(═O)-L⁴-R¹⁶ group (in which R¹⁵, R¹⁶and L⁴ are as hereinbefore defined), may be prepared by reaction ofcompounds of formula (Ic), wherein T¹, R⁵, R⁶ and m are as hereinbeforedefined, and R⁴ contains a —NH₂ group, with the appropriatelysubstituted acid HO—C(═O)—R¹⁵ or HO—C(═O)-L⁴-R¹⁶ (in which R¹⁵, R¹⁶ andL⁴ are as hereinbefore defined) respectively, in the presence ofO-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate and diisopropylethylamine in dimethylformamide, atroom temperature. Other standard peptide coupling procedures may beemployed for the reaction, such as treatment with a carbodiimide, forexample dicyclohexylcarbodiimide, in the presence of triethylamine, ortreatment with 1-hydroxybenzotriazole and a carbodiimide, such as1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, in an inert solvent suchas dimethylformamide and at a temperature at about room temperature.

[0548] As another example of the interconversion process, compounds offormula (Ic), wherein T¹, R⁵, R⁶ and m are as hereinbefore defined andR⁴ contains a —NH—C(═O)—R¹⁵ or a —NH—C(═O)-L⁴-R¹⁶ group (in which R¹⁵,R¹⁶ and L⁴ are as hereinbefore defined), may be prepared by reaction ofcompounds of formula (Ic), wherein T¹, R⁵, R⁶ and m are as hereinbeforedefined and R⁴contains a —NH₂ group, with the appropriately substitutedacid anhydride R¹⁵—C(═O)—O—C(═O)—R¹⁵ or R¹⁶-L⁴-C(═O)—O—C(═O)-L⁴-R¹⁶ (inwhich R¹⁵, R¹⁶ and L⁴ are as hereinbefore defined) in the presence oftriethylamine or pyridine, in an inert solvent, such as tetrahydrofuran,and at a temperature at about room temperature.

[0549] As another example of the interconversion process, compounds offormula (Ic), wherein T¹, R⁵, R⁶ and m are as hereinbefore defined andR⁴ contains a —NH—C(═O)—NH—R¹⁵ or —NH—C(═O)—NH-L⁴-R¹⁶ group (in whichR¹⁵, R¹⁶ and L⁴ are as hereinbefore defined), may be prepared byreaction of compounds of formula (Ic) wherein T¹, R⁵, R⁶ and m are ashereinbefore defined and R⁴contains a —NH₂ group, with the appropriatelysubstituted isocyanate O═C═N—R¹⁵ or O═C═N-L⁴-R¹⁶ (in which R¹⁵, R¹⁶ andL⁴ are as hereinbefore defined), in an inert solvent, such astetrahydrofuran, and at a temperature at about room temperature.

[0550] As another example of the interconversion process, compounds offormula (Ic) wherein T¹, R⁵, R⁶ and m are as hereinbefore defined, andR⁴ contains a —NH—(C═S)—NH—R¹⁵ or —NH—(C═S)—NH-L⁴-R¹⁶ group (in whichR¹⁵, R¹⁶ and L⁴ are as hereinbefore defined), may prepared by reactionof compounds of formula (Ic) wherein T¹, R⁵, R⁶ and m are ashereinbefore defined, and R⁴contains a —NH₂ group, with theappropriately substituted isothiocyanate S═C═N—R¹⁵ or S═C═N-L⁴-R¹⁶ (inwhich R¹⁵, R¹⁶ and L⁴ are as hereinbefore defined), in an inert solvent,such as tetrahydrofuran, and at a temperature at about refluxtemperature.

[0551] As another example of the interconversion process, compounds offormula (Ic), wherein T¹, R⁵, R⁶ and m are as hereinbefore defined andR⁴ contains a —CO₂H group, may be prepared by hydrolysis ofcorresponding compounds of formula (Ic), wherein T¹, R⁵, R⁶ and m are ashereinbefore defined and R⁴ contains a —CO₂R²¹ group (in which R²¹ is ashereinbefore defined). The hydrolysis may conveniently be carried out byalkaline hydrolysis using a base, such as an alkali metal hydroxide orcarbonate, in the presence of an aqueous/organic solvent mixture, usingorganic solvents such as dioxan, tetrahydrofuran or methanol, at atemperature from about ambient to about reflux. The hydrolysis may alsobe carried out by acid hydrolysis using an inorganic acid, such ashydrochloric acid, in the presence of an aqueous/inert organic solventmixture, using organic solvents such as dioxan or tetrahydrofuran, at atemperature from about 50° C. to about 80° C.

[0552] As another example of the interconversion process, compounds offormula (Ic), wherein T¹, R⁵, R⁶ and m are as hereinbefore defined andR⁴ contains a —C(═O)—NY⁴Y⁵ group (in which Y⁴ and Y⁵ are as hereinbeforedefined), may be prepared by reaction of compounds of formula (Ic),wherein T¹, R⁵, R⁶ and m are as hereinbefore defined and R⁴ contains a—CO₂H group, with an appropriately substituted amine of formula HNY⁴Y⁵(in which Y⁴ and Y⁵ are as hereinbefore defined). The coupling reactionmay conveniently be carried out in the presence of1-hydroxybenzotriazole and a carbodiimide such as1-(3-dimethylaminopropyl)-3-ethylcarbodiimide in an inert solvent suchas dimethylformamide and at a temperature at about room temperature.Alternatively the reaction may be carried out by initial conversion ofthe acid of formula (Ic), wherein R⁴ contains a —CO₂H group, to thecorresponding acid chloride (for example by reaction with thionylchloride or oxalyl chloride at room temperature) followed by treatmentwith an appropriately substituted amine of formula HNY⁴Y⁵.

[0553] As another example of the interconversion process, compounds offormula (I) containing sulphoxide linkages may be prepared by theoxidation of corresponding compounds containing —S— linkages. Forexample, the oxidation may conveniently be carried out by means ofreaction with a peroxyacid, e.g. 3-chloroperbenzoic acid, preferably inan inert solvent, e.g. dichloromethane, preferably at or near roomtemperature, or alternatively by means of potassium hydrogenperoxomonosulphate in a medium such as aqueous methanol, buffered toabout pH5, at temperatures between about 0° C. and room temperature.This latter method is preferred for compounds containing an acid-labilegroup.

[0554] As another example of the interconversion process, compounds offormula (Ic), wherein T¹, R⁵, R⁶ and m are as hereinbefore defined andR⁴ contains a —N(R¹⁰)—SO₂—R¹⁵ or —N(R¹⁰)—SO₂-L⁴-R¹⁶ group (in which R¹⁰,R¹⁵, R¹⁶ and L⁴ are as hereinbefore defined), may be prepared from thecorresponding compounds of of formula (Ic) wherein T¹, R⁵, R⁶ and m areas hereinbefore defined and R⁴ contains a —NH₂ group by treatment withthe appropriately substituted acid chloride Cl—SO₂—R¹⁵ or Cl—SO₂-L⁴-R¹⁶(in which R¹⁵, R¹⁶ and L⁴ are as hereinbefore defined), in presence of asuitable base, such as triethylamine, in an inert solvent, such astetrahydrofuran, and at a temperature at about room temperature.

[0555] As another example of the interconversion process, compounds offormula (I) containing sulphone linkages may be prepared by theoxidation of corresponding compounds containing —S— or sulphoxidelinkages. For example, compounds of formula (Ib) where R¹⁸ is —SO₂Me mayconveniently be prepared by means of reaction of compounds of formula(Ib) where R¹⁸ is —SMe with a peroxyacid, e.g. 3-chloroperbenzoic acid,preferably in an inert solvent, such as dichloromethane, at atemperature from about 0° C. to about room temperature.

[0556] As another example of the interconversion process, compounds offormula (Ib), wherein R⁴ and R⁵ are as hereinbefore defined and R¹⁸ is a—NY⁴Y⁵ group (in which Y⁴ is hydrogen and Y⁵ is as hereinbeforedefined), may be prepared by reaction of compounds of formula (Ib),where R¹⁸ is a —SO₂Me group, with an appropriately substituted amine offormula Y⁵ (in which Y⁵ is as hereinbefore defined). The reaction mayconveniently be carried out in an inert solvent such asdimethylformamide at a temperature up to about 100° C. When Y⁵ ishydrogen the reaction may be conveniently carried out in a sealedvessel. When Y⁵ is aryl, for example phenyl, the reaction may beconveniently carried out with the lithio-anion of the amine.

[0557] As another example of the interconversion process, compounds offormula (Ib), wherein R⁴ and R⁵ are as hereinbefore defined and R¹⁸ is a—OR¹⁷ group (in which R¹⁷ is as hereinbefore defined), may be preparedby reaction of compounds of formula (Ib), where R¹⁸ is a —SO₂Me group,with an appropriately substituted alcohol of formula R¹⁷OH (in which R¹⁷is as hereinbefore defined). The reaction may conveniently be carriedout in the presence of an alkali metal hydride, such as sodium hydride,in a mixture of inert solvents, for example tetrahydrofuran anddimethylformamide, and at a temperature at about room temperature.

[0558] It will be appreciated that compounds of the present inventionmay contain asymmetric centres. These asymmetric centres mayindependently be in either the R or S configuration. It will be apparentto those skilled in the art that certain compounds of the invention mayalso exhibit geometrical isomerism. It is to be understood that thepresent invention includes individual geometrical isomers andstereoisomers and mixtures thereof, including racemic mixtures, ofcompounds of formula (I) hereinabove. Such isomers can be separated fromtheir mixtures, by the application or adaptation of known methods, forexample chromatographic techniques and recrystallisation techniques, orthey are separately prepared from the appropriate isomers of theirintermediates. Additionally, in situations where tautomers of thecompounds of formula (I) are possible, the present invention is intendedto include all tautomeric forms of the compounds.

[0559] According to a further feature of the invention, acid additionsalts of the compounds of this invention may be prepared by reaction ofthe free base with the appropriate acid, by the application oradaptation of known methods. For example, the acid addition salts of thecompounds of this invention may be prepared either by dissolving thefree base in water or an aqueous alcohol solution or other suitablesolvents containing the appropriate acid and isolating the salt byevaporating the solution, or by reacting the free base and acid in anorganic solvent, such as tetrahydrofuran, in which case the saltseparates directly or can be obtained by concentration of the solution.

[0560] Compounds of this invention can be regenerated from their acidaddition salts by the application or adaptation of known methods. Forexample, parent compounds of the invention can be regenerated from theiracid addition salts by treatment with an alkali, e.g. aqueous sodiumbicarbonate solution or aqueous ammonia solution.

[0561] According to a further feature of the invention, base additionsalts of the compounds of this invention may be prepared by reaction ofthe free acid with the appropriate base, by the application oradaptation of known methods. For example, the base addition salts of thecompounds of this invention may be prepared either by dissolving thefree acid in water or aqueous alcohol solution or other suitablesolvents containing the appropriate base and isolating the salt byevaporating the solution, or by reacting the free acid and base in anorganic solvent, in which case the salt separates directly or can beobtained by concentration of the solution.

[0562] Compounds of this invention can be regenerated from their baseaddition salts by the application or adaptation of known methods. Forexample, parent compounds of the invention can be regenerated from theirbase addition salts by treatment with an acid, e.g. hydrochloric acid.

[0563] Compounds of the present invention may be conveniently prepared,or formed during the process of the invention, as solvates (e.g.hydrates). Hydrates of compounds of the present invention may beconveniently prepared by recrystallisation from water.

[0564] The starting materials and intermediates may be prepared by theapplication or adaptation of known methods, for example methods asdescribed in the Reference Examples or their obvious chemicalequivalents.

[0565] Intermediates of formula (II), wherein R¹ and R² are ashereinbefore defined, R¹⁹ is a 2-trimethylsilanyl-ethoxymethyl group andR²⁰ is —CH(OMe)₂, may be prepared by reaction of compounds of formula(II), wherein R¹ and R² are as hereinbefore defined, R¹⁹ is a2-trimethylsilanyl-ethoxymethyl group and R²⁰ is —CHO, withtrimethylorthoformate in the presence of an acid catalyst, such as4-toluene sulphonic acid, in methanol at reflux temperature.

[0566] Intermediates of formula (II), wherein R¹ and R² are ashereinbefore defined, R¹⁹ is a 2-trimethylsilanyl-ethoxymethyl group andR²⁰ is —CHO, may be prepared by reaction of compounds of formula (1):—

[0567] wherein R¹ and R² are as hereinbefore defined, R¹⁹ is a2-trimethylsilanyl-ethoxymethyl group, with an alkyllithium, such asbutyllithium or lithium diisopropylamide, in an inert solvent, such astetrahydrofuran, at a temperature at about −78° C., followed by reactionwith N-formylmorpholine.

[0568] Intermediates of formula (II), wherein R¹ and R² are ashereinbefore defined, R¹⁹ is hydrogen and R²⁰ is —CH(OMe)₂, may beprepared by reaction of compounds of formula (2):—

[0569] wherein R¹ and R² are as hereinbefore defined, with glyoxal1,1-dimethylacetal and ammonium acetate. The reaction may convenientlybe carried out in a mixture of inert solvents, such as tert-butylmethylether and methanol, and at a temperature at about room temperature.

[0570] Intermediates of formula (II), wherein R¹, R² are as hereinbeforedefined, R¹⁹ represents a -LI-R⁷or -L²-R⁸ group (in which R⁷, L¹ and L²is as hereinbefore defined and R⁸ is aryl, cycloalkenyl, cycloalkyl,heteroaryl, heterocycloalkyl) and R²⁰ is —CHO, may be similarly preparedby reaction of compounds of formula (1), wherein R¹, R² and R¹⁹ are asdefined immediately above, with butyl

[0571] Intermediate 1,3-propanediols of formula (III), wherein R⁴ is anazidomethyl group, R⁵ is a methyl group, R⁶ is hydrogen and m is 1, andwhere both R⁴ and R⁵ are attached in the 2-position, may be prepared byreaction of 5-azidomethyl-2,5-dimethyl-1,3-dioxane (prepared accordingto the procedure in J.Org.Chem., 1992, 57, page 6080) with a mineralacid, for example hydrochloric acid, in an aqueous organic solventmixture such as tetrahydrofuran and water, at reflux temperature.

[0572] Intermediate 1,3-propanediols of formula (III), wherein R⁴ is an—NHC(═O)CF₃ group, R⁵ is a methyl group, R⁶ is hydrogen and m is 1, andwhere both R⁴ and R⁵ are attached in the 2-position, may be prepared byreaction of 2-amino-2-methyl-1,3-propanediol with trifluoroacetic acidin the presence of a base, such as potassium carbonate, in an inertsolvent, such as dimethylformamide, and at a temperature at about roomtemperature.

[0573] Intermediate 1,3-propanediols of formula (III), wherein R⁴ is a—C(═O)—NY⁴Y⁵ group (in which Y⁴ and Y⁵ are as hereinbefore defined), R⁵is a methyl group, R⁶ is hydrogen and m is 1, and where both R⁴ and R⁵are attached in the 2-position, may be prepared by reaction of2-carboxy-2-methyl-1,3-propanediol with an amine of formula HNY⁴Y⁵,wherein Y⁴ and Y⁵ are as hereinbefore defined. The coupling mayconveniently be carried out with a carbodiimide, such asdicyclohexylcarbodiimide, in the presence of 1-hydroxybenzotriazole anddisisopropylethylamine, in an inert solvent, such as acetonitrile, andat a temperature from room temperature to about 55° C. Other standardpeptide coupling procedures may be employed for the reaction, such asthose described hereinbefore.

[0574] Resins of formula Resin C in which R³, R⁵, R⁶ and m are ashereinbefore defined, and R⁴ contains a —C(═O)—NY⁴Y⁵ group may beprepared from the corresponding Resin C, in which R³, R⁵, R⁶ and m areas hereinbefore defined and R⁴ contains a —C(═O)—OR²¹ group (in whichR²¹ is alkyl, aryl or arylalkyl), by:— (i) treatment with an alkalimetal hydroxide, such as sodium hydroxide, in a mixture of water and awater miscible inert organic solvent, such as tetrahydrofuran,and at atemperature from about room temperature to about 70° C.; (ii) treatmentof the resulting resin in which R⁴ contains a —C(═O)—OH group withoxalyl chloride solution in an inert solvent, such as dichloromethane,at a temperature at about room temperature; (iii) treatment of theresulting resin in which R⁴ contains a —C(═O)—Cl group with an amine offormula HNY⁴Y⁵ in an inert solvent, such as dichloromethane, at atemperature at about room temperature.

[0575] Resins of formula Resin C in which R³, R⁵, R⁶ and m are ashereinbefore defined, and R⁴ contains a —N(R¹⁰)—C(═O)—R¹⁵ or—N(R¹⁰)—C(═O)-L⁴-R¹⁶ group (in which R¹⁰, R¹⁵, R¹⁶ and L⁴ are ashereinbefore defined), may be prepared from the corresponding Resin C,in which R³, R⁵, R⁶ and m are as hereinbefore defined and R⁴ contains a—NH₂ group by treatment with the appropriately substituted acid chlorideCl—C(═O)—R¹⁵ or Cl—C(═O)-L⁴-R¹⁶ (in which R¹⁵, R¹⁶ and L⁴ are ashereinbefore defined), in the presence of triethylamine, in an inertsolvent, such as tetrahydrofuran, and at a temperature at about roomtemperature.

[0576] Resins of formula Resin C in which R³, R⁵, R⁶ and m are ashereinbefore defined, and R⁴ contains a —N(R¹⁰)—SO₂—R¹⁵ or—N(R¹⁰)—SO₂-L⁴-R¹⁶ group (in which R¹⁰, R¹⁵, R¹⁶ and L⁴ are ashereinbefore defined), may be prepared from the corresponding Resin C,in which R³, R⁵, R⁶ and m are as hereinbefore defined and R⁴ contains a—NH₂ group by treatment with the appropriately substituted acid chlorideCl—SO₂—R¹⁵ or Cl—SO₂-L⁴-R¹⁶ (in which R¹⁵, R¹⁶ and L⁴ are ashereinbefore defined), in the presence of triethylamine, in an inertsolvent, such as tetrahydrofuran, and at a temperature at about roomtemperature.

[0577] Compounds of formula (1), wherein R¹ and R² are as hereinbeforedefined, R¹⁹ is a 2-trimethylsilanyl-ethoxymethyl group, may be preparedby reaction of compounds of formula (1), wherein R¹ and R² are ashereinbefore defined, R¹⁹ is a hydrogen atom, with2-(trimethylsilyl)ethoxymethyl chloride in the presence of sodiumhydride, in an inert solvent such as dimethylformamide, and at atemperature at about room temperature.

[0578] Compounds of formula (1) wherein R¹ and R² are as hereinbeforedefined, R¹⁹ represents a group -L¹-R⁷ (where L¹ and R⁷ are ashereinbefore defined) or -L²-R⁸ (where L² is as hereinbefore defined andR⁸ is aryl, cycloalkenyl, cycloalkyl, heteroaryl, heterocycloalkyl) maybe similarly prepared by reaction of compounds of formula (1), whereinR¹ and R² are as hereinbefore defined, R¹⁹ is a hydrogen atom, with analkyl halide of formula (V) or (VI) respectively, in the presence ofsodium hydride.

[0579] Compounds of formula (1), wherein R¹ and R² are as hereinbeforedefined, R¹⁹ is a hydrogen atom, may be prepared by the application oradaptation of known literature methods, for example Boehm et. al.,J.Med.Chem., 1996, 39, page 3829.

[0580] Intermediates of formulae (II), (III), (IV), Resin C and Resin Dare novel compounds and, as such, they and their processes describedherein for their preparation constitute further features of the presentinvention.

[0581] The present invention is further Exemplified but not limited bythe following illustrative Examples and Reference Examples.

EXAMPLE 1

[0582] Compounds A, B and C

[0583] A solution of4-[5(4)-(4-fluoro-phenyl)-2-formyl-1-[(2-(trimethylsilyl)ethoxy)methyl]-1H-imidazol-4(5)-yl]-pyridine(1.1 g, Reference Example 1), 1,1,1-tris(hydroxymethyl)-ethane (1.66 g)and pyridinium-4-toluenesulphonate (0.13 g) in dry toluene (20 ml) wasgently refluxed for 20 hours with azeotropic removal of water. Aftercooling to room temperature the reaction mixture was treated with ethylacetate (100 ml), then washed three times with water (20 ml), then driedover magnesium sulphate and then evaporated. The residual oil wassubjected to flash chromatography, on silica, eluting with a mixture ofdichloromethane and methanol (24:1, v/v) to give{2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,cis-isomer, (Compound A) as a white solid, m.p. 270-272° C. [Elementalanalysis: —C,64.22; H,5.71; N,10.81; F,4.91%. Calculated forC₂₀H₂₀FN₃O₃.H₂O: —C,64.67; H,5.97; N, 11.31; F,5.11%]; and{2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound B) as a buff-coloured solid, m.p. 250-255° C.[Elemental analysis: —C,64.22; H,5.71; N,10.81; F,4.91%. Calculated:—C,65.03; H,5.46; N,11.38; F,5.14%].

[0584] By proceeding in a similar manner but using2,2-dimethyl-1,3-propanediol there was prepared4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-pyridine,(Compound C) as a cream solid, m.p. 248-249° C. (with decomposition).[Elemental analysis: —C,66.75; H,5.74; N,11.42%. Calculated forC₂₀H₂₀FN₃O₂.0.5H₂O: —C,66.28; H,5.84; N,11.59%].

EXAMPLE 2

[0585] Compound D

[0586] A solution of4-[2-(5-azidomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-pyridine,cis- and trans-isomers [1.56 g, Compound H] in methanol (100 ml) wastreated with ammonium formate (1 g), then with 10% palladium onactivated carbon (0.15 g). After stirring for 3.5 hours the reactionmixture was filtered through diatomaceous earth then evaporated. Theresidual orange solid was subjected to flash chromatography on silicaeluting with a mixture ofmethyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-yl]-methylamine,cis- and trans-isomers, Compound D, (0.68 g) as a yellow solid.

EXAMPLE 3

[0587] Compounds E to Z

[0588] A stirred solution of4-[2-dimethoxymethyl-5(4)-(4-fluoro-phenyl)-1H-imidazol4(5)-yl]-pyridine(5.75 g, Reference Example 3), and2-methyl-2-trifluoroacetamido-1,3-propanediol (7.38 g, Reference Example4) and 4-toluenesulphonic acid (8.03 g) in dry tetrahydrofuran (200 ml)was heated at reflux for 6 hours. After cooling the mixture was stood atroom temperature for 4 days then partitioned between ethyl acetate andsaturated sodium bicarbonate solution. The organic phase was washedtwice with water (100 ml), then with brine (100 ml), then dried overmagnesium sulphate and then evaporated to give2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2yl}-[1,3]dioxan-5-yl]-acetamide,cis- and trans-isomers (Compound E). The residue was subjected to flashchromatography on silica eluting with a mixture of dichloromethane andmethanol (95:5, v/v) to give:2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-yl]-acetamide,cis-isomer (Compound F); MH⁺451; and2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl{-[1,3]dioxan-5-yl]-acetamide,trans-isomer (Compound G). MH⁺ 451.

[0589] By proceeding in a similar manner but using2-azidomethyl-2-methyl-1,3-propanediol (Reference Example 5) there wasprepared4-[2-(5-azidomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-pyridine,cis- and trans-isomers (Compound H) as a white solid.

[0590] By proceeding in a similar manner but using2-benzyl-1,3-propanediol and subjecting the crude product to preparativethick layer chromatography on silica eluting with a mixture ofdichloromethane and methanol (9:1, v/v) there was prepared4-[2-(5-benzyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-pyridine,cis- and trans-isomers (Compound I). R_(F) 0.46 using a mixture ofdichloromethane and methanol (9:1, v/v). MH⁺ 416.

[0591] By proceeding in a similar manner but using methyl2,2-bis(hydroxymethyl)propionate and subjecting the crude product topreparative thick layer chromatography on silica eluting with a mixtureof dichloromethane and methanol (9:1, v/v) there was prepared2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methyl ester, cis- and trans-isomers (Compound J). R_(F) 0.71 usinga mixture of dichloromethane and methanol (9: 1, v/v). MH⁺ 398.

[0592] By proceeding in a similar manner but using2,2-bis(hydroxymethyl)-tetrahydropyran, carrying out the reaction indimethylformamide at 50° C. and subjecting the crude product topreparative thick layer chromatography on silica eluting twice with amixture of dichloromethane and methanol (19: 1, v/v) there was prepared4-[5-(4-fluoro-phenyl)-2-(1,8,10-trioxa-spirol5.5]undec-9-yl)-1H-imidazol-4-yl]-pyridine,(Compound K), as a mixture of isomers. R_(F) 0.45 and 0.48 using amixture of dichloromethane and methanol (19:1, v/v) as eluent. MH⁺ 396.

[0593] By proceeding in a similar manner but using2,2-bis(hydroxymethyl)-tetrahydrofuran, carrying out the reaction indimethylformamide at 50° C. and subjecting the crude product topreparative thick layer chromatography on silica eluting twice with amixture of dichloromethane and methanol (19:1, v/v) there was prepared4-[5-(4-fluoro-phenyl)-2-(1,7,9-trioxa-spiro[4.5]dec-8-yl)-1H-imidazol-4-yl]-pyridine,(Compound L), as a mixture of isomers. R_(F) 0.39 and 0.45 using amixture of dichloromethane and methanol (19:1, v/v) as eluent. MH⁺ 382.

[0594] By proceeding in a similar manner but using the appropriatelysubstituted 1,3-propanediols, carrying out the reaction indichloromethane at room temperature over 3 days, and subjecting thecrude product to preparative thick layer chromatography on silica, therewere prepared the Compounds M to Z depicted in Table 1. For Compounds Mto V and Compound Z the eluent used was a mixture of dichloromethane andmethanol (9: 1, v/v); for Compound W the eluent used was ethyl acetatethen a mixture of dichloromethane and methanol (14:1, v/v); and forCompounds X and Y the eluent used was a mixture of dichloromethane andmethanol (14:1, v/v). TABLE 1 STRUCTURE substituted MH⁺ and1,3-propanediol MOLECULAR (intensity) Compound number used in thereaction R_(F) FORMULA (MS-ESI)

0.41 C19H18FN3O2 340 (100%)

0.40 C19H16FN3O2 338 (100%)

0.37 C18H16FN3O2 326 (100%)

0.40 C19H18FN3O2 340 (100%)

0.44 C20H20FN3O2 354 (50%) 169 (100%)

0.47 & 0.31 C25H22FN3O3 432 (100%)

0.20 & 0.18 C24H20FN3O2 402 (100%)

0.43 C23H26FN3O2 396 (100%)

0.30 C22H24FN3O2 382 (100%)

0.30 C23H22FN3O2 392 (100%)

0.14 C26H23FN4O3 459 (100%)

0.20 C26H23F2N5O2S 508 (100%)

0.25 & 0.18 C28H28FN5O2S 518 (100%)

0.31 C23H21FN4O2 405 (100%)

EXAMPLE 4

[0595] Compounds AA and AB

[0596] A solution of2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylmethyl]-acetamide,trans-isomer [1.04 g, Compound AC] and potassium carbonate (1.55 g) inmethanol (150 ml) was heated at reflux for 24 hours. After cooling toroom temperature the mixture was partitioned between ethyl acetate andwater. The aqueous layer was treated with sodium chloride then extractedthree times with ethyl acetate (50 ml). The combined organic phases wereevaporated. The residual oil was subjected to flash chromatography onsilica eluting with a mixture ofmethyl-2-(5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl)-[1,3]dioxan-5-yl]-methylamine,trans-isomer (0.51 g, Compound AA). MH⁺ 369.

[0597] By proceeding in a similar manner but using2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylmethyl]-acetamide,trans-isomer, [Compound AD] there was preparedC-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-yl]-methylamine,cis-isomer (Compound AB). MH⁺ 369.

EXAMPLE 5

[0598] Compounds AC and AD

[0599] A suspension ofC-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-yl]-methylamine(0.68 g, cis- and trans-isomers, Compound D) in dichloromethane (35 ml)was treated with triethylamine (0.72 ml) then with trifluoroaceticanhydride (0.72 ml). After stirring at room temperature for 4.5 hoursthe reaction mixture was partitioned between ethyl acetate and water.The organic phase was washed with water, then with brine, then driedover magnesium sulphate and then evaporated. The residue was subjectedto flash chromatography on silica eluting with a mixture of ethylacetate and methanol (9:1, v/v) to give2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylmethyl]-acetamide,cis- and trans-isomers. The mixture was subjected to preparative HPLC,using methanol and water 40/60 to 5/95 v/v over 20 minutes to give2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylmethyl]-acetamide,trans-isomer (0.75 g, Compound AC, R_(T)=11.99,) and2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylmethyl]-acetamide,cis-isomer (0.3 g, Compound AD, R_(T)=10.8).

EXAMPLE 6

[0600] Compounds AE, AF and AG

[0601] A stirred solution of2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-yl]-acetamide,cis-isomer (1.75 g, Compound F) and potassium carbonate (1.07 g) in amixture of methanol (200 ml) and water (5 ml) was heated at reflux for 8hours. After cooling to room temperature the mixture evaporated and thenazeotroped with toluene. The residue was treated with silica andfiltered through a pad of silica washing with a mixture ofdichloromethane and methanol (4:1, v/v) to give5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylamine,cis-isomer (1.3 g, Compound AE) as a yellow solid.

[0602] By proceeding in a similar manner but using Compound G there wasprepared5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1.3]dioxan-5-ylamine,trans-isomer (Compound AF).

[0603] By proceeding in a similar manner but using Compound E there wasprepared5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylamine,cis- and trans-isomers (Compound AG).

EXAMPLE 7

[0604] Compounds AH and AI

[0605] A solution of2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methyl ester, cis- and trans-isomers (0.34 g, Compound J) inmethanol (15 ml) was treated with aqueous sodium hydroxide solution(1.71 ml, 1N) then heated at reflux for 7 hours. After cooling to roomtemperature the reaction mixture was evaporated. The residual creampowder was dissolved in methanol (10 ml) and the solution acidified topH 5-6 by addition of glacial acetic acid. The resulting whiteprecipitate was filtered and washed with pentane to give2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid, trans-isomer (0.11 g, Compound AH). R_(F) 0.15 (CH₂Cl₂/CH₃OH, 9:1developed five times), MH⁺ 384. The filtrate plus washings were absorbedonto silica and subjected to flash chromatography on silica eluting witha mixture of dichloromethane and methanol (9:1, v/v) to give2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1.3]dioxane-5-carboxylicacid, cis-isomer (0.14 g, Compound AI,) as a white solid. R_(F) 0.25(CH₂Cl₂/CH₃OH, 9:1, developed five times), MH⁺ 384.

EXAMPLE 8

[0606] Compounds AJ to CO and FS to GD

[0607] A solution of2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid, cis- or trans-isomer (1 equivalent, Compound AH or AI) anappropriately substituted amine of formula HNY⁴Y⁵ [1.1 equivalents, seetable 2], 1-(3-dimethylamino-propyl)-3-ethylcarbodiimide [1.1equivalents], 1-hydroxybenzotriazol hydrate [1.1 equivalents] andN,N-diisopropylethylamine [3 equivalents] in dry dimethylformamide wasstirred at room temperature for 18 hours. The reaction mixture wasevaporated and the residue was partitioned between ethyl acetate andwater. The organic phase was washed with brine then evaporated to giveCompounds AJ to GD and FS to GD depicted in Table 2 (Compound FV wasobtained following alkaline hydrolysis of the intermediate ester). TheR_(F) values indicated were determined using a mixture ofdichloromethane and methanol (9:1, v/v) as eluent [* in one case amixture of ethyl acetate and methanol (9:1, v/v) was used]. TABLE 2STRUCTURE MH⁺ and MOLECULAR (In- Compound number HNY⁴Y⁵ R_(F) FORMULAtensity)

0.33 C27H25FN4O3 473 (70%) 418 (100%)

0.35 C27H25FN4O3 473 (20%) 418 (100%)

0.13 C22H23FN4O4 427 (100%)

0.28 C23H25FN4O4 441 (20%) 384 (100%)

NH₃ 0.14 C20H19FN4O3 383 (100%)

0.29 C26H24FN5O3 474 (100%)

0.18 C26H24FN5O3 474 (100%)

0.16 C26H24FN5O3 474 (100%)

0.09 C25H28FN5O3 466 (100%)

0.14 C25H30FN5O3 468 (100%)

0.25 C30H28FN5O3 526 (100%)

0.09 C23H25FN4O4 441 (100%)

0.32 C25H27FN4O4 467 (100%)

0.32 C24H25FN4O4 453 (100%)

0.39 C24H25FN4O3 437 (50%) 384 (100%)

0.33 C24H27FN4O3 439 (100%)

0.41 C265H31FN4O3 467 (100%)

0.29 C24H27FN4O4 455 (40%) 384 (100%)

0.33 C28H27FN4O3 487 (100%)

0.24 C27H26FN5O3 488 (100%)

0.32 C25H23FN4O4 463 (100%)

0.36 C25H27FN4O3 451 (30%) 384 (100%)

0.28 C22H23FN4O3 411 (11%) 384 (100%)

0.29 C23H25FN4O3 425 (70%) 384 (100%)

0.22 C23H23FN4O3 423 (25%) 384 (100%)

0.32 C25H27FN4O3 451 (100%)

0.36 C26H29FN4O3 465 (100%)

0.29 C23H25FN4O4 441 (100%)

0.18 C22H23FN4O4 427 (100%)

NH₃ 0.16 C20H19FN4O3 383 (100%)

0.25 C26H24FN5O3 474 (100%)

0.13 C26H24FN5O3 474 (100%)

0.10 C26H24FN5O3 474 (100%)

0.36 C24H25FN4O4 453 (100%)

0.08 C25H28FN5O3 466 (100%)

0.13 C25H30FN5O3 468 (100%)

0.28 C30H28FN5O3 526 (100%)

0.08 C23H25FN4O4 441 (100%)

0.37 C28H27FN4O3 487 (100%)

0.28 C24H27FN4O4 455 (100%)

0.25 C27H26FN5O3 488 (100%)

0.33 C25H23FN4O4 463 (100%)

0.34 C25H27FN4O4 467 (100%)

0.38 C24H25FN4O3 437 (10%) 384 (100%)

0.40 C25H27FN4O3 451 (60%) 384 (100%)

0.26 C23H25FN4O3 425 (40%) 384 (100%)

0.31 C24H27FN4O3 439 (100%)

0.24 C23H23FN4O3 423 (15%) 384 (100%)

0.32 C25H27FN4O3 451 (35%) 384 (100%)

0.32 C26H29FN4O3 465 (100%)

H₂N—CH₃.HCl 0.22 C21H21FN4O3 397 (50%) 384 (100%)

0.11 C24H28FN5O3 454 (100%)

0.33 C22H23FN4O3 411 (70%) 384 (100%)

0.40 C26H31FN4O3 467 (100%)

0.30 C22H23FN4O3 411 (60%) 384 (100%)

H₂N—CH₃.HCl 0.15 C21H21FN4O3 397 (45%) 384 (100%)

0.07 C24H28FN5O3 454 (40%) 418 (100%)

0.23 C22H23FN4O3 411 (34%) 384 (100%)

0.55 C27H29FN4O5 467 (100%)

0.71 C25H27FN4O4 509 (100%)

0.73 C28H31FN4O5 523 (100%)

0.29 C26H27FN4O5 495 (100%)

0.76 C24H25FN4O3S 469 (100%)

0.4 C24H25FN4O5S 501 (100%)

0.62 C26H29FN4O4 481 (100%)

0.59 C25H27FN4O4 467 (100%)

0.71 C26H29FN4O4 481 (100%)

0.53 C24H25FN4O4 453 (100%)

0.58* C26H29FN4O4 481 (100%)

0.72 C27H31FN4O4 495 (100%)

EXAMPLE 9

[0608] Compounds CP to DF

[0609] A solution of5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylamine,cis- or trans-isomer (1 equivalent, Compound AE or AF), and anappropriately substituted isocyanate of formula O═C═N—R¹⁵ orO═C═N-L⁴-R¹⁶ [1 equivalent, see Table 3] in dry tetrahydrofuran wasstirred at room temperature for 30 minutes. The reaction mixture wasevaporated in vacuo to give Compounds CP to CZ depicted in Table 3. TheR_(F) values indicated were determined using a mixture ofdichloromethane and methanol (9: l,v/v) as eluent.

[0610] By proceeding in a similar manner but using Compound AA orCompound AB, there were prepared Compounds DA to DF depicted in Table 3.The R_(F) values indicated were determined using a mixture ofdichloromethane and methanol (9:1, v/v) as eluent. TABLE 3 STRUCTURE MH⁺and O═C═N-R¹⁵ or MOLECULAR (In- Compound number O═C═N-L⁴-R¹⁶ R_(F)FORMULA tensity)

0.46 C26H23FN5O3 474 (100%)

0.41 C22H24FN5O3 426 (100%)

0.41 C25H25FN6O4 493 (100%)

0.50 C27H26FN5O3 488 (70%) 423 (100%)

0.50 C26H26FN5O3S 508 (100%)

0.51 C28H26FN5O4 516 (100%)

0.40 C26H24FN5O3 474 (100%)

0.36 C27H24FN5O5 MH⁻516 (100%)

0.39 C27H26FN5O3 488 (100%)

0.24 C22H24FN5O3 426 (100%)

0.40 C26H26FN5O3S 508 (100%)

0.46 C28H28FN5O3 502 (100%)

0.39 C23H26FN5O3 440 (100%)

0.48 C27H26FN5O3 489 (100%)

0.42 C27H26FN5O3 488 (100%)

0.40 C28H28FN5O3 502 (100%)

0.23 C23H26FN5O3 440 (100%)

EXAMPLE 10

[0611] Compounds DG to DU

[0612] A solution of5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylamine,cis- or trans-isomer (1 equivalent, Compound AE or AF), an appropriatelysubstituted isothiocyanate of formula S═C═N—R¹⁵ or S═C═N-L⁴-R¹⁶ [1equivalent, see Table 3] [1 equivalent] in dry tetrahydrofuran washeated to reflux for 18 hours. After cooling the reaction mixture wasevaporated in vacuo and purified by preparative chromatography on silicaeel, eluting with a mixture of dichloromethane and methanol (9:1 v/v) togive Compounds DG to DK depicted in Table 4. The R_(F) values indicatedwere determined using a mixture of dichloromethane and methanol (9:1,v/v) as eluent.

[0613] By proceeding in a similar manner but using Compound AA orCompound AB, there were prepared Compounds DL to DU depicted in Table 4.The R_(F) values indicated were determined using a mixture ofdichloromethane and methanol (9:1, v/v) as eluent. TABLE 4 STRUCTURE MH⁺and S═C═N-R¹⁵ or MOLECULAR (In- Compound number S═C═N-L⁴-R¹⁶ R_(F)FORMULA tensity)

0.46 C26H31FN6O3S 527 (100%)

0.46 C25H24FN5O3S 494 (100%)

0.32 C25H23FN6O2S 491 (100%)

0.50 C28H26FN5O4S 548 (100%)

0.24 C27H24FN5O4S 534 (100%)

0.23 C26H25FN6O2S 505 (100%)

0.16 C27H33FN6O3S 541 (100%)

0.37 C26H26FN5O3S 508 (100%)

0.40 C29H28FN5O4S 562 (100%)

0.48 C29H28FN5O4S 562 (100%)

0.46 C26H26FN5O3S 508 (100%)

0.13 C28H26FN5O4S 548 (100%)

0.28 C26H25FN6O2S 505 (100%)

0.35 C27H33FN6O3S 541 (100%)

0.50 C28H26FN5O4S 548 (100%)

EXAMPLE 11

[0614] Compounds DV to FM

[0615] A stirred solution of5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylamine,cis- or trans-isomer (1 equivalent, Compound AE or AF) and triethylamine[1 equivalent] in dry tetrahydrofuran was treated with an appropriatelysubstituted acid chloride of formula Cl—C(═O)—R¹⁵ or Cl—C(═O)-L⁴-R¹⁶[1equivalent, see Table 4]. After stirring at room temperature for 18hours the reaction mixture was evaporated to give Compounds DV to EDdepicted in Table 5. The R_(F) values indicated were determined using amixture of dichloromethane and methanol (9:1, v/v) as eluent.

[0616] By proceeding in a similar manner using Compound AA or AA, therewere prepared Compounds EF to EM depicted in Table 4. The R_(F) valuesindicated were determined using a mixture of dichloromethane andmethanol (9:1, v/v) as eluent. TABLE 5 STRUCTURE MH⁺ and Cl—C(═O)-R¹⁵ orMOLECULAR (In- Compound number Cl—C(═O)-L⁴-R¹⁶ R_(F) FORMULA tensity)

0.41 C21H21FN4O3 397 (100%)

0.42 C27H25FN4O3 473 (100%)

0.46 C26H29FN4O3 465 (100%)

0.58 C28H27FN4O4 MH⁻501 (100%)

0.52 C28H27FN4O4 503 (100%)

0.34 C21H21FN4O3 397 (100%)

0.49 C27H25FN4O3 473 (100%)

0.51 C26H29FN4O3 465 (100%)

0.52 C26H23FN4O3 459 (100%)

0.55 C29H29FN4O4 517 (100%)

0.33 C27H25FN4O3 473 (100%)

0.22 C22H23FN4O3 411 (100%)

0.30 C28H27FN4O3 486 (100%)

0.29 C27H31FN4O3 479 (100%)

0.18 C22H23FN4O3 411 (100%)

0.45 C28H27FN4O3 487 (100%)

0.45 C27H31FN4O3 479 (100%)

0.45 C27H25FN4O3 473 (100%)

EXAMPLE 12

[0617] Compounds EN to ER

[0618] A solution of5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylamine,cis-isomer (1 equivalent, Compound AE), triethylamine (1.2 equivalents)and glutaric anhydride (1 equivalent) in dry tetrahydrofuran was heatedto reflux for 8 hours. The reaction mixture was evaporated to give4-{2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}-butyricacid, cis-isomer (Compound EN). MH⁺ 469. R_(F) 0.12 {determined using amixture of dichloromethane and methanol (9:1,v/v) as eluent}.

[0619] By proceeding in a similar manner but using Compound AB andglutaric anhydride, there was prepared4-({2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-carbamoyl)-butyricacid, cis-isomer (Compound EO). MH⁺483. R_(F) 0.10 {determined using amixture of dichloromethane, pentane, methanol and ammonia(55:25:18:2,v/v) as eluent}.

[0620] By proceeding in a similar manner but using Compound AE andsuccinic anhydride there was prepared4-{2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-lylcarbamoyl}-propionicacid, cis-isomer (Compound EP). MH⁺ 455. R_(F) 0.18 {determined using amixture of dichloromethane and methanol (9:1, v/v) as eluent}.

[0621] By proceeding in a similar manner but using Compound AB andsuccinic anhydride there was prepared4-({2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-carbamoyl)-propionicacid, cis-isomer (Compound EQ). MH⁺ 469. R_(F) 0.10 {determined using amixture of dichloromethane, pentane, methanol and ammonia(55:25:18:2,v/v) as eluent}.

[0622] By proceeding in a similar manner but using Compound AA andsuccinic anhydride there was prepared4-({2-[5-(4-fluoro-phenyl)-4-pyridin4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-carbamoyl)-propionicacid, trans-isomer (Compound ER). MH⁺ 469. R_(F) 0.11 {determined usinga mixture of dichloromethane, pentane, methanol and ammonia(55:25:18:2,v/v) as eluent}.

EXAMPLE 13

[0623] Compounds ES to FB

[0624] A solution of5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,33]dioxan-5-ylamine,cis-isomer [1 equivalent, Compound AE], and triethylamine [1 equivalent]in tetrahydrofuran was treated with methane sulphonyl chloride [1equivalent]. After stirring at room temperature for 48 hours thereaction mixture was evaporated and the residue was subjected topreparative thick chromatography on silica, eluting with a mixture ofdichloromethane and methanol (9:1, v/v), to giveN-{2-[5-(4-fluoro-phenyl)4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanesulphonamide,cis-isomer (Compound ES). MH⁺ 433. R_(F) 0.42 {determined using amixture of dichloromethane and methanol (9:1,v/v) as eluent}.

[0625] By proceeding in a similar manner but using Compound AA orCompound AB and an appropriately substituted sulphonyl chloride offormula Cl—SO₂—R¹⁵ or Cl—SO₂-L⁴-R¹⁵ there was prepared Compounds ET toFB depicted in Table 6. The R_(F) values indicated were determined usinga mixture of dichloromethane and methanol (9:1, v/v) as eluent. TABLE 6STRUCTURE and Cl—SO₂-R¹⁵ or MOLECULAR MH⁺ EXAMPLE NUMBER Cl—SO₂-L⁴-R¹⁵R_(F) FORMULA (Intensity)

0.21 C21H23FN4O4S 447 (100%)

0.28 C26H25FN4OS 509 (100%)

0.29 C27H27FN4O4S 523 (100%)

0.30 C24H23FN4O4S2 515 (100%)

0.30 C25H26FN5O5S 528 (100%)

0.32 C21H23FN4O4S 447 (100%)

0.53 C26H25FN4O4S 509 (100%)

0.50 C24H23FN4O4S2 515 (100%)

0.50 C25H26FN5O5S 528 (100%)

EXAMPLE 14

[0626] Compounds FC to FJ

[0627] A solution of({2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}-ethyl)-carbamicacid benzyl ester, trans-isomer (Compound FI) was treated withpalladium, 5% activated on carbon and stirred at room temperature undera hydrogen atmosphere for 8 hours. The reaction mixture was filteredthrough a pad of diatomaceous earth and evaporated to dryness. Theresidue was subjected to preparative thick layer chromatography onsilica, eluting with dichloromethane and methanol (7:3 v/v) to give3-amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl1-5-methyl-[1,31dioxan-5-yl]-propionamide,trans-isomer (Compound FC). MH⁺ 426. R_(F) 0.04 determined using amixture of dichloromethane and methanol (7:3, v/v) as eluent.

[0628] By proceeding in a similar manner but using Compound FJ there wasprepared3-amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-propionamide,cis-isomer (Compound FD). MH⁺ 426. R_(F) 0.04 determined using a mixtureof dichloromethane and methanol (7:3, v/v) as eluent.

[0629] By proceeding in a similar manner but using Compound FK there wasprepared4-amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,31dioxan-5-yl]-butyramide,trans-isomer (Compound FE). MH⁺ 440. R_(F) 0.03 determined using amixture of dichloromethane and methanol (7:3, v/v) as eluent.

[0630] By proceeding in a similar manner but using Compound FL there wasprepared4-amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-butyramide,cis-isomer (Compound FF). MH⁺440. R_(F) 0.03 determined using a mixtureof dichloromethane and methanol

[0631] By proceeding in a similar manner but using Compound FM there wasprepared2-amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-acetamide,trans-isomer (Compound FG). MH+ 412. R_(F) 0.01 determined using amixture of dichloromethane and methanol (9:1, v/v) as eluent with twodevelopments.

[0632] By proceeding in a similar manner but using Compound FN there wasprepared2-amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-acetamide,cis-isomer (Compound FH). MH⁺412. R_(F) 0.03 determined using a mixtureof dichloromethane and methanol (9:1, v/v) as eluent with twodevelopments.

EXAMPLE 15

[0633] Compounds FI to FP

[0634] A solution of5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylamine,cis- and trans-isomers [1 equivalent, Compound AG],N-benzyloxycarbonyl-β-alanine, [1 equivalent],1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride [1.1equivalents], N,N-diisopropylethylamine [3 equivalents] and1-hydroxybenzotriazole hydrate [1.1 equivalents] in drydimethylformamide was heated at 90° C. for 2.5 hours. The reactionmixture was cooled to room temperature, then evaporated. The residue waspartitioned between ethyl acetate (12 ml) and water (12 ml). The organicphase was separated and allowed to stand at room temperature. The solidwhich crystallised was filtered to give(3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}-ethyl)-carbamicacid benzyl ester, trans-isomer (Compound FI). The filtrate wassubjected to preparative chromatography on silica, eluting with amixture of dichloromethane and pentane (9:1, v/v) to give(3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}-ethyl)-carbamicacid benzyl ester, cis-isomer (Compound FJ).

[0635] By proceeding in a similar manner but usingN-benzyloxycarbonyl4-aminobutyric acid there was prepared(3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}-propyl)-carbamicacid benzyl ester, trans-isomer, (Compound FK) and(3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}-propyl-carbamicacid benzyl ester, cis-isomer (Compound FL).

[0636] By proceeding in a similar manner but usingN-benzyloxycarbonylglycine there was prepared(3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}-methyl)-carbamicacid benzyl ester, trans-isomer (Compound FM) and(3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1.3]dioxan-5-ylcarbamoyl}-methyl)-carbamicacid benzyl ester, cis-isomer (Compound FN).

[0637] By proceeding in a similar manner but using3-dimethylamino-propionic acid there was prepared4-dimethylamino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-butyramide,cis- and trans-isomers Compound FO. MH⁺468. R_(F) 0.32 determined usinga mixture of dichloromethane and methanol (7:3, v/v) as eluent.

EXAMPLE 16

[0638] Compound FP

[0639] A solution of{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer (7.43 g, Compound AW) in hot tetrahydrofuran (500 ml) wastreated with a solution of methane sulphonic acid (1.578 g) intetrahydrofuran. After standing at room temperature for 18 hours thereaction mixture was filtered and the solid recrystallised fromacetonitrile with hot filtration through celite to give{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanonemethane sulphonic acid salt, trans-isomer (6.00 g, Compound FP) as apale yellow crystalline solid, m.p. 242-246° C. (with decomposition).[Elemental analysis:—C,54.76; H,5.25; N,10.44; S, 5.89%. Calculated forC₂₄H₂₅FN₄O₄.CH₃SO₃H:—C,54.73; H,5.32; N,10.21; S,5.84%].

EXAMPLE 17

[0640] Compound FQ

[0641] A solution ofN-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-benzamide,trans-isomer (0.85 g, Compound FR) in tetrahydrofuran (100 ml) wastreated with methane sulphonic acid (0.178 g). The reaction mixture wasagitated for 5 minutes then evaporated to dryness and dried under highvacuum. The residual solid was recrystallised from ethyl acetatecontaining a minimum volume of acetonitrile to giveN-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-(1,3)dioxan-5-yl]-benzamide,methane sulphonic acid salt, trans-isomer (1.20 g, Compound FQ) as ayellow crystalline solid, m.p. 165-169° C. [Elemental analysis:—C,57.93;H,5.41; N,8.73%. Calculated for C₂₆H₂₃FN₄O₃.CH₃SO₃H.CH₃CO₂C₂H₅:—C,52.94;H,5.123; N,9.88%].

EXAMPLE 18

[0642] Compound FR

[0643] A stirred suspension of5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl[1,3]dioxan-5-ylamine,trans isomer (1.76 g, Compound AF), benzoic acid (0.67 g) anddiusopropylethylamine (1.39 ml) in dry dimethylformamide (50 ml) wastreated with {0-(7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate} (1.88 g) under a nitrogen atmosphere. Afterstirring at room temperature for 2 hours the reaction mixture wasevaporated to dryness. The residue was partitioned between ethyl acetate(70 ml) and saturated sodium bicarbonate (50 ml). The organic phase waswashed twice with water (50 ml), then with brine (30 ml) and thenevaporated. The residue was subjected to flash chromatography on silicaeluting with ethyl acetate to giveN-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-benzamide,trans-isomer (0.85 g, Compound FR) as a cream coloured solid, m.p.235-236° C. R_(F): 0.42 determined using a mixture of dichloromethaneand methanol (9:1, v/v) as eluent. MH⁺459.

EXAMPLE 19

[0644] Compound AW

[0645] Method A:2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid, trans-isomer (7.70 g, Compound AH) was added portionwise tostirred thionyl chloride. The reaction mixture was stirred at roomtemperature for 1.25 hours then evaporated. The residue was azeotropedwith dry toluene to yield the crude acid chloride. This was treated withdry dichloromethane (150 ml) followed by morpholine (30 ml) undernitrogen. The mixture was stirred at room temperature for 2.5 hours thenevaporated. The residue was partitioned between ethyl acetate (250 ml)and saturated sodium bicarbonate (200 ml). The insoluble product at theinterface was filtered off and washed with methanol (10 ml), then withwater (20 ml) and then with diethyl ether (20 ml) to give{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer (7.63 g, Compound AW), m.p. 288-291° C. MH⁺453.

[0646] Method B:4-[2-(Dimethoxymethyl)-5-(4-fluorophenyl)-1H-4-imidazolyl]pyridine (62.7g) and 3-hydroxy-2-(hydroxymethyl)-2-methyl-1-morpholino-1-propanone(44.8 g, Reference Example 6) were added to toluene (440 ml), undernitrogen. The mixture was stirred and heated to reflux under a Dean andStark trap for 20 minutes. N,N-dimethylformamide (160 ml) andmethanesulphonic acid (2 ml) were added and the mixture heated to agentle reflux over 4hours, removing a total of 150 ml distillate at afairly uniform rate. The reaction mixture was then evaporated in vacuoto remove as much toluene as possible. The resulting suspension wastreated with triethylamine (8 ml) and then water (600 ml) was addeddropwise over 1 hour. The mixture was filtered to give a damp, crudesolid mixture of cis- and trans-isomers after washing with water andallowing the cake to suck on the filter for 1 hour. This then cooled to5° C. The solid was filtered and then washed with methanol to give{2-[4-(4-fluoro-phenyl)-5-pyridin4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer (46.4 g, Compound AW), m.p. 214° C. (with decomposition).¹H NMR (δ, CDCl₃): 8.52 (d, 0.6H); 8.39 (d, 1.4H); 7.32-7.49 (m, 4H);7.29 (t, 1.4H); 7.13 (t, 0.6H); 5.59 (s, 1H,); 4.07 (s, 4H); 3.51 (bd,8H); 1.56 (s, 3H).

EXAMPLE 20

[0647] Compound GE A stirred suspension of{2-[4-(4-fluoro-phenyl)-5-pyridin4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer (4.52 g, Compound AW) in a mixture of ethanol and methanol(45 ml, 95:5, v/v) was treated with aqueous hydrobromic acid (1.2 ml,48%). The mixture was heated to reflux, then water (15 ml) was added andthen the mixture was heated again to reflux. The solution formed wasallowed to cool to room temperature then filtered. The solid was washedthree times with a mixture of ethanol and methanol (10 ml, 95:5, v/v) togive{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanonemonohydrobromide dihydrate, trans-isomer (4.5 g, Compound GE) as anoff-white crystalline solid, m.p. 276-277° C. (with decomposition). ¹HNMR (CD₃)₂SO: δ1.53 (s, 3H), 3.49 (bd, 8H), 4.08 (s, 4H), 5.64 (s, 1H),7.36 (t, 2H), 7.53-7.58 (m, 2H), 7.84 (d, 2H), 8.63 (d, 2H).

EXAMPLE 21

[0648] Compound GF

[0649]{2-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer (25.2 g, Compound AW), stirred in isopropanol (300 ml), wastreated with concentrated hydrochloric acid (5 ml) and water (440 ml)and the mixture was heated to reflux for 15 minutes. The mixture wascooled to room temperature and then filtered. The solid was washed withisopropanol to give{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanonemonohydrochloride dihydrate, trans-isomer (22.5 g, Compound GF) as anoff-white solid, m.p. 245-248° C. (with decomposition). ¹H NMR (CD₃)₂SO:δ1.58 (s, 3H), 3.55 (bd, 8H), 4.12 (s, 4H), 5.68 (s, 1H), 7.49 (t, 2H),7.58-7.62 (m, 2H), 7.89 (d, 2H).

EXAMPLE 22

[0650] Compound GG

[0651]{2-[4-(4-Fluoro-phenyl)-5-pyridin4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer (4.52 g, Compound AW), stirred in a mixture of ethanol andmethanol (45 ml, 95:5, v/v), was treated with d-10-camphorsulphonic acid(2.55 g). The mixture was heated to reflux and the resulting solutionallowed to cool to room-temperature. The resulting solid was collectedby filtration and washed three times with a mixture of ethanol andmethanol (10 ml, 95:5, v/v) to give{2-[4-(4-fluoro-phenyl)-5-pyridin4-yl-1H-imidazol-2-yl]-5-methyl-[1.3]dioxan-5-yl}-morpholin-4-yl-methanoned-10-camphorsulphonic acid salt. trans-isomer (6.0 g, Compound GG) aspale yellow crystals, m.p. 265-267° C (with decomposition). ¹H NMR(CD₃)₂SO: δ0.74 (s, 3H), 1.05 (s, 3H), 1.33-1.43 (m, 2H), 1.58 (s, 3H),1.80 (d, 1H), 1.81-1.89 (m, 1H), 1.94 (t, 1H), 1.94 (t, 1H), 2.24 (dt,1H), 2.49 (d, 1H), 2.64-2.72 (m, 1H), 2.89 (d, 1H), 33.53 (d, 8H), 4.12(s, 4H), 5.69 (s, 1H), 7.40 (t, 2H), 7.57-7.63 (m, 2H), 7.90 (d, 2H),8.68 (d, 2H).

EXAMPLE 23

[0652] Compounds GH to HK

[0653] (a) A solution of{2-[4-(4-fluoro-phenyl)-5-(2-methanesulphonylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans isomer (1 equivalent, Compound KH) and cyclopropylamine (5equivalents) in dry dimethylformamide was heated at 100° C. for 16hours. The solvent was evaporated and the residue subjected to highpressure liquid chromatography on a C18 Dynamax 60 Å column usinggradient elution with a mixture of acetonitrile and water as the mobilephase (0-2 minutes 20% acetonitrile; 3-16 minutes ramp up to 80%acetonitrile; 17 minutes to end of run 80% acetonitrile) and UVdetection at 238nm to give{2-[5-(2-cyclopropylaminopyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1.3]dioxan-5-yl}-morpholin-4-yl-methanone,trans isomer (Compound GH), HPLC retention time=8.0 minutes. MH⁺ 509.

[0654] (b) By proceeding in a similar manner to Example 23(a), butreplacing cyclopropylamine with an appropriately substituted amine offormula HNY⁴Y⁵ [5 equivalents, see Table 7], there were preparedCompounds GI to HK in Table 7. For Compound GI the reaction was carriedout in the absence of dimethylformamide in a sealed vessel. For CompoundGW the lithio-anion of the aniline (generated by reaction of anilinewith butyl lithium in tetrahydrofuran according to standard reactionconditions) was used to replace the cyclopropylamine. Compounds GI to GLwere obtained as solids on treating the crude reaction product withacetonitrile. The R_(T) values indicated in Table 7 refer to highpressure liquid chromatography retention times determined on a C18Dynamax 60 Å column using gradient elution with a mixture ofacetonitrile and water as the mobile phase (0-{2 minutes 5% acetonitrileramp up to 80% acetonitrile; 12 minutes to end of run 80% acetonitrile).The R_(F) values indicated in Table 7 were determined using a mixture ofethyl acetate and methanol (19:1, v/v) [the eluant for Compounds HJ andHK was a mixture of dichloromethane and methanol (9:1, v/v)]. TABLE 7STRUCTURE and MOLECULAR MH⁺ Compound number HNY⁴Y⁵ R_(T) R_(F) FORMULA(Intensity)

NH₃ 9 C23H25FN5O4 469 (100%)

0.5 C25H29FN6O4 497 (100%)

0.07 C26H31FN6O5 527 (100%)

0.19 C26H31FN6O5 527 (100%)

H₂N— 9 C24H27FN6O4 483 (100%)

10 C31H38FN7O6 624 (100%)

11 C29H35FN6O4 551 (100%)

8 C25H29FN6O5 513 (100%)

6 C25H30FN7O4 512 (100%)

7 C29H33FN8O4 577 (100%)

7 C30H38FN7O5 596 (100%)

11 C30H31FN6O4 559 (100%)

11 C31H33FN6O4 573 (100%)

11 C31H33FN6O4 573 (100%)

11.5 C29H29FN6O4 545 (100%)

10 C28H33FN6O4 537 (100%)

7 C29H30FN7O4 560 (100%)

7 C29H30FN7O4 560 (100%)

7 C29H30FN7O4 560 (100%)

10.5 C28H29FN6O5 549 (100%)

13 C28H29FN6O4S 565 (100%)

9 C28H33FN6O5 553 (100%)

7 C28H34FN7O4 552 (100%)

9 C27H31FN6O5 539 (100%)

8 C27H33FN6O5 541 (100%)

7 C28H36FN7O4 554 (100%)

7 C27H34FN7O4 540 (100%)

0.22 C25H27FN6O6 527 (100%)

0.24 C26H29FN6O6 541 (100%)

[0655] (c) By proceeding in the same manner to Example 23(b) and usingthe appropriately substituted amine of formula HNY⁴Y⁵ there are preparedCompounds A1 to A16.

[0656]{2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A1);

[0657]{2-[5-(2-allylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, trans-isomer, (Compound A2);

[0658]{2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin4-yl-methanone,trans-isomer, (Compound A3);

[0659](4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(morpholine-4-carbonyl)-[1,3]dioxan-2yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-acetonitrile,trans-isomer, (Compound A4);

[0660]3-(4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(morpholine-4-carbonyl)-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-propionitrile,trans-isomer, (Compound A5);

[0661](2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound A6);

[0662](2-{4-(4-fluoro-phenyl)-5-[2-(pyridin4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound A7);

[0663]2-(4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(morpholine4-carbonyl)-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-acetamide,trans-isomer, (Compound A8);

[0664]3-(4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(morpholine4-carbonyl)-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-propionamide,trans-isomer, (Compound A9);

[0665]{2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A 10);

[0666]{2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A11);

[0667]2-[5-(2-(4-fluorobenzyl)amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone, trans-isomer, (Compound A12);

[0668]2-[5-(2-(4-methoxybenzyl)amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A13);

[0669]{2-[4-(4-fluoro-phenyl)-5-(2-(4-fluorophenyl)amino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A14);

[0670]{2-[4-(4-fluoro-phenyl)-5-(2-(3,4-difluorophenyl)amino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A15);

[0671]{2-[4-(4-fluoro-phenyl)-5-(2-(3-methoxyphenyl)amino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A16);

[0672] (d) By proceeding in a similar manner to Example 23(b) but using2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonylpyrimidin-4-yl)-1H-imidazol-2-yl]-5,5-dimethyl-[1,3]dioxane(Compound KI) there were prepared Compounds HL to IN in Table 7a. TABLE7a STRUCTURE and MOLECUKAR MH⁺ COMPOUND NUMBER HNY⁴Y⁵ R_(T) FORMULA(Intensity)

NH₃ 10.31 C19H20FN5O2 370 (100%)

10.58 C20H22FN5O2 384 (100%)

10.88 C21H24FN5O2 398 (100%)

11.05 C22H24FN5O2 410 (100%)

12.7 C25H30FN5O2 452 (100%)

9.76 C21H24FN5O3 414 (100%)

8.85 C21H25FN6O2 413 (100%)

9.16 C25H25FN7O2 478 (100%)

9.68 C22H26FN5O2 428 (100%)

12.4 C26H26FN5O2 446 (100%)

13.01 C27H28FN5O2 474 (100%)

13.01 C27H28FN5O2 474 (100%)

12.53 C25H24FN5O2 446 (100%)

12.23 C24H28FN5O2 438 (100%)

8.97 C25H25FN6O2 461 (100%)

8.87 C25H25FN6O2 461 (100%)

8.94 C25H25FN6O2 461 (100%)

11.99 C24H24FN5O3 450 (100%)

12.3 C24H24FN5O2S 466 (100%)

11.29 C24H28FN5O3 454 (100%)

9.43 C24H29FN6O2 453 (100%)

11.1 C23H26FN5O3 440 (100%)

11.1 C23H28FN5O3 442 (100%)

10.78 C22H26FN5O3 410 (100%)

9.07 C24H31FN6O2 455 (100%)

9.14 C23H29FN6O2 441 (100%)

[0673] (e) By proceeding in a similar manner to Example 23(d) and usingthe appropriately substituted amine of formula HNY⁴Y⁵ there are preparedCompounds A17 to A35.

[0674]{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-aceticacid, (Compound A17);

[0675]3-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionicacid, (Compound A8);

[0676] {4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-piperidin-4-yl-amine,(Compound A19);

[0677]{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-pyrimidin-2-yl}-isopropyl-amine,(Compound A20);

[0678]allyl-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-amine,(Compound A21);

[0679]cyclopropylmethyl-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-amine,(Compound A22);{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-acetonitrile,(Compound A23);

[0680]3-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-pyrimidin-2-ylamino}-propionitrile,(Compound A24);

[0681]{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-pyridin-3-yl-amine,(Compound A25);

[0682]{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-pyrimidin-2-yl}-pyridin-4-yl-amine,(Compound A26);

[0683]2-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4yl]-pyrimidin-2-ylamino}-acetamide,(Compound A27);

[0684]3-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4]-pyrimidin-2-ylamino}-propionamide,(Compound A28);

[0685]{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-propyl-amine,(Compound A29);

[0686]4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-2-pyrrolidin-1-yl-pyrimidine,(Compound A30);

[0687]4-fluorobenzyl-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-amine,(Compound A31);

[0688]4-methoxybenzyl-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-amine,(Compound A32);

[0689]{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-4-fluorophenyl-amine,(Compound A33);

[0690]{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-3,4-difluorophenyl-amine,(Compound A34);

[0691]{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-3-methoxyphenyl-amine,(Compound A35);

[0692] (f) By proceeding in a similar manner to Example 23(a), but using{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans isomer, (Compound KJ) and replacing cyclopropylamine with liquidammonia and carrying out the reaction under pressure for 2 days, therewas prepared following preparative thin layer chromatography on silicagel [eluting with a mixture of dichloromethane, methanol and ammonia(90:10:2, v/v/v)]{2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanoltrans-isomer (Compound IO) as a white solid. MH⁺386. R_(F): 0.41(solvent as described immediately above).

[0693] (g) By proceeding in a similar manner to Example 23(b) but using{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans isomer, (Compound KJ) there are prepared Compounds A36 to A79:—

[0694]{2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A36);

[0695]{2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A37);

[0696]{2-[5-(2-cyclopropylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A38);

[0697](2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-methanol,trans-isomer, (Compound A39);

[0698]{2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A40);

[0699]2-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-5-methyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-ethanol,trans-isomer, (Compound A41);

[0700]{2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A42);

[0701][2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4yl}-1H-imidazol-2yl)-5-methyl-[1,3]dioxan-5-yl]-methanol,trans-isomer, (Compound A43);

[0702](2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-methanol,trans-isomer, (Compound A44);

[0703]3-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-5-methyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propan-1-ol,trans-isomer, (Compound A45);

[0704]{2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3dioxan-5-yl}-methanol,trans-isomer, (Compound A46);

[0705]{2-[5-(2-(4-fluorobenzyl)amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A47);

[0706]{2-[5-(2-(4-methoxybenzyl)amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A48);

[0707](2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-methanol,R isomer, trans-isomer, (Compound A49);

[0708](2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-methanol,S isomer, trans-isomer, (Compound A50);

[0709]{2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A51);

[0710]{2-[4-(4-fluoro-phenyl)-5-(2-(4-fluorophenyl)amino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A52);

[0711]{2-[4-(4-fluoro-phenyl)-5-(2-(3,4-difluorophenyl)amino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A53);

[0712]{2-[4-(4-fluoro-phenyl)-5-(2-(3-methoxyphenyl)amino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A54);

[0713]{2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A55);

[0714][2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-methanol,trans-isomer, (Compound A56);

[0715][2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-methanol,trans-isomer, (Compound A57);

[0716][2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-methanol,trans-isomer, (Compound A58);

[0717][2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-methanol,trans-isomer, (Compound A59);

[0718][2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-methanol,trans-isomer, (Compound A60);

[0719][2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-methanol,trans-isomer, (Compound A61);

[0720](2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-methanol,trans-isomer, (Compound A62);

[0721]{2-[4-(4-fluoro-phenyl)-5-(2-morpholin4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A63);

[0722](2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-methanol,trans-isomer, (Compound A64);

[0723](2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-methanol,trans-isomer, (Compound A65);

[0724]{2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A66);

[0725]{2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A67);

[0726]{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-5-methyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-aceticacid, trans-isomer, (Compound A68);

[0727]3-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-5-methyl-1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionicacid, trans-isomer, (Compound A69);

[0728]{2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A70);

[0729]{2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A71);

[0730]{2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A72);

[0731]{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-5-methyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-acetonitrile,trans-isomer, (Compound A73);

[0732]3-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-5-methyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionitrile,trans-isomer, (Compound A74);

[0733](2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-methanol,trans-isomer, (Compound A75);

[0734](2-{4-(4-fluoro-phenyl)-5-[2-(pyridin4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-methanol,trans-isomer, (Compound A76);

[0735]2-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-5-methyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-acetamide,trans-isomer, (Compound A77);

[0736]3-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-5-methyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionamide,trans-isomer, (Compound A78);

[0737]{2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A79);

[0738] (h) By proceeding in a similar manner to Example 23(g) but using{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,cis-isomer, (Compound KK) there are prepared the correspondingcis-isomers of Compounds A36 to A79.

[0739] (i) By proceeding in a similar manner to Example 23(b) but using2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methylene-[1,3]dioxane(Compound KL) there are prepared compounds A80 to A125:—

[0740]4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol4-yl]-pyrimidin-2-ylamine,(Compound A80);

[0741]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol4-yl]-pyrimidin-2l-yl}-methyl-amine,(Compound A81);

[0742]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol}4-yl]-pyrimidin-2-yl}-dimethyl-amine,(Compound A82);

[0743]cyclopropyl-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-amine,(Compound A83);

[0744]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol4-yl]-pyrimidin-2-yl}-piperidin-4-yl-amine,(Compound A84);

[0745]cyclohexyl-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-amine,(Compound A85);

[0746]2-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol4-yl]-pyrimidin-2-ylamino}-ethanol,(Compound A86);

[0747]N1-{4-[5-(4-fluoro-phenyl)-2-(5-methylene[1,3]dioxan-2-yl)-3H-imidazol-4]-pyrimidin-2-yl}-ethane-1,2-diamine,(Compound A87);

[0748]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol4-yl]-pyrimidin-2-yl}-[3-(5-H-imidazol-1-yl)-propyl]-amine,(Compound A88);

[0749]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol4-yl]-pyrimidin-2-yl}-(3-morpholin-4-yl-propyl)-amine,(Compound A89);

[0750]3-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol4-yl]-pyrimidin-2-ylamino}-propan-1-ol,(Compound A90);

[0751]benzyl-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol4yl]-pyrimidin-2-yl}-amine,(Compound A91);

[0752]4-fluorobenzyl-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-amine,(Compound A92);

[0753]4-methoxybenzyl-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-amine,(Compound A93);

[0754]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(1-phenyl-ethyl)-amine,R isomer, (Compound A94);

[0755]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]doxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(1-phenyl-ethyl)-amine,S isomer, (Compound A95);

[0756]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-phenyl-amine,(Compound A96);

[0757]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol4-yl]-pyrimidin-2-yl}-4-fluorophenyl-amine,(Compound A97);

[0758]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol4-yl]-pyrimidin-2-yl}-3,4-difluorophenyl-amine,(Compound A98);

[0759]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-3-methoxyphenyl-amine,(Compound A99);

[0760]4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-2-piperidin-1-yl-pyrimidine,(Compound A100);

[0761]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-31H-imidazol-4-yl]-pyrimidin-2-yl}-pyridin-4-ylmethyl-amine,(Compound A101);

[0762]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-pyridin-3-ylmethyl-amine,(Compound A102);

[0763]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol4-yl]-pyrimidin-2-yl}-pyridin-2-ylmethyl-amine,(Compound A103);

[0764]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(furan-2-ylmethyl)-amine,(Compound A104);

[0765]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol4-yl]-pyrimidin-2-yl}-(thiophen-2-ylmethyl)-amine,(Compound A 105);

[0766]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol4-yl]-pyrimidin-2-yl}-(tetrahydro-furan-2-ylmethyl)-amine,(Compound A 106);

[0767]4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-2-(4-methyl-piperazin-1-yl)-pyrimidine,(Compound A107);

[0768]4-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4yl]-pyrimidin-2-yl}-morpholine,(Compound A108);

[0769]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(3-methoxy-propyl)-amine,(Compound A109);

[0770]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(2-methoxy-ethyl)-amine,(Compound A110);

[0771]N-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-N′,N′-dimethyl-propane-1,3-diamine,(Compound A111);

[0772]N-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-N′,N′-dimethyl-ethane-1,2-diamine,(Compound A 112);

[0773]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-aceticacid, (Compound A113);

[0774]3-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionicacid, (Compound A114);

[0775]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-isopropyl-amine,(Compound A115);

[0776]allyl-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-amine,(Compound A116);

[0777]cyclopropylmethyl-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]doxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-amine,(Compound A117);

[0778]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]doxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-acetonitrile,(Compound A118);

[0779]3-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]doxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionitrile, (Compound A119);

[0780]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2yl}-pyridin-3-yl-amine,(Compound A120);

[0781]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-pyridin-4-yl-amine,(Compound A121);

[0782]2-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4yl]-pyrimidin-2-ylamino}-acetamide,(Compound A122);

[0783]3-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionamide,(Compound A123);

[0784]{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazo-4-yl]-pyrimidin-2-yl}-propyl-amine,(Compound A124);

[0785]4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-2-pyrrolidin-1-yl-pyrimidine,(Compound A125);

[0786] (j) By proceeding in a similar manner to Example 23(b) but using4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-2-methylsulphonyl-pyrimidine(Compound KM) there are prepared Compounds A126 to A170:—

[0787] 4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl-pyrimidin-2-ylamine, (Compound A126);

[0788]{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-methyl-amine,(Compound A127);

[0789]{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-dimethyl-amine,(Compound A128);

[0790]cyclopropyl-{4-[2-[,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-amine,(Compound A129);

[0791]{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-piperidin-4-yl-amine,(Compound A130);

[0792]cyclohexyl-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-amine,(Compound A131);

[0793]2-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl-pyrimidin-2-ylamino}-ethanol,(Compound A132);

[0794]N1-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-pyrimidin-2-yl}-ethane-1,2-diamine,(Compound A133);

[0795]{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-pyrimidin-2-yl-[3-(5H-imidazol-1-yl)-propyl]-amine, (Compound A134);

[0796]{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-pyrimidin-2-yl}-(3-morpholin-4-yl-propyl)-amine,(Compound A135);

[0797]3-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propan-1-ol,(Compound A136);

[0798]benzyl-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2yl}-amine,(Compound A137);

[0799]4-fluorobenzyl-{4-[2-[1,3]doxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-amine,(Compound A138);

[0800]4-methoxybenzyl-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-amine,(Compound A139);

[0801]{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(1l-phenyl-ethyl)-amine,R isomer, (Compound A140);

[0802] {4-[2-+8,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(1-phenyl-ethyl)-amine,S isomer, (Compound A141);

[0803]{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-phenyl-amine,(Compound A142);

[0804]{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-pyrimidin-2-yl}-(4-fluorophenyl)-amine,(Compound A143);

[0805]{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-pyrimidin-2-yl}-(3,4-difluorophenyl)-amine,(Compound A144);

[0806]{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-pyrimidin-2-yl}-(4l-methoxyphenyl)-amine,(Compound A145);

[0807]4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-2-piperidin-1-yl-pyrimidine,(Compound A146);

[0808]{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-pyrimidin-2-yl}-pyridin-4-ylmethyl-amine,(Compound A147);

[0809]{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-pyridin-3-ylmethyl-amine,(Compound A148);

[0810]{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyridin-2-ylmethyl-amine,(Compound A149);

[0811]{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(furan-2-ylmethyl)-amine{4-[2-[1,13]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4l-yl]-pyrimidin-2-yl}-thiophen-2-ylmethyl)-amine,(Compound A150);

[0812]{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-pyrimidin-2-yl}-(tetrahydro-furan-2-ylmethyl)-amine,(Compound A 151);

[0813]4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-2-(4-methyl-piperazin-1-yl)-pyrimidine,(Compound A152);

[0814]4-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-morpholine,(Compound A153);

[0815]{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(3-methoxy-propyl)-amine,(Compound A154);

[0816]{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(2-methoxy-ethyl)-amine,(Compound A155);

[0817]N-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-N′-N′-dimethyl-propane-1,3-diamine,(Compound A156);

[0818]N-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-N′,N′-dimethyl-ethane-1,2-diamine,(Compound A157);

[0819]{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-pyrimidin-2-ylamino}-aceticacid, (Compound A158);

[0820]3-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2l-ylamino}-propionicacid, (Compound A159);

[0821]{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-pyrimidin-2-yl}-isopropyl-amine,(Compound A160);

[0822]allyl-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-pyrimidin-2-yl}-amine,(Compound A161);

[0823]cyclopropylmethyl-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-amine,(Compound A162);

[0824]{4-[2-[1,3]doxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-acetronitrile,(Compound A163);

[0825]3-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionitrile,(Compound A164);

[0826]{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-pyridin-3yl-amine,(Compound A165);

[0827]{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-pyridin-4-amine,(Compound A166);

[0828]2-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-acetamide,(Compound A167);

[0829]3-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-pyrimidin-2-ylamino}-propionamide,(Compound A168);

[0830]{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-propyl-amine,(Compound A169);

[0831]4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-2-pyrrolidin-1-yl-pyrimidine,(Compound A170);

[0832] (k) By proceeding in a similar manner to Example 23(b) but using{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound KN) there are prepared Compounds A171 to A215:—

[0833]{2-[5-(2-amino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A171);

[0834]{2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A172);

[0835]{2-[5-(2-dimethylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-[1,3dioxan-5-yl}-methanol,trans-isomer, (Compound A173);

[0836]{2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A174);

[0837](2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2yl}-[1,3dioxan-5-yl)-methanol,trans-isomer, (Compound A175);

[0838]{2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A176);

[0839]2-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-ethanol,trans-isomer, (Compound A177);

[0840]{2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A178);

[0841][2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-[1,3]dioxan-5-yl]-methanol,trans-isomer, (Compound A179);

[0842](2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-H-imidazol-2-yl}-[1,3]dioxan-5-yl)-methanol,trans-isomer, (Compound A180);

[0843]3-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propan-1-ol,trans-isomer, (Compound A181);

[0844]{2-[5-(2-benzylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A182);

[0845]{2-[5-(2-(4-fluorobenzyl)amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A183);

[0846]{2-[5-(2-(4-methoxybenzyl)amino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A184);

[0847](2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-[1,3]dioxan-5-yl)-methanol,R isomer, trans-isomer, (Compound A185);

[0848](2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-[1,3]dioxan-5-yl)-methanol,S isomer, trans-isomer, (Compound A186);

[0849]{2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5l-yl}-methanol,trans-isomer, (Compound A187);

[0850]{2-[4-(4-fluoro-phenyl)-5-(2-(4-fluorophenyl)amino-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A188);

[0851]{2-[4-(4-fluoro-phenyl)-5-(2-(3,4-difluorophenyl)amino-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A189);

[0852]{2-[4-(4-fluoro-phenyl)-5-(2-(4-methoxyphenyl)amino-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A190);

[0853]{2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A191);

[0854][2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2yl)-[1,3]dioxan-5-yl]-methanol,trans-isomer, (Compound A192);

[0855][2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-[1,3]dioxan-5-yl]-methanol,trans-isomer, (Compound A193);

[0856][2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4yl}-1H-imidazol-2-yl)-[1,3]dioxan-5-yl]-methanol,trans-isomer, (Compound A194);

[0857][2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4y}-1H-imidazol-2-yl)-[1,3]dioxan-5-yl]-methanol,trans-isomer, (Compound A195);

[0858][2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-[1,3]dioxan-5-yl]-methanol,trans-isomer, (Compound A196);

[0859][2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-[1,3]dioxan-5-yl]-methanol,trans-isomer, (Compound A197);

[0860](2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-[1,3]dioxan-5-yl)-methanol,trans-isomer, (Compound A198);

[0861]{2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A199);

[0862](2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A199);

[0863](2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4yl]-1H-imidazol-2-yl}-[1,3]dioxan-5-yl)-methanol,trans-isomer, (Compound A200);

[0864](2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-[1,3]dioxan-5-yl)-methanol,trans-isomer, (Compound A201);

[0865]{2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A202);

[0866]{2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A203);

[0867]{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-aceticacid, trans-isomer, (Compound A204);

[0868]3-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionicacid, trans-isomer, (Compound A205);

[0869]{2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A206);

[0870]{2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A207);

[0871]{2-[5-[2-(isopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A208);

[0872]{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-acetonitrile,trans-isomer, (Compound A209);

[0873]3-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionitrile,trans-isomer, (Compound A210);

[0874](2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-[1,3]dioxan-5-yl)-methanol,trans-isomer, (Compound A211);

[0875](2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-[1,3]dioxan-5-yl)-methanol,trans-isomer, (Compound A212);

[0876]2-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-acetamide,trans-isomer, (Compound A213);

[0877]3-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionamide,trans-isomer, (Compound A214);

[0878]{2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol.,trans-isomer, (Compound A215);

[0879] (l) By proceeding in a similar manner to Example 23 (k) but using{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,cis-isomer, (Compound KO) there are prepared the correspondingcis-isomers of Compounds A171 to A215.

EXAMPLE 24

[0880] Compounds IP to IW

[0881] (a) A stirred solution of{2-[4-(4-fluoro-phenyl)-5-(2-methanesulphonylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans isomer, (1 equivalent, Compound KB) and an appropriatelysubstituted alcohol or phenol [5 equivalents, see table 8] in drydimethylformamide, at room temperature, was treated with sodium hydride[6 equivalents]. After stirring for 16 hours the reaction mixture wasevaporated and the residue partitioned between water and ethyl acetate.The organic phase was evaporated to give Compounds IP to IW depicted inTable 8. The R_(F) values indicated in Table 8 were determined using amixture of ethyl acetate and methanol (9:1, v/v) as eluant [the eluantfor Compound IT was a mixture of ethyl acetate and methanol (1:1, v/v)].TABLE 8 STRUCTURE and MOLECULAR MH⁺ Compound number R¹⁷OH R_(F) FORMULA(Intensity)

0.37 C24H26FN5O5 484 (100%)

0.45 C30H30FN5O5 560 (100%)

0.41 C29H28FN5O5 546 (100%)

0.28 C26H30FN5O6 528 (100%)

0.19 C27H33FN6O5 541 (100%)

0.43 C29H34FN5O5 552 (100%)

0.43 C26H30FN5O5 512 (100%)

[0882] (b) By proceeding in the same manner to Example 24(a) there areprepared Compounds A216 to A219.

[0883]{2-[4-(4-fluoro-phenyl)-5-(2-hydroxypyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A216);

[0884]{2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,tans-isomer, (Compound A217);

[0885](2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin4-yl-methanone,trans-isomer, (Compound A218);

[0886](2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2}-5-methyl-

[0887] (c) By proceeding in a similar manner to Example 24(a) but using2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonylpyrimidin-4-yl)-1H-imidazol-2-yl]-5,5-dimethyl-[1,3]dioxane(Compound KI) there were prepared Compounds IY to JE in Table 8a. TABLE8a

11.44 C20H21FN4O3 386 (100%)

13.40 C26H25FN4O3 461 (100%)

13.15 C25H23FN4O3 447 (100%)

11.08 C22H25FN4O4 429 (100%)

9.60 C23H28FN5O3 442 (100%)

13.52 C25H29FN4O3 453 (100%)

12.14 C22H25FN4O3 413 (100%)

[0888] (d) By proceeding in the same manner to Example 24(c) there areprepared Compounds A220 to A222.

[0889]4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-2-propoxy-pyrimidine,(Compound A220);

[0890]2-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-pyrimidin-2-yloxy}-ethanol,(Compound A221);

[0891]3-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yloxy}-propan-1-ol,(Compound A222);

[0892] (e) By proceeding in a similar manner to Example 24(a) but using{2-[5-(2-methanesulphonyl-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound KJ) there are prepared Compounds A223 to A232:—

[0893]{2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomers, trans-isomer, (Compound A223);

[0894]{2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A224);

[0895]{2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A225);

[0896](2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-methanol,trans-isomer, (Compound A226);

[0897]{2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A227);

[0898]{2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A228);

[0899]{2-[5-(2-isopropoxy-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A229);

[0900]{2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A230);

[0901]2-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-5-methyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yloxy}-ethanol,trans-isomer, (Compound A231);

[0902]3-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-5-methyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yloxy}-propan-1-ol.,trans-isomer, (Compound A232);

[0903] (f) By proceeding in a similar manner to Example 24 (e) but using{2-[5-(2-methanesulphonyl-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,cis-isomer, (Compound KK) there are prepared the correspondingcis-isomers of Compounds A223 to A232.

[0904] (g) By proceeding in a similar manner to Example 24(a) but using{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound KN) there are prepared Compounds A233 to A242:—

[0905]{2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A233);

[0906]{2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A234);

[0907]{2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A235);

[0908](2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-[1,3]dioxan-5-yl)-methanol,trans-isomer, (Compound A236);

[0909]{2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A237);

[0910]{2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A238);

[0911]{2-[5-(2-isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A239);

[0912]{2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound A240);

[0913]2-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yloxy}-ethanol,trans-isomer, (Compound A241);

[0914]3-{4-[5-(4-fluoro-phenyl)-2-(5-hydroxymethyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]pyrimidin-2-yloxy}-propan-1-ol,trans-isomer, (Compound A242);

[0915] (h) By proceeding in a similar manner to Example 24 (g) but using{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,cis-isomer, (Compound KO) there are prepared the correspondingcis-isomers of Compounds A233 to A242.

[0916] (i) By proceeding in a similar manner to Example 24(a) but using4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-2-methylsulphonyl-pyrimidine(Compound KL) there are prepared Compounds A243 to A252:—

[0917]4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-2-methoxy-pyrimidine,(Compound A243);

[0918]2-benzyloxy-4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidine,(Compound A244);

[0919]4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-2-phenoxy-pyrimidine,(Compound A245);

[0920]4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-2-(2-methoxy-ethoxy)-pyrimidine,(Compound A246);

[0921](2-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yloxy)-ethyl)-dimethyl-amine,(Compound A247);

[0922]2-cyclohexyloxy4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidine,(Compound A248);

[0923]2-cyclopropoxy-4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidine,(Compound A249);

[0924]4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-2-propoxy-pyrimidine,(Compound A250);

[0925]2-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yloxy}-ethanol,(Compound A251);

[0926]3-{4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-yloxy}-propan-1-ol,(Compound A252);

[0927] (j) By proceeding in a similar manner to Example 24(a) but using4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-2-methylsulphonyl-pyrimidine(Compound KM) there are prepared Compounds A253 to A262:—

[0928]4-[2-[(1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-2-methoxy-pyrimidine,(Compound A253);

[0929]2-benzyloxy-4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidine,(Compound A254);

[0930]4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-2-phenoxy-pyrimidine,(Compound A255);

[0931]4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-2-(2-methoxy-ethoxy)-pyrimidine,(Compound A256);

[0932](2-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yloxy}-ethyl)-dimethyl-amine,(Compound A257);

[0933]2-cyclohexyloxy-4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-pyrimidine,(Compound A258);

[0934]2-isopropyloxy-4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidine,(Compound A259);

[0935]4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol4-yl]-2-propoxy-pyrimidine,(Compound A260);

[0936]2-{4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yloxy}-ethanol,(Compound A261);

[0937]3-{4-[2-[1,3dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yloxy}-propan-1-ol,(Compound A262);

EXAMPLE 25

[0938] Compounds JF to KG

[0939] (a) A solution of2,2,2-trifluoro-N-[2-{4-(4-fluoro-phenyl)-5-(2-methanesulphonylpyrimidin-4-yl)-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl]acetamide,cis-isomer, (1 equivalent, Compound KP) and an appropriately substitutedamine of formula HNY⁴Y⁵ [5 equivalents, see Table 9] in drydimethylformamide was heated at 100° C. for 8 hours (or in the case ofJF reacted without a solvent in a pressure vessel). The reaction mixturewas then treated with aqueous potassium carbonate solution (2equivalents) and then heated at 100° C. for 24 hours. The mixture waspartitioned between water and dichloromethane. The organic phase wasseparated, evaporated and the residue subjected to high pressure liquidchromatography, on a C18 Dynamax 60 Å column using gradient elution witha mixture of acetonitrile and water as the mobile phase (0.3 minutes,20% acenotrile, 2.15 minutes ramp up to 80% acetonitrile; 16 minutes toend of run 80% acetonitrile) and LW detection at 254 nm, to giveCompounds JF to KG depicted in Table 9. The RT values indicated in Table9 refer to the high pressure liquid chromatography retention timesdetermined as described above. TABLE 9 STRUCTURE and R_(T) MOLECULAR MH⁺EXAMPLE NUMBER HNY⁴Y⁵ (minutes) FORMULA (Intensity)

NH₃ 11.41 C18H19FN6O2 371 (100%)

11.65 C19H21FN6O2 385 (100%)

11.85 C20H23FN6O2 399 (100%)

12.10 C21H23FN6O2 411 (100%)

2.70 C23H28FN7O2 545 (100%)

10.91 C24H29FN6O2 453 (100%)

10.30 C20H23FN6O3 415 (100%)

1.96 C20H24FN7O2 414 (100%)

1.98 C24H27FN8O2 470 (100%)

2.02 C25H32FN7O2 498 (100%)

10.40 C21H25FN6O2 413 (100%)

10.18 C25H25FN6O2 461 (100%)

10.91 C26H27FN6O2 475 (100%)

10.91 C26H27FN6O2 475 (100%)

11.01 C24H23FN6O2 447 (100%)

13.15 C23H27FN6O2 439 (100%)

3.95 C24H24FN7O2 462 (100%)

2.14 C24H24FN7O2 462 (100%)

1.96 C24H24FN7O2 462 (100%)

11.93 C23H23FN6O3 451 (100%)

12.10 C23H23FN6O2S 467 (100%)

12.44 C23H27FN6O3 455 (100%)

2.10 C23H28FN7O2 454 (100%)

12.20 C22H25FN6O3 441 (100%)

11.10 C22H27FN6O3 443 (100%)

11.86 C21H25FN6O3 429 (100%)

2.02 C23H30FN7O2 456 (100%)

2.04 C22H28FN7O2 442 (100%)

[0940] (b) By proceeding in the same manner Example 25(a) there areprepared Compounds A263 to A280.

[0941]{4-L2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol4-pyrimidin-2-ylamino}-aceticacid, cis-isomer, (Compound A263);

[0942]3-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionicacid, cis-isomer, (Compound A264);

[0943]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-isopropyl-amine,cis-isomer, (Compound A265);

[0944]allyl-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-amine,cis-isomer, (Compound A266);

[0945]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-cyclopropylmethyl-amine,cis-isomer, (Compound A267);

[0946]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-acetonitrile,cis-isomer, (Compound A268);

[0947]3-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2l-ylamino}-propionitrile,cis-isomer, (Compound A269);

[0948]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-pyridin-3-yl-amine,cis-isomer, (Compound A270);

[0949]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-pyridin-4-yl-amine,cis-isomer, (Compound A271);

[0950]2-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-acetamide,cis-isomer, (Compound A272);

[0951]3-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionamide,cis-isomer, (Compound A273);

[0952]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-propyl-amine,cis-isomer, (Compound A274);

[0953]2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylamine,cis-isomer, (Compound A275);

[0954]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(4-fluorobenzyl)-amine,cis-isomer, (Compound A276);

[0955]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(4-methoxybenzyl)-amine,cis-isomer, (Compound A277);

[0956]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(4-fluorophenyl)-amine,cis-isomer, (Compound A278);

[0957]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(3,4-difluorophenyl)-amine,cis-isomer, (Compound A279);

[0958]{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl}-(4-methoxyphenyl)-amine,cis-isomer, (Compound A280);

[0959] (c) By proceeding in a similar manner to Example 25(a) butreplacing the amine with a single equivalent of the sodium salt of anappropriately substituted alcohol or phenol there are prepared CompoundsA281 to A290.

[0960]2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylamine,cis-isomer, (Compound A281);

[0961]2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylamine,cis-isomer, (Compound A282);

[0962]2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylamine,cis-isomer, (Compound A283);

[0963]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylamine,cis-isomer, (Compound A284);

[0964]2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylamine,cis-isomer, (Compound A285);

[0965]2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylamine,cis-isomer, (Compound A286);

[0966]2-[5-(2-Isolopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylamine,cis-isomer, (Compound A287);

[0967]2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylamine,cis-isomer, (Compound A288);

[0968]2-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yloxy}-ethanol,cis-isomer, (Compound A289);

[0969]3-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-3-yl]-pyrimidin-2-yloxy}-propan-1-ol,cis-isomer, (Compound A290);

[0970] (d) By proceeding in a similar manner to Example 25(a) but using2,2,2-trifluoro-N-{2-[5-(2-methylsulphonyl-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,trans isomer (Compound LL) there are prepared Compounds A291 to A337.

[0971]4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamine,trans-isomer, (Compound A291);

[0972]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-methyl-amine,trans-isomer, (Compound A292);

[0973]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-dimethyl-amine,trans-isomer, (Compound A293);

[0974]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-cyclopropyl-amine,trans-isomer, (Compound A294);

[0975]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-piperidin-4-yl-amine,trans-isomer, (Compound A295);

[0976]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-cyclohexyl-amine,trans-isomer, (Compound A296);

[0977]2-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-ethanol,trans-isomer, (Compound A297);

[0978]N1-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-ethane-1,2-diamine,trans-isomer, (Compound A298);

[0979]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-[3-(5H-imidazol-1-yl)-propyl]-amine,trans-isomer, (Compound A299);

[0980]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(3-morpholin-4-yl-propyl)-amine,trans-isomer, (Compound A300);

[0981]3-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propan-1-ol,trans-isomer, (Compound A301);

[0982]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-benzyl-amine,trans-isomer, (Compound A302);

[0983]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(4-fluorobenzyl)-amine,trans-isomer, (Compound A303);

[0984]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(4-methoxybenzyl)-amine,trans-isomer, (Compound A304);

[0985]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(1-phenyl-ethyl)-amine,R isomer, trans-isomer, (Compound A305);

[0986]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(1-phenyl-ethyl)-amine,S isomer, trans-isomer, (Compound A306);

[0987]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-phenyl-amine,trans-isomer, (Compound A307);

[0988]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(4-fluorophenyl)-amine,trans-isomer, (Compound A308);

[0989]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(3,4-difluorophenyl)-amine,trans-isomer, (Compound A309);

[0990]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(3-methoxyphenyl)-amine,trans-isomer, (Compound A310);

[0991]C-{2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methylamine,trans-isomer, (Compound A311);

[0992]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-pyridin-4-ylmethyl-amine,trans-isomer, (Compound A312);

[0993]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-pyridin-3-ylmethyl-amine,trans-isomer, (Compound A313);

[0994]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-pyridin-2-ylmethyl-amine,trans-isomer, (Compound A314);

[0995]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(furan-2-ylmethyl)-amine,trans-isomer, (Compound A315);

[0996]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(thiophen-2-ylmethyl)-amine,trans-isomer, (Compound A316);

[0997]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl]-(tetrahydro-furan-2-ylmethyl)-amine,trans-isomer, (Compound A317);

[0998]C-(2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-methylamine,trans-isomer, (Compound A318);

[0999]C-{2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methylamine,trans-isomer, (Compound A319);

[1000]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(3-methoxy-propyl)-amine,trans-isomer, (Compound A320);

[1001]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(2-methoxy-ethyl)-amine,trans-isomer, (Compound A321);

[1002]N-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-N′,N′-dimethyl-propane-1,3-diamine,trans-isomer, (Compound A322);

[1003]N-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-N′,N′-dimethyl-ethane-1,2-diamine,trans-isomer, (Compound A323);

[1004]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-aceticacid, trans-isomer, (Compound A324);

[1005]3-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionicacid, trans-isomer, (Compound A325);

[1006]C-{2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methylamine,trans-isomer, (Compound A326);

[1007]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-isopropyl-amine,trans-isomer, (Compound A327);

[1008]allyl-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-amine,trans-isomer, (Compound A328);

[1009]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-cyclopropylmethyl-amine,trans-isomer, (Compound A329);

[1010]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-acetonitrile,trans-isomer, (Compound A330);

[1011]3-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino3-propionitrile,trans-isomer, (Compound A331);

[1012]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-pyridin-3-yl-amine,trans-isomer, (Compound A332);

[1013]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-pyridin-4-yl-amine,trans-isomer, (Compound A333);

[1014]2-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-acetamide,trans-isomer, (Compound A334);

[1015]3-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionamide,trans-isomer, (Compound A335);

[1016]{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-propyl-amine,trans-isomer, (Compound A336);

[1017]C-{2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methylamine,trans-isomer, (Compound A337);

[1018] (e) By proceeding in a similar manner to Example 25(d) but using2,2,2-trifluoro-N-{2-[5-(2-methylsulphonyl-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis isomer (Compound LK) there are prepared the corresponding cisisomers of Compounds A291 to A337.

[1019] (f) By proceeding in a similar manner to Example 25(d) but using2,2,2-trifluoro-N-{2-[5-(2-methylsulphonyl-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,trans isomer (Compound LL) there are prepared Compounds A338 to A347.

[1020]C-{2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methylamine,trans-isomer, (Compound A338);

[1021]C-{2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methylamine,trans-isomer, (Compound A339);

[1022]C-{2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methylamine,trans-isomer, (Compound A340);

[1023]C-(2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-methylamine,trans-isomer, (Compound A341);

[1024](2-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yloxy}-ethyl)-dimethyl-amine,trans-isomer, (Compound A342);

[1025]C-{2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methylamine,trans-isomer, (Compound A343);

[1026]C-{2-[5-(2-isopropoxy-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methylamine,trans-isomer, (Compound A344);

[1027]C-{2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methylamine,trans-isomer, (Compound A345);

[1028]2-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yloxy}-ethanol,trans-isomer, (Compound A346);

[1029]3-{4-[2-(5-aminomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yloxy}-propan-1-ol,trans-isomer, (Compound A347);

[1030] (g) By proceeding in a similar manner to Example 25(f) but using2,2,2-trifluoro-N-{2-[5-(2-methylsulphonyl-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis isomer, (Compound LK) there are prepared the corresponding cisisomers of Compounds A338 to A347.

EXAMPLE 26

[1031] Compounds A348 to A575

[1032] (a) (i) Treatment ofC-{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methylamine,cis-isomer (Compound KZ) with either acetyl chloride, benzoyl chloride,phenylacetyl chloride according to method described in Example 11 ormethanesulphonyl chloride according to method described in Example 13;

[1033] (ii) Treatment of compounds obtained from (i) withm-chloroperbenzoic acid according to method described for Example 27;

[1034] (iii) Treatment of compounds from (ii) with amines of formulaHNY⁴Y⁵ or sodium salts of appropriately substituted alcohols or phenolsaccording to methods described in Example 23 or Example 24;

[1035] gives compounds A348 to A575:—

[1036]N-{2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A348);

[1037]N-{2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A349):

[1038]N-{2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A350);

[1039]N-{2-[5-(2-cyclopropylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A351);

[1040]N-(2-{4-(4-fluoro-phenyl)-5-[2-(piperidin4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-acetamide,cis-isomer, (Compound A352);

[1041]N-{2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A353);

[1042]N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-H-imidazol-2yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-acetamide,cis-isomer, (Compound A354);

[1043]N-{2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A355);

[1044]N-[2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-acetamide,cis-isomer, (Compound A356);

[1045]N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-acetamide,cis-isomer, (Compound A357);

[1046]N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-acetamide,cis-isomer, (Compound A358);

[1047]N-{2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A359);

[1048]N-{2-[5-(2-(4-fluorobenzyl)amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A360);

[1049]N-{2-[5-(2-(4-methoxybenzyl)amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A361);

[1050]N-(2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-acetamide,R isomer, cis-isomer, (Compound A362);

[1051]N-(2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-acetamide,S isomer, cis-isomer, (Compound A363);

[1052]N-{2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A364);

[1053]N-{2-[4-(4-fluoro-phenyl)-5-(2-(4-fluorophenyl)amino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A365);

[1054]N-{2-[4-(4-fluoro-phenyl)-5-(2-(3,4-difluorophenyl)amino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A366);

[1055]N-{2-[4-(4-fluoro-phenyl)-5-(2-(3-methoxyphenyl)amino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A367);

[1056]N-{2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A368);

[1057]N-[2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-acetamide,cis-isomer, (Compound A369);

[1058]N-[2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-acetamide,cis-isomer, (Compound A370);

[1059]N-[2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-acetamide,cis-isomer, (Compound A371);

[1060]N-[2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-acetamide,cis-isomer, (Compound A372);

[1061]N-[2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-acetamide,cis-isomer, (Compound A373);

[1062]N-[2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-acetamide,cis-isomer, (Compound A374);

[1063]N-(2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-acetamide,cis-isomer, (Compound A375);

[1064]N-{2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A376);

[1065]N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-acetamide,cis-isomer, (Compound A377);

[1066]N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-acetamide,cis-isomer, (Compound A378);

[1067]N-{2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A379);

[1068]N-{2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A380);

[1069]{4-[2-[5-(acetylamino-methyl)-5-methyl-[1,3]dioxan-2-yl]-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-aceticacid, cis-isomer, (Compound A381);

[1070]3-{4-[2-[5-(acetylamino-methyl)-5-methyl-[1,3]dioxan-2-yl]-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionicacid, cis-isomer, (Compound A382);

[1071]N-{2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A383);

[1072]N-{2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A384);

[1073]N-{2-[5-(2-benzyloxy-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A385);

[1074]N-{2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A386);

[1075]N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-acetamide,cis-isomer, (Compound A387);

[1076]N-{2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A388);

[1077]N-{2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A389);

[1078]N-{2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A390);

[1079]N-{2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A391);

[1080]N-{2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A392);

[1081]N-{2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A393);

[1082]N-{2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A394);

[1083]N-{2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A395);

[1084]N-(2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-acetamide,cis-isomer, (Compound A396);

[1085]N-(2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-acetamide,cis-isomer, (Compound A397);

[1086]2-{4-[2-[5-(acetylamino-methyl)-5-methyl-[1,3]dioxan-2-yl]-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-acetamide,cis-isomer, (Compound A398);

[1087]3-{4-[2-[5-(acetylamino-methyl)-5-methyl-[1,3]dioxan-2-yl]-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionamide,cis-isomer, (Compound A399);

[1088]N-{2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A400);

[1089]N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-acetamide,cis-isomer, (Compound A401);

[1090]N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2}-5-methyl-[1,3]dioxan-5-ylmethyl)-acetamide,cis-isomer, (Compound A402);

[1091]N-{2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A403);

[1092]N-{2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound A404);

[1093]N-{2-[5-(2-amino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A405);

[1094]N-{2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A406);

[1095]N-{2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A407);

[1096]N-{2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A408);

[1097]N-(2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-methanesulfonamide,cis-isomer, (Compound A409);

[1098]N-{2-[5-(2-cyclohexylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A410);

[1099]N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl_56-5-methyl-[1,3]dioxan-5-ylmethyl)-methanesulfonamide, cis-isomer,(Compound A411);

[1100]N-{2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A412);

[1101]N-[2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-methanesulfonamide,cis-isomer, (Compound A413);

[1102]N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-methanesulfonamide,cis-isomer, (Compound A414);

[1103]N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-methanesulfonamide,cis-isomer, (Compound A415);

[1104]N-{2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A416);

[1105]N-{2-[5-(2-(4-fluorobenzyl)amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A417);

[1106]N-{2-[5-(2-(4-methoxybenzyl)amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A418);

[1107]N-(2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-methanesulfonamide,R isomer, cis-isomer, (Compound A419);

[1108]N-(2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-methanesulfonamide,S isomer, cis-isomer, (Compound A420);

[1109]N-{2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A421);

[1110]N-{2-[4-(4-fluoro-phenyl)-5-(2-(4-fluorophenyl)amino-pyrimidin-4-yl)-1H-imidazol-2yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A422);

[1111]N-{2-[4-(4-fluoro-phenyl)-5-(2-(3,4-difluorophenyl)amino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A423);

[1112]N-{2-[4-(4-fluoro-phenyl)-5-(2-(3-methoxyphenyl)amino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A424);

[1113]N-{2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A425);

[1114]N-[2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-methanesulfonamide,cis-isomer, (Compound A426);

[1115]N-[2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-methanesulfonamide,cis-isomer, (Compound A427);

[1116]N-[2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-methanesulfonamide,cis-isomer, (Compound A428);

[1117]N-[2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-methanesulfonamide,cis-isomer, (Compound A429);

[1118]N-[2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-methanesulfonamide,cis-isomer, (Compound A430);

[1119]N-[2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-methanesulfonamide,cis-isomer, (Compound A431);

[1120]N-(2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-methanesulfonamide,cis-isomer, (Compound A432);

[1121]N-{2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A433);

[1122]N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-methanesulfonamide,cis-isomer, (Compound A434);

[1123]N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-methanesulfonamide,cis-isomer, (Compound A435);

[1124]N-{2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A436);

[1125]N-{2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A437);

[1126](4-{5-(4-fluoro-phenyl)-2-[5-(methanesulfonylamino-methyl)-5-methyl-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-aceticacid, cis-isomer, (Compound A438);

[1127]3-(4-{5-(4-fluoro-phenyl)-2-[5-(methanesulfonylamino-methyl)-5-methyl-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-propionicacid, cis-isomer, (Compound A439);

[1128]N-{2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A440);

[1129]N-{2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A441);

[1130]N-{2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A442);

[1131]N-{2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A443);

[1132]N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-methanesulfonamide,cis-isomer, (Compound A444);

[1133]N-{2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-y]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A445);

[1134]N-{2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A446);

[1135]N-{2-[5-(2-Isopropoxy-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A447);

[1136]N-{2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A448);

[1137]N-{2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A449);

[1138]N-{2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A450);

[1139]N-{2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A451);

[1140]N-{2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A452);

[1141]N-(2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-methanesulfonamide,cis-isomer, (Compound A453);

[1142]N-(2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-methanesulfonamide,cis-isomer, (Compound A454);

[1143]2-(4-{5-(4-fluoro-phenyl)-2-[5-(methanesulfonylamino-methyl)-5-methyl-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-acetamide,cis-isomer, (Compound A455);

[1144]3-(4-{5-(4-fluoro-phenyl)-2-[5-(methanesulfonylamino-methyl)-5-methyl-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-propionamide,cis-isomer, (Compound A456);

[1145]N-{2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A457);

[1146]N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-methanesulfonamide,cis-isomer, (Compound A458);

[1147]N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5l-methyl-[1,3]dioxan-5-ylmethyl)-methanesulfonamide,cis-isomer, (Compound A459);

[1148]N-{2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A460);

[1149]N-{2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulfonamide,cis-isomer, (Compound A461);

[1150]N-{2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A462);

[1151]N-{2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A463);

[1152]N-{2-[5-(2-dimethylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A464);

[1153]N-{2-[5-(2-cyclopropylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A465);

[1154]N-(2-{4-(4-fluoro-phenyl)-5-[2-(piperidin4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-benzamide,cis-isomer, (Compound A466);

[1155]N-{2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A467);

[1156]N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-benzamide,cis-isomer, (Compound A468);

[1157]N-{2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A469);

[1158]N-[2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-benzamide,cis-isomer, (Compound A470);

[1159]N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-benzamide,cis-isomer, (Compound A471);

[1160]N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-benzamide,cis-isomer, (Compound A472);

[1161]N-{2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A473);

[1162]N-{2-[5-(2-(4-fluorobenzyl)amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A474);

[1163]N-{2-[5-(2-(4-methoxybenzyl)amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A475);

[1164]N-(2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-benzamide,R isomer, cis-isomer, (Compound A476);

[1165]N-(2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-benzamide,S isomer, cis-isomer, (Compound A477);

[1166]N-{2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A478);

[1167]N-{2-[4-(4-fluoro-phenyl)-5-(2-(4-fluorophenyl)amino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A479);

[1168]N-{2-[4-(4-fluoro-phenyl)-5-(2-(3,4-difluorophenyl)amino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A480);

[1169]N-{2-[4-(4-fluoro-phenyl)-5-(2-(3-methoxyphenyl)amino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A481);

[1170]N-{2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A482);

[1171]N-[2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-benzamide,cis-isomer, (Compound A483);

[1172]N-[2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-benzamide,cis-isomer, (Compound A484);

[1173]N-[2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-benzamide,cis-isomer, (Compound A485);

[1174]N-[2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-benzamide,cis-isomer, (Compound A486);

[1175]N-[2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-benzamide,cis-isomer, (Compound A487);

[1176]N-[2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-benzamide,cis-isomer, (Compound A488);

[1177]N-(2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-benzamide,cis-isomer, (Compound A489);

[1178]N-{2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A490);

[1179]N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-ylδ-5-methyl-[1,3]dioxan-5-ylmethyl)-benzamide,cis-isomer, (Compound A491);

[1180]N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-benzamide,cis-isomer, (Compound A492);

[1181]N-{2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A493);

[1182]N-{2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A494);

[1183]{4-[2-[5-(benzoylamino-methyl)-5-methyl-[1,3]dioxan-2-yl]-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-aceticacid, cis-isomer, (Compound A495);

[1184] 3-{4-[2-[5-(benzoylamino-methyl)-5-methyl-[1,3]dioxan-2-yl]-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionicacid, cis-isomer, (Compound A496);

[1185]N-{2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A497);

[1186]N-{2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A498);

[1187]N-{2-[5-(2-benzyloxy-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A499);

[1188]N-{2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A500);

[1189]N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-benzamide,cis-isomer, (Compound A501);

[1190]N-{2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A502);

[1191]N-{2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A503);

[1192]N-{2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A504);

[1193]N-{2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A505);

[1194]N-{2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A506);

[1195]N-{2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A507);

[1196]N-{2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A508);

[1197]N-{2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A509);

[1198]N-(2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-benzamide, cis-isomer, (Compound A510);

[1199]N-(2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-benzamide,cis-isomer, (Compound A511);

[1200]N-{2-[5-[2-(Carbamoylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A512);

[1201]N-{2-[5-[2-(2-Carbamoyl-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A513);

[1202]N-{2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A514);

[1203]N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-benzamide,cis-isomer, (Compound A515);

[1204]N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-benzamide,cis-isomer, (Compound A516);

[1205]N-{2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A517);

[1206]N-{2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzamide,cis-isomer, (Compound A518);

[1207]N-{2-[5-(2-amino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A519);

[1208]N-{2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-1H-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A520);

[1209]N-{2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A521);

[1210]N-{2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A522);

[1211]N-(2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide,cis-isomer, (Compound A523);

[1212]N-{2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A524);

[1213]N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2l-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide,cis-isomer, (Compound A525);

[1214]N-{2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A526);

[1215]N-[2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-2-phenyl-acetamide,cis-isomer, (Compound A527);

[1216]N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide,cis-isomer, (Compound A528);

[1217]N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide,cis-isomer, (Compound A529);

[1218]N-{2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A530);

[1219]N-{2-[5-(2-(4-fluorobenzyl)amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A531);

[1220]N-{2-[5-(2-(4-methoxybenzyl)amino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A532);

[1221]N-(2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide,R isomer, cis-isomer, (Compound A533);

[1222]N-(2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide,S isomer, cis-isomer, (Compound A534);

[1223]N-{2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A535);

[1224]N-{2-[4-(4-fluoro-phenyl)-5-(2-(4-fluorophenyl)amino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A536);

[1225]N-{2-[4-(4-fluoro-phenyl)-5-(2-(3,4-difluorophenyl)amino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A537);

[1226]N-{2-[4-(4-fluoro-phenyl)-5-(2-(3-methoxyphenyl)amino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A538);

[1227]N-{2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A539);

[1228]N-[2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-2-phenyl-acetamide,cis-isomer, (Compound A540);

[1229]N-[2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2yl)-5-methyl-[1,3]dioxan-S-ylmethyl]-2-phenyl-acetamide, cis-isomer, (Compound A541);

[1230]N-[2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-2-phenyl-acetamide,cis-isomer, (Compound A542);

[1231]N-[2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-2-phenyl-acetamide,cis-isomer, (Compound A543);

[1232]N-[2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-2-phenyl-acetamide,cis-isomer, (Compound A544);

[1233]N-[2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-ylmethyl]-2-phenyl-acetamide,cis-isomer, (Compound A545);

[1234]N-(2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide,cis-isomer, (Compound A546);

[1235]N-{2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A547);

[1236]N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide,cis-isomer, (Compound A548);

[1237]N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide,cis-isomer, (Compound A549);

[1238]N-{2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A550);

[1239]N-{2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A551);

[1240](4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(phenylacetylamino-methyl)-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-aceticacid, cis-isomer, (Compound A552);

[1241]3-(4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(phenylacetylamino-methyl)-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-propionicacid, cis-isomer, (Compound A553);

[1242]N-{2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A554);

[1243]N-{2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A555);

[1244]N-{2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A556);

[1245]N-{2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A557);

[1246]N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide,cis-isomer, (Compound A558);

[1247]N-{2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A559);

[1248]N-{2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A560);

[1249]N-{2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A561);

[1250]N-{2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A562);

[1251]N-{2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A563);

[1252]N-{2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A564);

[1253]N-{2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A565);

[1254]N-{2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A566);

[1255]N-(2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide,cis-isomer, (Compound A567);

[1256]N-(2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide,cis-isomer, (Compound A568);

[1257]2-(4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(phenylacetylamino-methyl)-[1,3]dioxan-2yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-acetamide,cis-isomer, (Compound A569);

[1258]3-(4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(phenylacetylamino-methyl)-[1,3]dioxan-2yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-propionamide,cis-isomer, (Compound A570);

[1259]N-{2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A571);

[1260]N-(2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide,cis-isomer, (Compound A572);

[1261]N-(2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylmethyl)-2-phenyl-acetamide,cis-isomer, (Compound A573);

[1262]N-{2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A574);

[1263]N-{2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound A575).

[1264] (b) By proceeding in a similar manner to Example 26(a) but usingC-{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methylamine,cis-isomer, there are prepared the corresponding trans-isomers ofCompounds A348 to A575.

EXAMPLE 27

[1265] Compounds KH to KP

[1266] A suspension of{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans isomer, (5.00 g, Compound KQ) in dichloromethane at 0° C. wastreated with meta-chloroperbenzoic acid (2 equivalents) and the mixturestirred at 0-5° C. for 2 hours and then at room temperature for afurther 16 hours. The reaction mixture was treated with aqueoussaturated sodium bicarbonate solution. The organic layer was separatedthen evaporated. The residue was triturated with ether to give12-[4-(4-fluoro-phenyl)-5-(2-methylsulphonylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans isomer, (4.9 g, Compound KH) as a yellow solid, m.p. 264-266° C.MH⁺ 532.

[1267] By proceeding in a similar manner but using2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5,5-dimethyl-[1,3]dioxane(Compound KR) there was prepared2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonylipyrimidin-4-yl)1H-imidazol-2-yl]-5,5-dimethyl-[1,3]dioxane (Compound KI) as a creamsolid, m.p. 204-206° C. MH⁺ 433.

[1268] By proceeding in a similar manner but using{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer (Compound KU) there is prepared2-4-(4-fluoro-phenyl)-5-(2-methylsulphonyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer (Compound KJ).

[1269] By proceeding in a similar manner but using{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,cis-isomer (Compound KT) there is prepared{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3dioxan-5-yl}-methanol,cis-isomer (Compound KK).

[1270] By proceeding in a similar manner but using2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methylene-[1,3]dioxane(Compound KV) there is prepared2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methylene-[1,3]dioxane(Compound KL).

[1271] By proceeding in a similar manner but using4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-2-methylsulphanyl-pyrimidine(Compound KW) there is prepared4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4l-yl]-2-methylsulphonyl-pyrimidine(Compound KM).

[1272] By proceeding in a similar manner but using{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer (Compound KX) there is prepared{2-[4-(4-fluoro-phenyl)5-(2-methylsulphonyl-pyrimidin-4yl)-1H-imidazol-2-yl]-[1,39dioxan-5-yl}-methanol, trans-isomer (Compound KN).

[1273] By proceeding in a similar manner but using{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,cis-isomer (Compound KY) there is prepared{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,cis-isomer (Compound KO).

[1274] By proceeding in a similar manner but using2,2,2-trifluoro-N-[2-{4-(4-fluoro-phenyl)-5-(2-methylsulphanylpyrimidin-4-yl)-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl]acetamide,cis-isomer (Compound KQ) there was prepared2,2,2-trifluoro-N-[2-{4-(4-fluoro-phenyl)-5-(2-methanesulphonylpyrimidin-4-yl)-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl]acetamide,cis-isomer (Compound KP) as a yellow solid, m.p. 236-238° C. MH⁺ 530.

EXAMPLE 28

[1275] Compounds KQ and KY

[1276] A solution of4-[2-dimethoxymethyl-5(4)-(4-fluoro-phenyl)-1H-imidazol-4(5)-yl]-2-methanesulphanylpyrimidine(16.0g, Reference Example 7), p-toluenesulphonic acid (21.13g), and3-hydroxy-2-hydroxymethyl-2-methyl-1-morpholino-1-propanone (10.82g,Reference Example 6) in a mixture of dry tetrahydrofuran and drydimethylformamide was heated at reflux under a soxhlet apparatus chargedwith molecular seives (3 Å) for 26 hours. The reaction mixture wasevaporated and the residue treated with ethyl acetate and aqueoussaturated sodium bicarbonate solution. The organic phase was evaporatedand the residue was subjected to flash chromatography on silica elutingwith a mixture of ethyl acetate and methanol (9: 1, v/v) to give{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans isomer, (13.8 g, Compound KQ) as a colourless solid, m.p. 160° C.(with decomposition). MH⁺ 500.

[1277] By proceeding in a similar manner but using2,2-dimethylpropan-1,3-diol there was prepared2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanylpyrimidin-4-yl)-1H-imidazol-2-yl]-5,5-dimethyl-[1,3]dioxane(Compound KR) as a colourless solid, m.p. 163-165° C. (withdecomposition). MH⁺ 401.

[1278] By proceeding in a similar manner but using2-methyl-2-trifluoroacetamido-1,3-propanediol (Reference Example 4)there was prepared2,2,2-trifluoro-N-[2-{4-(4-fluoro-phenyl)-5-(2-methylsulphanyl-pyrimidin-4-yl)-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl]acetamide,cis-isomer, (Compound KS) as a colourless solid. MH⁺ 498. R_(F): 0.55determined on silica gel plates using a mixture of ethyl acetate andmethanol (19:1, v/v).

[1279] By proceeding in a similar manner but using1,1,1-tris(hydroxymethyl)ethane there was prepared{2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,cis isomer (Compound KT) as white solid [MH⁺ 417. R_(F)=0.32 determinedon silica gel plates eluting with a mixture of ethyl acetate andmethanol (19:1, v/v)] and{2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans isomer (Compound KU) as a white solid (MH⁺ 417, R_(F)=0.24,determined on silica gel plates eluting with a mixture of ethyl acetateand methanol (19:1, v/v)].

[1280] By proceeding in a similar manner but using2-methylene-1,3-propanediol there is prepared4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-2-methylsulfanyl-pyrimidine(Compound KV).

[1281] By proceeding in a similar manner but using 1,3-propanediol thereis prepared4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-2-methylsulphanyl-pyrimidine(Compound KW).

[1282] By proceeding in a similar manner but using2-(hydroxymethyl)-1,3-propanediol there is prepared{2-[4-(4-fluorophenyl)-5-(2-methylsulphanyl-pyrimidin-4-yl)-1H-imidazol-2-yl}-[1,3]dioxan-5-yl}-methanol,trans-isomer (Compound KX) and{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,cis-isomer (Compound KY).

EXAMPLE 29

[1283] Compound KZ

[1284] A solution of2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5methyl-[1,3]dioxane-5-carboxylicacid amide, cis isomer (0.5 g, Compound LA) in tetrahydrofuran wastreated with lithium aluminium hydride (0.18 g) and the mixture heatedat reflux for 0.5 hour. To the cooled solution was added water (0.2 ml),then aqueous sodium hydroxide (15%, 0.2 ml) and then water (0.6 ml). Themixture was then filtered and the filtrate was evaporated. The residuewas subjected to flash chromatography on silica, eluting with a mixtureof methanol and ethyl acetate (3:7, v/v) to giveC-{2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methylamine,cis isomer (69 mg, Compound KZ) as a gum. MH⁺ 416. R_(F)=0.3 determinedon silica gel plates using methanol.

EXAMPLE 30

[1285] Compound LA

[1286] To a solution of2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid, cis isomer (1.3 g, Compound LB), diethyl isopropyl amine (0.85 g)and O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate (1.14 g) in dimethylformamide (anhydrous) was addedammonia (1.2 mL, 0.5M solution in 1,4-dioxane). The solution was stirredat room temperature for 3 hours and then evaporated. The residue wasstirred with water and the solid filtered to give2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1-Himidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylic acid amide, cis isomer(1.2 g, Compound LA) as white solid. MH⁺ 430. R_(F)=0.27 [determined onsilica gel plates using a mixture of ethyl acetate and methanol (8:2v/v)].

EXAMPLE 31

[1287] Compound LB

[1288] A solution of2-[4-(4-fluorophenyl)-5-(2-methylenesulphanylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-carboxylicacid methyl ester, cis isomer, (5.1 g, Compound LD) and aqueous sodiumhydroxide (34.4 ml, 1N) in methanol was heated at reflux for 6 hours. Tothe cold solution was added aqueous hydrochloric acid (34.4. ml, 1N) andthe methanol evaporated. The aqueous was decanted and the residuetriturated with acetonitrile to give2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid, cis isomer (4.43 g, Compound LB) as a white solid. MH+ 431. TLCR_(F)=0.22 (eluting with ethyl Acetate and methanol (8:2, v/v) on silicagel).

EXAMPLE 32

[1289] Compound LC and LD

[1290] A solution of2-dimethoxymethyl-4-(4-fluorophenyl)-5-(2-methylylsulphanylpyrimidin-4-yl)-1H-imidazole(4.5 g, Reference Example 7), methyl 2,2-bis(hydroxymethyl)propionate(10 g) and methylorthoformate (11.9 ml) in dimethylformamide was treatedwith 4-toluenesulphonic acid (20.6 g) and then heated at 80° C. for 4hours. The reaction mixture was evaporated then partitioned betweenethyl acetate and aqueous sodium bicarbonate solution. The organic phasewas evaporated and the residue purified using flash chromatography onsilica gel eluting with a ethyl acetate to give2-[4-(4-fluorophenyl)-5-(2-methylsulphanylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-carboxylicacid methyl ester, trans isomer, (4.95 g, Compound LC), [MH⁺ 445, m.p.199-200° C.] and2-[4-(4-fluorophenyl)-5-(2-methylsulphanylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3dioxan-5-carboxylicacid methyl ester, cis isomer, (7.11 g, Compound LD), MH⁺ 445, m.p.161-163° C.).

EXAMPLE 33

[1291] Compound LE To a solution of{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5nitro-[1,3dioxan-5-yl}-methanol,cis isomer (0.1 g, Compound LG) in ethanol was added palladium on carbon(5%, 0.2 g) and the mixture was hydrogenated at 1 atmosphere ofhydrogen, at 50° C., for 6 hours. The solution was filtered throughCelite, the solvent evaporated and the residue subjected to flashchromatography on silica gel, eluting with a mixture of methanol andethyl acetate (1:1, v/v) to give{5-Amino-2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,cis isomer, (77 mg, Compound LE) as a gum. MH⁺ 371. TLC R_(F)=0.27(eluting with methanol on silica gel).

EXAMPLE 34

[1292] Compound LF

[1293] To a solution of{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-nitro-[1,3,]dioxan-5-yl}-methanol,trans isomer (0.1 g, Compound LH) in ethanol was added palladium oncarbon (5%, 0.2 g) and the mixture was hydrogenated, at 1 atmosphere ofhydrogen, at 50° C. for 8 hours. The solution was filtered throughcelite and the solvent was evaporated and the residue subjected to flashchromatography on silica gel, eluting with a mixture of methanol andethyl acetate (1:1, v/v) to give{5-Amino-2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans isomer, (75 mg, Compound LF) as a gum. MH+ 371. TLC R_(F)=0.19(eluting with a mixture of ethyl acetate:methanol 1:1 on silica gel).

EXAMPLE 35

[1294] Compound LG and LH

[1295] A solution of of4-[2-dimethoxymethyl-5(4)-(4-fluoro-phenyl)-1H-imidazol-4(5)-yl]-pyridine(2.2 g, Reference Example 3), p-toluenesulphonic acid (1.74 g) andtris(hydroxymethyl)-nitromethane (4.24 g) in tetrahydrofuran (anhydrous)and dimethylformamide (anhydrous) was heated at reflux under a soxhletapparatus charged with molecular sieve (3 Å) for 48 hours. The solventwas evaporated and the residue partitioned between ethyl acetate andaqueous saturated sodium carbonate solution. The organic layer wasevaporated and the residue subjected to flash chromatography on silica,eluting with a mixture of methanol and ethyl acetate (1:9, v/v) to give{2-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-nitro-[1,3]dioxan-5-yl]-methanol,cis isomer, (0.61 g, Compound LG) as white solid (MH⁺ 401, TLCR_(F)=0.3, eluting with a mixture of Ethyl acetate:Methanol 8:2 onsilica gel) and{2-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-nitro-[1,3]dioxan-5-yl{-methanol,trans isomer,(0.39 g, Compound LH) as a yellow gum (MH⁺ 401, TLCR_(F)=0.55, eluting with a mixture of ethyl acetate:methanol 8:2 onsilica gel).

EXAMPLE 36

[1296] Compound LI

[1297] To a solution of4-[2-(5,5-Dimethyl-4-nitromethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyridine(115mg, Compound LJ) in methanol was added to a suspension of nickelboride which had been previously prepared by sonication of nickelchloride and sodium borohydride. The mixture was stirred and sodiumborohydride (250 mg) added in portions over 1 hour. The reaction mixturewas of dichloromethane, pentane, methanol and ammonia (55:25:18:2, v/v)to giveC-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5.5-dimethyl-[1,3]dioxan4-yl}-methylamine(57 mg Compound LI). MH⁺ 383. R_(F)=0.54, eluting twice withdichloromethane, pentane, methanol and ammonia (55:25:18:2, v/v).

EXAMPLE 37

[1298] Compound LJ

[1299] To a solution of4-[2-dimethoxymethyl-5(4)-(4-fluoro-phenyl)-1H-imidazol-4(5)-yl]-pyridine(115 mg, Reference Example 3) in dry tetrahydrofuran was added2,2-dimethyl-4-nitrobutane-1,3-diol (150 mg) and p-toluenesulphonicacid. The mixture was heated under reflux for 7 hours beforepartitioning between water and ethyl acetate and purifying using flashchromatography on silica gel eluting with ethyl acetate:methanol (9:1,v/v) to give4-[2-(5,5-dimethyl-4-nitromethyl-[1,3]dioxan-2-yl)-4-fluoro-phenyl)-3H-imidazol-4-yl]-pyridine(130 mg, Compound LJ). MH⁺ 413. TLC R_(F)=0.36 (eluting twice with ethylacetate: on silica gel).

EXAMPLE 38

[1300] Compound LK and LL

[1301] (i)_Treatment ofC-{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methylamine,cis-isomer (Compound KZ) with trifluoroacetic anhydride (according tomethod described in Example 12); followed by (ii) treatment of compoundsobtained from (i) with meta-chloroperbenzoic acid (according to methoddescribed for Example 27) gives2,2,2-trifluoro-N-{2-[5-(2-methylsulphonyl-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis isomer (Compound LK).

[1302] By proceeding in a similar manner but using the trans-isomer ofCompound KZ there is prepared 22,2-trifluoro-N-{2-[5-(2-methylsulphonyl-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,trans isomer (Compound LL).

EXAMPLE 39

[1303] Compound LM and LN

[1304] A solution of2-[4-(4-fluorophenyl)-5-(2-methylsulphanylpyrimidin-4-yl)-1H-imidazol-2]-5-methyl-[1,3]dioxan-5-carboxylicacid methyl ester, trans isomer, (3.15 g, Compound LC) in a mixture ofpg,156 equivalents) and stirred at room temperature for 16 hours. Thesolution was diluted with ether and shaken with aqueous saturated sodiumbicarbonate solution. The organic solution was evaporated and theresidue triturated with a mixture of ethyl acetate and ether to give2-[4-(4-fluorophenyl)-5-(2-methylsulphonylpyrimidin4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3dioxan-5-carboxylicacid methyl ester trans isomer (2.95 g, Compound LM) as a colourlesscrystalline solid, m.p. 186-187° C. MH⁺ 477.

[1305] By proceeding in a similar manner but using2-[4-(4-fluorophenyl)-5-(2-methylsulphanylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-carboxylicacid methyl ester, cis isomer (Compound LD) there is prepared2-[4-(4-fluorophenyl)-5-(2-methylenesulphonylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-carboxylicacid methyl ester, cis isomer (Compound LN).

EXAMPLE 40

[1306] Compound GT and A557 to A2062

[1307] (a)

[1308] Step 1: A suspension of Merrifield resin (20 g,chloromethylpolystyrene resin, Novabiochem) in dimethylformamide (150ml) was treated with potassium thioacetate (21 g). After stirring atroom temperature for 24 hours the mixture was filtered and the modifiedresin was washed with dimethylformamide, then with tetrahydrofuran, thenwith water, then with tetrahydrofuran, then with dichloromethane andthen dried under high vacuum at 60° C. to give Resin A (20.5 g). IR:3024 s, 2920 s, 1691 s, 1599 m, 1493 s, 1453 s, 1130 m, 758 s, 700 s.

[1309] Step 2: A suspension of Resin A from Step 1 (20.5 g) intetrahydrofuran (150 ml) was treated with lithium borohydride (5 g).After stirring at room temperature for 24 hours the mixture was filteredand the modified resin was washed with tetrahydrofuran, then with amixture of hydrochloric acid (1N) and tetrahydrofuran (3:7, v/v), thenwith water, then with tetrahydrofuran, then with methanol, then withdichloromethane and then dried under high vacuum at 60° C. to give ResinB (20 g). IR: 3026 s, 2924 s, 1599 w, 1493 s, 1452 s, 757 s, 700 s.

[1310] Step 3: A suspension of Resin B from Step 2 (0.1 g) indimethylformamide (0.5 ml) was treated with sodium hydride (5 mg, 60%dispersion in mineral oil), then stirred at room temperature for 15minutes, then treated with2-[4-(4-fluorophenyl)-5-(2-methylylsulphonylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-carboxylicacid methyl ester, trans isomer, (60 mg, Compound LM) and then heated at80° for 20 hours. The reaction mixture was filtered and the modifiedresin was washed with dimethylformamide, then with tetrahydrofuran, thenwith methanol, then with dichloromethane and then dried under highvacuum at 60° C. to give Resin C (0.11 g). IR: 3021 m, 2920 m, 1732 m,1569 m, 1487 s, 1452 s, 1091 m, 835 m, 757 s, 699 s.

[1311] Step 4: A suspension of Resin C (0.09 g) in tetrahydrofuran wastreated with aqueous sodium hydroxide solution (IN, 0.3 ml) and thenstirred at 70° C. for 8 hours. The reaction mixture was filtered and themodified resin was washed with tetrahydrofuran, then with a mixture oftetrahydrofuran and hydrochloric acid (1N), then with tetrahydrofuran,then with dimethylformamide, then with tetrahydrofuran, then withmethanol then with dichloromethane and then dried under high vacuum at60° C. to give Resin D (0.09 g). IR: 3060 w, 3025 m, 2923 m, 2852 w,1720 w, 1601 m, 1571 s, 1493 s, 1452 s, 1335 s, 1235 m, 1199 m, 1183 m,1097 s, 838 m, 760 s, 704 s.

[1312] Step 5: A suspension of Resin D (0.07 g) in dichloromethane wastreated with oxalyl chloride solution in dichloromethane (16%) thenstirred at room temperature for 10 minutes and then filtered. Thisprocedure was repeated three times. The modified resin was washed withdichloromethane, then treated with a solution of morpholine (0.1 g) indichloromethane (0.8 ml). After stirring at room temperature for 10minutes this reaction mixture was filtered and the further modifed resinwas washed with dichloromethane, then with tetrahydrofuran, then withmethanol, then with dichloromethane and then dried under high vacuum at60° C. to give Resin E (0.07 g). IR: 3025 s, 2922 s, 1636 w, 1600 w,1570 w, 1493 s, 1452 s, 1329 w, 1181 w, 1115 w, 759 m, 704 s.

[1313] Step 6: A suspension of Resin E (0.06 g) in a mixture ofdichloromethane (0.8 ml) and methanol (0.1 ml) was treated withm-chloroperoxybenzoic acid (0.24 g). After stirring at room temperaturefor 96 hours the reaction mixture was filtered and the modified resinwas washed with dichloromethane, then with tetrahydrofuran, then withmethanol, then with dichloromethane and then dried under high vacuum at60° C. to give Resin F (0.06 g). IR: 3082 m, 3026 s, 2927 s, 2851 w,1635 w, 1602 m, 1582 m, 1493 m, 1452 s, 1350 w, 1240 m, 1180 m, 1117 m,1032 m, 761 s, 705 s.

[1314] Step 7: A suspension of Resin F (0.04 g) in dimethoxyethane (0.4ml) was treated with benzylamine (0.01 ml) and then heated at 70° C. for6 hours. The reaction mixture was filtered to remove resin and thefiltrate was evaporated. The residue was subjected to high pressureliquid chromatography (gradient elution using water and acetonitrilemixtures as follows: 0-2 minutes 20% acetonitrile, 2-16 minutes ramp upto 80% acetonitrile) to give the{2-[4-(4-fluorophenyl)-5-(2-benzylaminopyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans isomer (Compound GT). MH⁺ 559. High pressure liquid chromatographyretention time=11 minutes.

[1315] (b) By proceeding in a similar manner but using amines of formulaHNY⁴Y⁵ in Step 5; and amines of formula HNY⁴Y⁵ or sodium salts ofappropriately substituted alcohols or phenols in Step 7 there isprepared Compounds A557 to A2062:-

[1316][5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-carboxylicacid amide, trans-isomer, (Compound A577);

[1317]2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A578);

[1318]2-[5-(2-dimethylamino-pyrimidin4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A579);

[1319]2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A581);

[1320]2-[5-(2-cyclohexylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A582);

[1321]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A583);

[1322]2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A584);

[1323]2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A585);

[1324]2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A586);

[1325]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A587);

[1326]2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A588);

[1327]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid amide, R-isomer, trans-isomer, (Compound A589);

[1328]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-methyl-[1,3]dioxane-5-carboxylicacid amide, S-isomer, trans-isomer, (Compound A590);

[1329]2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A591);

[1330]2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A592);

[1331]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A593);

[1332]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A594);

[1333]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A595);

[1334]2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2)-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A596);

[1335]2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A597);

[1336]2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A598);

[1337]2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A599);

[1338]2-[4-(4-fluoro-phenyl)-5-(2-morpholin4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A600);

[1339]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A601);

[1340]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A602);

[1341]2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A603);

[1342]2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A604);

[1343]{4-[2-(5-Carbamoyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-aceticacid, trans-isomer, (Compound A605);

[1344]3-{4-[2-(5-Carbamoyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionicacid, trans-isomer, (Compound A606);

[1345]2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3dioxane-5-carboxylicacid amide, trans-isomer, (Compound A607);

[1346]2-[5-(2-allylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3dioxane-5-carboxylicacid amide, trans-isomer, (Compound A608);

[1347]2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A609);

[1348]2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A610);

[1349]2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A611);

[1350]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A612);

[1351]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A613);

[1352]2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A614);

[1353]2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A615);

[1354]2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A616);

[1355]2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A617);

[1356]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A618);

[1357]2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A619);

[1358]2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A620);

[1359]2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A621);

[1360]2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A622);

[1361]2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A623);

[1362]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A624);

[1363]2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A625);

[1364]2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A626);

[1365]2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A627);

[1366]2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A628);

[1367]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A629);

[1368]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A630);

[1369]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound A631);

[1370]2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A632);

[1371]2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A633);

[1372]2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A634);

[1373]2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A635);

[1374]2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A636);

[1375]2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A637);

[1376]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A638);

[1377]2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A639);

[1378]2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A640);

[1379]2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A641);

[1380]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A642);

[1381]2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A643);

[1382]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, R-isomer, trans-isomer, (Compound A644);

[1383]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, S-isomer, trans-isomer, (Compound A645);

[1384]2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A646);

[1385]2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A647);

[1386]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A648);

[1387]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A649);

[1388]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A650);

[1389]2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A651);

[1390]2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A652);

[1391]2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A653);

[1392]2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A654);

[1393]2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A655);

[1394]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A656);

[1395]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A657);

[1396]2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A658);

[1397]2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A659);

[1398]{4-[5-(4-fluoro-phenyl)-2-(5-methyl-5-methylcarbamoyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-aceticacid, trans-isomer, (Compound A660);

[1399]3-{4-[5-(4-fluoro-phenyl)-2-(5-methyl-5-methylcarbamoyl-[1,3]dioxan-2-yl)-3-imidazol-4-yl]-pyrimidin-2-ylamino}-propionicacid, trans-isomer, (Compound A661);

[1400]2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A662);

[1401]2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A663);

[1402]2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A664);

[1403]2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A665);

[1404]2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A666);

[1405]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A667);

[1406]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A668);

[1407]2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A669);

[1408]2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A670);

[1409]2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A671);

[1410]2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A672);

[1411]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A673);

[1412]2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A674);

[1413]2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A675);

[1414]2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A676);

[1415]2-[5-(2-benzyloxy-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A677);

[1416]2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A678);

[1417]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A679);

[1418]2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A680);

[1419]2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A681);

[1420]2-[5-(2-Isopropoxy-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A682);

[1421]2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A683);

[1422]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A684);

[1423]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A685);

[1424]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound A686);

[1425]2-[5-(2-amino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A687);

[1426]2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A688);

[1427]2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A689);

[1428]2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A690);

[1429]2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A691);

[1430]2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A692);

[1431]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A693);

[1432]2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A694);

[1433]2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A695);

[1434]2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-y-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A696);

[1435]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A697);

[1436]2-[5-(2-benzylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A698);

[1437]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, R-isomer, trans-isomer, (Compound A699);

[1438]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, S-isomer, trans-isomer, (Compound A700);

[1439]2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A701);

[1440]2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A702);

[1441]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A703);

[1442]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A704);

[1443]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A705);

[1444]2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A706);

[1445]2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A707);

[1446]2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A708);

[1447]2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A709);

[1448]2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A710);

[1449]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A711);

[1450]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A712);

[1451]2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A713);

[1452]2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A714);

[1453]{4-[2-(5-dimethylcarbamoyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-aceticacid, trans-isomer, (Compound A715);

[1454]3-{4-[2-(5-dimethylcarbamoyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionicacid, trans-isomer, (Compound A716);

[1455]2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A717);

[1456]2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A718);

[1457]2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A719);

[1458]2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A720);

[1459]2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A721);

[1460]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A722);

[1461]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A723);

[1462]2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A724);

[1463]2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A725);

[1464]2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A726);

[1465]2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A727);

[1466]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A728);

[1467]2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A729);

[1468]2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A730);

[1469]2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A73 1);

[1470]2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A732);

[1471]2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A733);

[1472]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A734);

[1473]2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A735);

[1474]2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A736);

[1475]2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A737);

[1476]2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A738);

[1477]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A739);

[1478]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A740);

[1479]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound A741);

[1480]2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A742);

[1481]2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A743);

[1482]2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A744);

[1483]2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A745);

[1484]2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A746);

[1485]2-[5-(2-cyclohexylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A747);

[1486]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A748);

[1487]2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A749);

[1488]2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A750);

[1489]2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A751);

[1490]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A752);

[1491]2-[5-(2-benzylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A753);

[1492]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, R-isomer, trans-isomer, (Compound A754);

[1493]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, S-isomer, trans-isomer, (Compound A755);

[1494]2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A756);

[1495]2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A757);

[1496]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A758);

[1497]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A759);

[1498]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A760);

[1499]2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A761);

[1500]2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A762);

[1501]2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A763);

[1502]2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A764);

[1503]2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A765);

[1504]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A766);

[1505]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A767);

[1506]2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A768); p12-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A769);

[1507]{4-[2-(5-cyclopropylcarbamoyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-aceticacid, trans-isomer, (Compound A770);

[1508]3-{4-[2-(5-cyclopropylcarbamoyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionicacid, trans-isomer, (Compound A771);

[1509]2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A772);

[1510]2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A773);

[1511]2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A774);

[1512]2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A775);

[1513]2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A776);

[1514]2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A777);

[1515]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A778);

[1516]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A779);

[1517]2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A780);

[1518]2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A781);

[1519]2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A782);

[1520]2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A783);

[1521]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A784);

[1522]2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A785);

[1523]2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A786);

[1524]2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A787);

[1525]2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A788);

[1526]2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A789);

[1527]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A790);

[1528]2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A791);

[1529]2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A792);

[1530]2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A793);

[1531]2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A794);

[1532]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A795);

[1533]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A796);

[1534]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound A797);

[1535]2-[5-(2-amino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A798);

[1536]2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A799);

[1537]2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A800);

[1538]2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A801);

[1539]2-{4-(4-fluoro-phenyl)-5-[2-(piperidin4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A802);

[1540]2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A803);

[1541]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A804);

[1542]2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A805);

[1543]2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A806);

[1544]2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A807);

[1545]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A808);

[1546]2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A809);

[1547]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, R-isomer, trans-isomer, (Compound A810);

[1548]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl]-5-methyl-[1,3dioxane-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, S-isomer, trans-isomer, (Compound A811);

[1549]2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A812);

[1550]2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A813);

[1551]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A814);

[1552]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A815);

[1553]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl)}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A816);

[1554]2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A817);

[1555]2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A818);

[1556]2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A819);

[1557]2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A820);

[1558]2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A821);

[1559]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A822);

[1560]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A823);

[1561]2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A824);

[1562]2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A825);

[1563]{4-[5-(4-fluoro-phenyl)-2-(5-methyl-5-propylcarbamoyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-aceticacid, trans-isomer, (Compound A826);

[1564]3-{4-[5-(4-fluoro-phenyl)-2-(5-methyl-5-propylcarbamoyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionicacid, trans-isomer, (Compound A827);

[1565]2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A828);

[1566]2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A829);

[1567]2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A830);

[1568]2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A831);

[1569]2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A832);

[1570]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A833);

[1571]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A834);

[1572]2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A835);

[1573]2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A836);

[1574]2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A837);

[1575]2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A838);

[1576]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A839);

[1577]2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A840);

[1578]2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A841);

[1579]2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A842);

[1580]2-[5-(2-benzyloxy-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A843);

[1581]2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A844);

[1582]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A845);

[1583]2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A846);

[1584]2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A847);

[1585]2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A848);

[1586]2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A849);

[1587]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A850);

[1588]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A85 1);

[1589]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound A852);

[1590]2-[5-(2-amino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A853);

[1591]2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A854);

[1592]2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A855);

[1593]2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A856);

[1594]2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A857);

[1595]2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A858);

[1596]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A859);

[1597]2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A860);

[1598]2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A861);

[1599]2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A862);

[1600]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A863);

[1601]2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A864);

[1602]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, R-isomer, trans-isomer, (Compound A865);

[1603]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, S-isomer, trans-isomer, (Compound A866);

[1604]2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A867);

[1605]2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A868);

[1606]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A869);

[1607]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A870);

[1608]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A871);

[1609]2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A872);

[1610]2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A873);

[1611]2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A874);

[1612]2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A875);

[1613]2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A876);

[1614]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A877);

[1615]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A878);

[1616]2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5methyl-[1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer,(Compound A879);

[1617]2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A880);

[1618]{4-[2-(5-cyclohexylcarbamoyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-aceticacid, trans-isomer, (Compound A881);

[1619]3-{4-[2-(5-cyclohexylcarbamoyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionicacid, trans-isomer, (Compound A882);

[1620]2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A883);

[1621]2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A884);

[1622]2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A885);

[1623]2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A886);

[1624]2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A887);

[1625]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A888);

[1626]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylic acid cyclohexylamide, trans-isomer,(Compound A889);

[1627]2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A890);

[1628]2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A891);

[1629]2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A892);

[1630]2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A893);

[1631]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A894);

[1632]2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A895);

[1633]2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A896);

[1634]2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A897);

[1635]2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A898);

[1636]2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A899);

[1637]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A900);

[1638]2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A901);

[1639]2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A902);

[1640]2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A903);

[1641]2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A904);

[1642]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A905);

[1643]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A906);

[1644]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound A907);

[1645]2-[5-(2-amino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A908);

[1646]2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A909);

[1647]2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A910);

[1648]2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A9 11);

[1649]2-{4-(4-fluoro-phenyl)-5-[2-(piperidin4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A912);

[1650]2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A913);

[1651]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A914);

[1652]2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A915);

[1653]2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A916);

[1654]2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A917);

[1655]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A918);

[1656]2-[5-(2-benzylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A919);

[1657]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, R-isomer, trans-isomer, (Compound A920);

[1658]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, S-isomer, trans-isomer, (Compound A921);

[1659]2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A922);

[1660]2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A923);

[1661]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A924);

[1662]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A925);

[1663]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A926);

[1664]2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A927);

[1665]2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A928);

[1666]2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A929);

[1667]2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A930);

[1668]2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A93 1);

[1669]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A932);

[1670]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A933);

[1671]2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A934);

[1672]2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A935);

[1673](4-{5-(4-fluoro-phenyl)-2-[5-(2-hydroxy-ethylcarbamoyl)-5-methyl-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-aceticacid, trans-isomer, (Compound A936);

[1674]3-(4-{5-(4-fluoro-phenyl)-2-[5-(2-hydroxy-ethylcarbamoyl)-5-methyl-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-propionicacid, trans-isomer, (Compound A937);

[1675]2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A938);

[1676]2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A939);

[1677]2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A940);

[1678]2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A941);

[1679]2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A942);

[1680]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A943);

[1681]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A944);

[1682]2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A945);

[1683]2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A946);

[1684]2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A947);

[1685]2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A948);

[1686]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A949);

[1687]2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A950);

[1688]2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A951);

[1689]2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A952);

[1690]2-[5-(2-benzyloxy-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A953);

[1691]2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A954);

[1692]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A955);

[1693]2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A956);

[1694]2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A957);

[1695]2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A958);

[1696]2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A959);

[1697]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A960);

[1698]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A961);

[1699]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound A962);

[1700]2-[5-(2-amino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A963);

[1701]2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A964);

[1702]2-[5-(2-dimethylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A965);

[1703]2-[5-(2-cyclopropylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A966);

[1704]2-{4-(4-fluoro-phenyl)-5-[2-(piperidin4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A967);

[1705]2-[5-(2-cyclohexylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A968);

[1706]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A969);

[1707]2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A970);

[1708]2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A971);

[1709]2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A972);

[1710]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A973);

[1711]2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A974);

[1712]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, R-isomer, trans-isomer, (Compound A975);

[1713] 2-{4-(4-fluoro-phenyl)-5-[2-(I-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, S-isomer, trans-isomer, (Compound A976);

[1714]2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A977);

[1715]2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A978);

[1716]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A979);

[1717]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A980);

[1718]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A981);

[1719]-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A982);

[1720]2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A983);

[1721]2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A984);

[1722]2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A985);

[1723]2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A986);

[1724]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A987);

[1725]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A988);

[1726]2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A989);

[1727]2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]5-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[

[1728] [1,3]dioxane-5-carboxylic acid (2-amino-ethyl) -amide,trans-isomer, (Compound A990);

[1729]{4-[2-[5-(2-amino-ethylcarbamoyl)-5-methyl-[1,3]dioxan-2-yl]-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-aceticacid, trans-isomer, (Compound A991);

[1730]3-{4-[2-[5-(2-amino-ethylcarbamoyl)-5-methyl-[1,3]dioxan-2-yl]-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionicacid, trans-isomer, (Compound A992);

[1731]2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A993);

[1732]2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A994);

[1733]2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A995);

[1734]2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A996);

[1735]2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A997);

[1736]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A998);

[1737]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A999);

[1738]2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A1000);

[1739]2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A1001);

[1740]2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A1002);

[1741]2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A1003);

[1742]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A1004);

[1743]2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A1005);

[1744]2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A1006);

[1745]2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A1007);

[1746]2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A1008);

[1747]2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A1009);

[1748]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A1010);

[1749]2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A1011);

[1750]2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A1012);

[1751]2-[5-(2-Isopropoxy-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A1013);

[1752]2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A 1014);

[1753]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A1015);

[1754]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A1016);

[1755]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-amino-ethyl)-amide, trans-isomer, (Compound A1017);

[1756]2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1018);

[1757]2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1019);

[1758]2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1020);

[1759]2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1021);

[1760]2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1022);

[1761]2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1023);

[1762]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1024);

[1763]2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1025);

[1764]2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1026);

[1765]2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1027);

[1766]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1028);

[1767]2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1029);

[1768]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, R-isomer, trans-isomer, (Compound A1030);

[1769]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, S-isomer, trans-isomer, (Compound A1031);

[1770]2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1032);

[1771]2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1033);

[1772]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1034);

[1773]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1035);

[1774]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1036);

[1775]2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1037);

[1776]2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1038);

[1777]2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1039);

[1778]2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1040);

[1779]2-[4-(4-fluoro-phenyl)-5-(2-morpholin4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1041);

[1780]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1042);

[1781]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1043);

[1782]2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1044);

[1783]2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1045);

[1784](4-{5-(4-fluoro-phenyl)-2-[5-(3-hydroxy-propylcarbamoyl)-5-methyl-[1,3]dioxan-2]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-aceticacid, trans-isomer, (Compound A1046);

[1785]3-(4-{5-(4-fluoro-phenyl)-2-[5-(3-hydroxy-propylcarbamoyl)-5-methyl-[1,3]dioxan-2]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-propionicacid, trans-isomer, (Compound A 1047);

[1786]2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1048);

[1787]2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1049);

[1788]2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1050);

[1789]2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1051);

[1790]2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1052);

[1791]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl3-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1053);

[1792]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-H1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1054);

[1793]2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1055);

[1794]2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1056);

[1795]2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1057);

[1796]2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1058);

[1797]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1059);

[1798]2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1060);

[1799]2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1061);

[1800]2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1062);

[1801]2-[5-(2-benzyloxy-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1063);

[1802]2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1064);

[1803]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1065);

[1804]2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1066);

[1805]2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1067);

[1806]2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1068);

[1807]2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1069);

[1808]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1070);

[1809]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1071);

[1810]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound A1072);

[1811]2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1073);

[1812]2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1074);

[1813]2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1075);

[1814]2-[5-(2-cyclopropylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1076);

[1815]2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1077);

[1816]2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1078);

[1817]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1079);

[1818]2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1080);

[1819]2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1081);

[1820]2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1082);

[1821]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1083);

[1822]2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1084);

[1823]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, R-isomer, trans-isomer, (Compound A1085);

[1824]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, S-isomer, trans-isomer, (Compound A1086);

[1825]2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1087);

[1826]2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1088);

[1827]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1089);

[1828]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1090);

[1829]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1091);

[1830]2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1092);

[1831]2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A11093);

[1832]2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1094);

[1833]2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1095);

[1834]2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1096);

[1835]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1097);

[1836]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1098);

[1837]2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1099);

[1838]2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1100);

[1839] {4-[2-(5-benzylcarbamoyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-aceticacid, trans-isomer, (Compound A1101);

[1840]3-{4-[2-(5-benzylcarbamoyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionicacid, trans-isomer, (Compound A1102);

[1841]2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1103);

[1842]2-[5-(2-allylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1104);

[1843]2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1105);

[1844]2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1106);

[1845]2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1107);

[1846]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1108);

[1847]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1109);

[1848]2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1110);

[1849]2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1111);

[1850]2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1112);

[1851]2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1113);

[1852]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1114);

[1853]2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1115);

[1854]2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1116);

[1855]2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1117);

[1856]2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1118);

[1857]2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1119);

[1858]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1120);

[1859]2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1121);

[1860]2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1122);

[1861]2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1123);

[1862]2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1124);

[1863]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1125);

[1864]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1126);

[1865]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound A1127);

[1866]2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1128);

[1867]2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1129);

[1868]2-[5-(2-dimethylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1130);

[1869]2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1131);

[1870]2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1132);

[1871]2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1133);

[1872]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1134);

[1873]2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1135);

[1874]2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2yl)-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1136);

[1875]2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1137);

[1876]2-{⁴-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1138);

[1877]2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1139);

[1878]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, R-isomer, trans-isomer, (Compound A1140);

[1879]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, S-isomer, trans-isomer, (Compound A1141);

[1880]2-[⁴-(⁴-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1142);

[1881]2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicphenylamide, trans-isomer, (Compound A1143);

[1882]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1144);

[1883]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1145);

[1884] 2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1146);

[1885]2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1147);

[1886]2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1148);

[1887]2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1149);

[1888]2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1150);2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1151);

[1889]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1152);

[1890]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1153);

[1891]2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1154);

[1892]2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1155);

[1893]{4-[5-(4-fluoro-phenyl)-2-(5-methyl-5-phenylcarbamoyl-[1,3]dioxan-2-yl)-3H-imidazol-4yl]-pyrimidin-2-ylamino}-aceticacid, trans-isomer, (Compound A1156);

[1894]3-{4-[5-(4-fluoro-phenyl)-2-(5-methyl-5-phenylcarbamoyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionicacid, trans-isomer, (Compound A1157);

[1895]2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1158);

[1896]2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1159);

[1897]2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1160);

[1898]2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1161);

[1899]2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylic acid phenylamide, trans-isomer,(Compound A1162);

[1900]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1163);

[1901]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1164);

[1902]2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1165);

[1903]2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1166);

[1904]2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1167);

[1905]2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1168);

[1906]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2yl}-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1169);

[1907]2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1170);

[1908]2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1171);

[1909]2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1172);

[1910]2-[5-(2-benzyloxy-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1173);

[1911]2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1174);

[1912]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1175);

[1913]2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1176);

[1914]2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1177);

[1915]2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1178);

[1916]2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1179);

[1917]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1180);

[1918]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1181);

[1919]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenylamide, trans-isomer, (Compound A1182);

[1920]{2-[5-(2-amino-pyrimidin4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1183);

[1921]{2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1184);

[1922]{2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1185);

[1923]{2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1186);

[1924](2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-piperidin-1-yl-methanone,trans-isomer, (Compound A1187);

[1925]{2-[5-(2-cyclohexylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1188);

[1926](2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-piperidin-1-yl-methanone,trans-isomer, (Compound A1189);

[1927]{2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1190);

[1928][2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-piperidin-1-yl-methanone,trans-isomer, (Compound A1191);

[1929](2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-piperidin-1-yl-methanone,trans-isomer, (Compound A1192);

[1930](2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-piperidin-1-yl-methanone,trans-isomer, (Compound A1193);

[1931]{2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1194);

[1932](2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-piperidin-1-yl-methanone,R-isomer, trans-isomer, (Compound A1195);

[1933](2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-piperidin-1-yl-methanone,S-isomer, trans-isomer, (Compound A1196);

[1934]{2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1197);

[1935]{2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1198);

[1936][2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-piperidin-1-yl-methanone,trans-isomer, (Compound A1199);

[1937][2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-piperidin-1-yl-methanone,trans-isomer, (Compound A1200);

[1938][2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-piperidin-1-yl-methanone,trans-isomer, (Compound A1201);

[1939][2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2yl)-5-methyl-[1,3]dioxan-5-yl]-piperidin-1-yl-methanone,trans-isomer, (Compound A1202);

[1940][2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2yl)-5-methyl-[1,3]dioxan-5-yl]-piperidin-1-yl-methanone,trans-isomer, (Compound A1203);

[1941][2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-piperidin-1-yl-methanone,trans-isomer, (Compound A1204);

[1942](2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-piperidin-1-yl-methanone,trans-isomer, (Compound A1205);

[1943]{2-[4-(4-fluoro-phenyl)-5-(2-morpholin4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1206);

[1944](2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-piperidin-1-yl-methanone,trans-isomer, (Compound A1207);

[1945](2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-piperidin-1-yl-methanone,trans-isomer, (Compound A1208);

[1946]{2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1209);

[1947]{2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1210);

[1948](4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(piperidine-1-carbonyl)-[1,3]dioxan-2-yl]-3H-imidazol-4yl}-pyrimidin-2-ylamino)-aceticacid, trans-isomer, (Compound A1211);

[1949]3-(4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(piperidine-1-carbonyl)-[1,3]dioxan-2-yl]-3H-imidazol-4yl}-pyrimidin-2-ylamino)-propionicacid, trans-isomer, (Compound A1212);

[1950]{2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1213);

[1951]{2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1214);

[1952]{2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1215);

[1953](4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(piperidine-1-carbonyl)-[1,3]dioxan-2-yl]-3H-imidazol-4yl}-pyrimidin-2-ylamino)-acetonitrile,trans-isomer, (Compound A1216);

[1954]3-(4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(piperidine-1-carbonyl)-[1,3]dioxan-2yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-propionitrile,trans-isomer, (Compound A1217);

[1955](2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-piperidin-1-yl-methanone,trans-isomer, (Compound A1218);

[1956](2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-piperidin-1-yl-methanone,trans-isomer, (Compound A1219);

[1957]{2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1220);

[1958]{2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1221);

[1959](2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-piperidin-1-yl-methanone,trans-isomer, (Compound A1222);

[1960]{2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1223);

[1961](2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-methyl-[1,3]dioxan-5-yl)-piperidin-1-y-methanone,trans-isomer, (Compound A1224);

[1962]{2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1225);

[1963](2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-piperidin-1-yl-methanone,trans-isomer, (Compound A1226);

[1964]{2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1227);

[1965]{2-[5-(2-benzyloxy-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1228);

[1966]{2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1229);

[1967](2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-piperidin-1-yl-methanone,trans-isomer, (Compound A1230);

[1968]{2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1231);

[1969]{2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1232);

[1970]{2-[5-(2-Isopropoxy-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1233);

[1971]{2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1234);

[1972](2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-piperidin-1-yl-methanone,trans-isomer, (Compound A1235);

[1973](2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-piperidin-1-yl-methanone,trans-isomer, (Compound A1236);

[1974]{2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,trans-isomer, (Compound A1237);

[1975]2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1238);

[1976]2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1239);

[1977]2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1240);

[1978]2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1241);

[1979]2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1242);

[1980]2-[5-(2-cyclohexylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1243);

[1981]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1244);

[1982]2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-]1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1245);

[1983]2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1246);

[1984]2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1247);

[1985]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1248);

[1986]2-[5-(2-benzylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1249);

[1987]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, R-isomer, trans-isomer,(Compound A1250);

[1988]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, S-isomer, trans-isomer,(Compound A1251);

[1989]2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA11252);

[1990]2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1253);

[1991]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1254);

[1992]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5methyl-[1,3]dioxane-5-carboxylic acid(tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound A1255);

[1993]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1256);

[1994]2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1257);

[1995]2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1258);

[1996]2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1259);

[1997]2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1260);

[1998]2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1261);

[1999]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1262);

[2000]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1263);

[2001]2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1264);

[2002] 2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1265);

[2003][4-(5-(4-fluoro-phenyl)-2-{5-methyl-5-[(tetrahydro-furan-2-ylmethyl)-carbamoyl]-[1,3]dioxan-2-yl}-3H-imidazol-4-yl)-pyrimidin-2-ylamino]-aceticacid, trans-isomer, (Compound A1266);

[2004] 3-[4-(5-(4-fluoro-phenyl)-2-{5-methyl-5-[(tetrahydro-furan-2-ylmethyl)-carbamoyl]-[1,3]dioxan-2-yl}-3H-imidazol-4-yl)-pyrimidin-2-ylamino]-propionicacid, trans-isomer, (Compound A1267);

[2005]2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1268);

[2006]2-[5-(2-allylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA11269);

[2007]2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1270);

[2008]2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1271);

[2009]2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1272);

[2010]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}--5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1273);

[2011]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}--5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1274);

[2012]2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1275);

[2013]2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1276);

[2014]2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1277);

[2015]2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1278);

[2016]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1279);

[2017] 2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1280);

[2018]2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1281);

[2019]2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1282);

[2020]2-[5-(2-benzyloxy-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1283);

[2021]2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1284);

[2022]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1285);

[2023]2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1286);

[2024]2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1287);

[2025]2-[5-(2-Isopropoxy-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1288);

[2026]2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1289);

[2027]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1290);

[2028]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1291);

[2029]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (CompoundA1292);

[2030]{2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1293);

[2031]{2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1294);

[2032]{2-[5-(2-dimethylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1295);

[2033]{2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1296);

[2034](2-{4-(4-fluoro-phenyl)-5-[2-(piperidin4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1297);

[2035]{2-[5-(2-cyclohexylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1298);

[2036](2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1299);

[2037]{2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1300);

[2038][2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1301);

[2039](2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A11302);

[2040](2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1303);

[2041]{2-[5-(2-benzylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1304);

[2042](2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone,R-isomer, trans-isomer, (Compound A1305);

[2043](2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone,S-isomer, trans-isomer, (Compound A1306);

[2044]{2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1307);

[2045]{2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1308);

[2046][2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2yl)-5-methyl-[1,3]dioxan-5-yl]-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1309);

[2047][2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1310);

[2048][2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2yl)-5-methyl-[1,3]dioxan-5-yl]-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1311);

[2049][2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2yl)-5-methyl-[1,3]dioxan-5-yl]-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1312);

[2050][2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2yl)-5-methyl-[1,3]dioxan-5-yl]-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1313);

[2051][2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1314);

[2052](2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1315);

[2053]{2-[4-(4-fluoro-phenyl)-5-(2-morpholin4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1316);

[2054](2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1317);

[2055](2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1318);

[2056]{2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1319);

[2057]{2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1320);

[2058](4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(4-methyl-piperazine-1-carbonyl)-[1,3]dioxan-2yl]-3H-imidazol4-yl}-pyrimidin-2-ylamino)-aceticacid, trans-isomer, (Compound A1321);

[2059]3-(4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(4-methyl-piperazine-1-carbonyl)-[1,3]dioxan-2-yl]-3H-imidazol4-yl}-pyrimidin-2-ylamino)-propionicacid, trans-isomer, (Compound A1322);

[2060]{2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1323);

[2061]{2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1324);

[2062]{2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1325);

[2063](4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(4-methyl-piperazine-1-carbonyl)-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-acetonitrile,trans-isomer, (Compound A1326);

[2064]3-(4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(4-methyl-piperazine-1-carbonyl)-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-propionitrile,trans-isomer, (Compound A1327);

[2065](2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1328);

[2066](2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1329);

[2067]{2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1330);

[2068]{2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1331);

[2069](2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1332);

[2070]{2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1333);

[2071](2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1334);

[2072]{2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1335);

[2073](2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2}-5-methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1336);

[2074]{2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1 337);

[2075]{2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1338);

[2076]{2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1339);

[2077](2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1340);

[2078]{2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1341);

[2079]{2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1342);

[2080]{2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1343);

[2081]{2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1344);

[2082](2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1345);

[2083](2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1346);

[2084]{2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound A1347);

[2085]{2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A1348);

[2086]{2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A1349);

[2087]{2-[5-(2-dimethylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A1350);

[2088]{2-[5-(2-cyclopropylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A1351);

[2089](2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound A1352);

[2090]{2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin4-yl-methanone,trans-isomer, (Compound A1353);

[2091](2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin4-yl-methanone,trans-isomer, (Compound A1354);

[2092]{2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A1355);

[2093][2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-morpholin4-yl-methanone,trans-isomer, (Compound A1356);

[2094](2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound A1357);

[2095](2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound A1358);

[2096]{2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A1359);

[2097](2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,R-isomer, trans-isomer, (Compound A1360);

[2098](2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,S-isomer, trans-isomer, (Compound A1361);

[2099]{2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A1362);

[2100]{2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin4-yl-methanone,trans-isomer, (Compound A1363);

[2101][2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone,trans-isomer, (Compound A1364);

[2102][2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-morpholin4-yl-methanone,trans-isomer, (Compound A1365);

[2103][2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-morpholin4-yl-methanone,trans-isomer, (Compound A1366);

[2104][2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone,trans-isomer, (Compound A11367);

[2105][2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-morpholin4-yl-methanone,trans-isomer, (Compound A1368);

[2106][²-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-1H-imidazol-2-yl)-5-methyl-[1,³]dioxan-5-yl]-morpholin-4-yl-methanone,trans-isomer, (Compound A1369);

[2107](2-{⁴-(⁴-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,³]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound A1370);

[2108]{2-[4-(4-fluoro-phenyl)-5-(2-morpholin14-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin4-yl-methanone,trans-isomer, (Compound A1371);

[2109](2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound A1372);

[2110](2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin4-yl-methanone,trans-isomer, (Compound A1373);

[2111]{2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin4-yl-methanone,trans-isomer, (Compound A1374);

[2112]{2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A1375);

[2113](4-14-fluoro-phenyl)-2-[5-methyl-5-(morpholine4-carbonyl)-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-aceticacid, trans-isomer, (Compound A11376);

[2114]3-(4-{5-(⁴-fluoro-phenyl)-2-[5-methyl-5-(morpholine4-carbonyl)-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-propionicacid, trans-isomer, (Compound A1377);

[2115]{2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin4-yl-methanone,trans-isomer, (Compound A1378);

[2116]{2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin4-yl-methanone,trans-isomer, (Compound A1379);

[2117]{2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A1380);

[2118](4-1-(4-fluoro-phenyl)-2-[5-methyl-5-(morpholine4-carbonyl)-[3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-acetonitrile,trans-isomer, (Compound A1381);

[2119]3-(4-{-(4-fluoro-phenyl)-2-[S-methyl-5-(morpholine-4-carbonyl)-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-propionitrile,trans-isomer, (Compound A1382);

[2120](2-{4-(4-fluoro-phenyl)-5-[²-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound A1383);

[2121](2-{4-(4-fluoro-phenyl)-5-[²-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound A1384);

[2122]{2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-y)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A1385);

[2123]{²-[⁴-(⁴-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin4-yl-methanone,trans-isomer, (Compound A1386);

[2124](2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound A1387);

[2125]{2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A1388);

[2126](2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound A1389);

[2127]{2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin4-yl-methanone,trans-isomer, (Compound A1390);

[2128](2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound A11391);

[2129]{2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A1392);

[2130]{2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A1393);

[2131]{2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A1394);

[2132](2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound A1395);

[2133]{2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin4-yl-methanone,trans-isomer, (Compound A1396);

[2134]{2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A1397);

[2135]{2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A1398);

[2136]{2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A1399);

[2137](2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morphine-4yl-methanone,trans-isomer, (Compound A1400);

[2138](2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy),pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morphine-4yl-methanone,trans-isomer, (Compound A1401);

[2139]{2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound A1402);

[2140]2-[5-(2-amino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1403);

[2141]2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1404);

[2142]2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1405);

[2143]2-[5-(2-cyclopropylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1406);

[2144]2-{4-(4-fluoro-phenyl)-5-[2-(piperidin4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1407);

[2145]2-[5-(2-cyclohexylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1408);

[2146]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1409);

[2147]2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1410);

[2148]2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1411);

[2149]2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1412);

[2150]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1413);

[2151]2-[5-(2-benzylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1414);

[2152]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, R-isomer, trans-isomer, (Compound A1415);

[2153]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, S-isomer, trans-isomer, (Compound A1416);

[2154]2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1417);

[2155]2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1418);

[2156]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1419);

[2157]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1420);

[2158]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1421);

[2159]2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1422);

[2160]2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1423);

[2161]2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1424);

[2162]2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1425);

[2163]2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1426);

[2164]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1427);

[2165]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1428);

[2166]2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1429);

[2167]2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-44-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1430);

[2168](4-{5-(4-fluoro-phenyl)-2-[5-(3-methoxy-propylcarbamoyl)-5-methyl-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-aceticacid, trans-isomer, (Compound A1431);

[2169]3-(4-{5-(4-fluoro-phenyl)-2-[5-(3-methoxy-propylcarbamoyl)-5-methyl-[1,3]dioxan-2yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-propionicacid, trans-isomer, (Compound A1432);

[2170]2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1433);

[2171]2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1434);

[2172]2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1435);

[2173]2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1436);

[2174]2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1437);

[2175]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1438);

[2176]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1439);

[2177]2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1440);

[2178]2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1441);

[2179]2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1442);

[2180]2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1443);

[2181]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1444);

[2182]2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5methyl-[

[2183] 1,3]dioxane-5-carboxylic acid (3-methoxy-propyl)-amide,trans-isomer, (Compound A1445);

[2184]2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1446);

[2185]2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1 447);

[2186]2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1448);

[2187]2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1449);

[2188]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1450);

[2189]2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1451);

[2190]2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1452);

[2191]2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1453);

[2192]2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1454);

[2193]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1455);

[2194]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1456);

[2195]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound A1457);

[2196]2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1458);

[2197]2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1459);

[2198]2-[5-(2-dimethylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1460);

[2199]2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1461);

[2200]2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide,trans-isomer, (Compound A1462);

[2201]2-[5-(2-cyclohexylamino-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1463);

[2202]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1464);

[2203]2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1465);

[2204]2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1466);

[2205]2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1467);

[2206]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1468);

[2207]2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1469);

[2208]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, R-isomer, trans-isomer, (Compound A1470);

[2209]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, S-isomer, trans-isomer, (Compound A1471);

[2210]2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1472);

[2211]2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1473);

[2212]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1474);

[2213]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1475);

[2214]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1476);

[2215]2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1477);

[2216]2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1478);

[2217]2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1479);

[2218]2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1480);

[2219]2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1481);2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1482);

[2220]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1483);

[2221]2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1484);

[2222] 2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1485);

[2223](4-{5-(4-fluoro-phenyl)-2-[5-(2-methoxy-ethylcarbamoyl)-5-methyl-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-aceticacid, trans-isomer, (Compound A1486);

[2224]3-(4-{5-(4-fluoro-phenyl)-2-[5-(2-methoxy-ethylcarbamoyl)-5-methyl-[1,3]dioxan-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-propionicacid, trans-isomer, (Compound A1487);

[2225]2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1488);

[2226]2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1489);

[2227]2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1490);

[2228]2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1491);

[2229]2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1492);

[2230]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1493);

[2231]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1494);

[2232]2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1495);

[2233]2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1496);

[2234]2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1497);

[2235]2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1498);

[2236]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2yl}-5-methyl-[1,3]dioxane-5-carboxylic acid (2-methoxy-ethyl)-amide,trans-isomer, (Compound A1499);

[2237]2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1500);

[2238]2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1501);

[2239]2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1502);

[2240]2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1503);

[2241]2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1504);

[2242]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1505);

[2243]2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1506);

[2244]2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]-dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1507);

[2245]2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1508);

[2246]2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1509);

[2247]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1510);

[2248]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1511);

[2249]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound A1512);

[2250]2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1513);

[2251]2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1514);

[2252]2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1515);

[2253]2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1516);

[2254]2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1517);

[2255]2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1518);

[2256]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1519);

[2257]2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1520);

[2258]2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1521);

[2259]2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1522);

[2260]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1523);

[2261]2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1524);

[2262]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, R-isomer, trans-isomer, (CompoundA1525);

[2263]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, S-isomer, trans-isomer, (CompoundA1526);

[2264]2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1527);

[2265]2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1528);

[2266]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1529);

[2267]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1530);

[2268]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1531);

[2269]2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1532);

[2270]2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1533);

[2271]2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1534);

[2272]2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1535);

[2273]2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1536);

[2274]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1537);

[2275]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1538);

[2276]2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl[-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1539);

[2277]2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1540);

[2278]{4-[2-[5-(3-dimethylamino-propylcarbamoyl)-5-methyl-[1,3]dioxan-2-yl]-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-aceticacid, trans-isomer, (Compound A1541);

[2279]3-{4-[2-[5-(3-dimethylamino-propylcarbamoyl)-5-methyl-[1,3]dioxan-2-yl]-5-(4fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionicacid, trans-isomer, (Compound A1542);

[2280]2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1543);

[2281]2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1544);

[2282]2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1545);

[2283]2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1546);

[2284]2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1547);

[2285]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1548);

[2286]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1549);

[2287]2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1550);

[2288]2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1551);

[2289]2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1552);

[2290]2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1553);

[2291]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1554);

[2292]2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1555);

[2293]2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1556);

[2294]2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1557);2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1558);

[2295]2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1559);

[2296]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1560);

[2297]2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1561);

[2298]2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1562);

[2299]2-[5-(2-Isopropoxy-pyrimidin-4-yl)4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1563);

[2300]2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1564);

[2301]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1565);

[2302]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1566);

[2303]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound A1567);

[2304]2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1568);

[2305]2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1569);

[2306]2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1570);

[2307]2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1571);

[2308]2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1572);

[2309]2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1573);

[2310]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1574);

[2311]2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1575);

[2312]2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1576);

[2313]2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1577);

[2314]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1578);

[2315]2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1579);

[2316]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, R-isomer, trans-isomer, (CompoundA1580);

[2317]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, S-isomer, trans-isomer, (CompoundA1581);

[2318]2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1582);

[2319]2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1583);

[2320]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1584);

[2321]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1585);

[2322]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1586);

[2323]2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1587);

[2324]2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1588);

[2325]2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1589);

[2326]2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1590);

[2327]2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1591);

[2328]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1592);

[2329]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}5-methyl-[1,3]dioxane-5-carboxylic acid (2-dimethylamino-ethyl)-amide,trans-isomer, (Compound A1593);

[2330]2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1594);

[2331]2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1595);

[2332]{4-[2-[5-(2-dimethylamino-ethylcarbamoyl)-5-methyl-[1,3]dioxan-2-yl]-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-aceticacid, trans-isomer, (Compound A1596);

[2333]3-{4-[2-[5-(2-dimethylamino-ethylcarbamoyl)-5-methyl-[1,3]dioxan-2-yl]-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionicacid, trans-isomer, (Compound A1597);

[2334]2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1598);

[2335]2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1599);

[2336]2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1600);

[2337]2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1601);

[2338]2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1602);

[2339]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1603);

[2340]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}--5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1604);

[2341]2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1605);

[2342]2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1606);

[2343]2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1607);

[2344]2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1608);

[2345]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1609);

[2346]2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1610);

[2347]2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1611);

[2348]2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1612);

[2349]2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1613);

[2350]2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1614);

[2351]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1615);

[2352]2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1616);

[2353]2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1617);

[2354]2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1618);

[2355]2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1619);

[2356]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1620);

[2357]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1621);

[2358]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound A1622);

[2359]{2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1623);

[2360]{2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1624);

[2361]{2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1625);

[2362]{2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1626);

[2363](2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A 1627);

[2364]{2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1628);

[2365](2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1629);

[2366]{2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A 1630);

[2367][2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1631);

[2368](2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1632);

[2369](2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2yl}-5-methyl-[1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1633);

[2370]{2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1634);

[2371](2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone,R-isomer, trans-isomer, (Compound A1635);

[2372](2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone,S-isomer, trans-isomer, (Compound A 1636);

[2373]{2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A 1637);

[2374]{2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1638);

[2375][2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1639);

[2376][2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1640);

[2377][2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2yl)-5-methyl-[1,3]dioxan-5-yl]-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1641);

[2378][2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1642);

[2379][2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2yl)-5-methyl-[1,3]dioxan-5-yl]-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1643);

[2380][2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1644);

[2381](2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1645);

[2382]{2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A 1646);

[2383](2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1647);

[2384](2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1648);

[2385]{2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1649);

[2386]{2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1650);

[2387](4-{5-(4-fluoro-phenyl)-2-[5-(3-hydroxy-pyrrolidine-1-carbonyl)-5-methyl-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-aceticacid, trans-isomer, (Compound A1651);

[2388]3-(4-{5-(4-fluoro-phenyl)-2-[5-(3-hydroxy-pyrrolidine-1-carbonyl)-5-methyl-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-propionicacid, trans-isomer, (Compound A1652);

[2389]{2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1653);

[2390]{2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1654);

[2391]{2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1655);

[2392](4-{5-(4-fluoro-phenyl)-2-[5-(3-hydroxy-pyrrolidine-1-carbonyl)-5-methyl-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-acetonitrile,trans-isomer, (Compound A1656);

[2393]3-(4-{5-(4-fluoro-phenyl)-2-[5-(3-hydroxy-pyrrolidine-1-carbonyl)-5-methyl-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-propionitrile,trans-isomer, (Compound A1657);

[2394](2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1658);

[2395](2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1659);

[2396]{2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1660);

[2397]{2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1661);

[2398](2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1662);

[2399]{2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1663);

[2400](2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1664);

[2401]{2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1665);

[2402](2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1666);

[2403]{2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1667);

[2404]{2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1668);

[2405]{2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-y)-methanone,trans-isomer, (Compound A1669);

[2406](2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1670);

[2407]{2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1671);

[2408]{2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1672);

[2409]{2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1673);

[2410]{2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1674);

[2411](2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1675);

[2412](2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1676);

[2413]{2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl[-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans-isomer, (Compound A1677);

[2414]2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1678);

[2415]2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1679);

[2416]2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1680);

[2417]2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1681);

[2418]2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1682);

[2419]2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1683);

[2420]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1684);

[2421]2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1685);

[2422]2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1686);

[2423]2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1687);

[2424]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1688);

[2425]2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1689);

[2426]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, R-isomer, trans-isomer, (Compound A1690);

[2427]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, S-isomer, trans-isomer, (Compound A1691);

[2428]2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1692);

[2429]2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1693);

[2430]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1694);

[2431]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1695);

[2432]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1696);

[2433]2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1697);

[2434]2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1698);

[2435]2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1699);

[2436]2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1700);

[2437]2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1701);

[2438]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1702);

[2439]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1703);

[2440]2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1704);

[2441]2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1705);

[2442]{4-[5-(4-fluoro-phenyl)-2-(5-isopropylcarbamoyl-5-methyl-[1,3]dioxan-2-yl)-3H-imidazol-4yl]-pyrimidin-2-ylamino}-aceticacid, trans-isomer, (Compound A1706);

[2443]3-{4-[5-(4-fluoro-phenyl)-2-(5-isopropylcarbamoyl-5-methyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionicacid, trans-isomer, (Compound A1707);

[2444]2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1708);

[2445]2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1709);

[2446]2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1710);

[2447]2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1711);

[2448]2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1712);

[2449]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1713);

[2450]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1714);

[2451]2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1715);

[2452]2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1716);

[2453]2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1717);

[2454]2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1718);

[2455]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1719);

[2456]2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1720);

[2457]2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1721);

[2458]2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1722);

[2459]2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1723);

[2460]2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1724);

[2461]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1725);

[2462]2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1726);

[2463]2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1727);

[2464]2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1728);

[2465]2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1729);

[2466]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1730);

[2467]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1731);

[2468]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid isopropyl-amide, trans-isomer, (Compound A1732);

[2469]2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1733);

[2470]2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1734);

[2471]2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1735);

[2472]2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1736);

[2473]2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1737);

[2474]2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1738);

[2475]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1739);

[2476]2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1740);

[2477]2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1741);

[2478]2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1742);

[2479]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1743);

[2480]2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1744);

[2481] 2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, R-isomer, trans-isomer, (Compound A1745);

[2482]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylic acid allylamide, S-isomer,trans-isomer, (Compound A1746);

[2483]2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1747);

[2484]2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1748);

[2485]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1749);

[2486]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1750);

[2487]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1751);

[2488]2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1752);

[2489]2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1753);

[2490]2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1754);

[2491]2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1755);

[2492]2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1756);

[2493]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1757);

[2494]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1758);

[2495]2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1759);

[2496]2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1760);

[2497]{4-[2-(5-allylcarbamoyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-aceticacid, trans-isomer, (Compound A1761);

[2498]3-{4-[2-(5-allylcarbamoyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionicacid, trans-isomer, (Compound A1762);

[2499]2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1763);

[2500]2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1764);

[2501]2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1765);

[2502]2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1766);

[2503]2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1767);

[2504]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1768);

[2505]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1769);

[2506]2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1770);

[2507]2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1771);

[2508]2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1772);

[2509]2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1773);

[2510]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1774);

[2511]2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1775);

[2512]2-{4-(4-fluoro-phenyl)-5-2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2yl}-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1776);

[2513]2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1777);

[2514]2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1778);

[2515]2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1779);

[2516]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1780);

[2517]2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1781);

[2518]2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1782);

[2519]2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1783);

[2520]2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1784);

[2521]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1785);

[2522]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1786);

[2523]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid allylamide, trans-isomer, (Compound A1787);

[2524]2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1788);

[2525]2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1789);

[2526]2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1790);

[2527]2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1791);

[2528]2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1792);

[2529]2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1793);

[2530]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1794);

[2531]2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1795);

[2532]2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1796);

[2533]2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1797);

[2534]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1798);

[2535]2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1799);

[2536]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, R-isomer, trans-isomer, (Compound A1800);

[2537]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, S-isomer, trans-isomer, (Compound A1801);

[2538]2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1802);

[2539]2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1803);

[2540]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1804);

[2541]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1805);

[2542]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1806);

[2543]2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1807);

[2544] 2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1808);

[2545]2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1809);

[2546]2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1810);

[2547]2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1811);

[2548]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1812);

[2549]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1813);

[2550]2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1814);

[2551]2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1815);

[2552]{4-[2-[5-(cyclopropylmethyl-carbamoyl)-5-methyl-[1,3]dioxan-2-yl]-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-aceticacid, trans-isomer, (Compound A1816);

[2553]3-(4-[2-[5-(cyclopropylmethyl-carbamoyl)-5-methyl-[1,3]dioxan-2-yl]-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionicacid, trans-isomer, (Compound A1817);

[2554]2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1818);

[2555]2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1819);

[2556]2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1820);

[2557]2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1821);

[2558]2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1822);

[2559]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1823);

[2560]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1824);

[2561]2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1825);

[2562]2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1826);

[2563]2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1827);

[2564]2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1828);

[2565]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1829);

[2566]2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1830);

[2567]2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1831);

[2568]2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1832);

[2569]2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylic acid cyclopropylmethyl-amide, trans-isomer, (CompoundA1833);

[2570]2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1834);

[2571]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1835);

[2572]2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1836);

[2573]2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1837);

[2574]2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1838);

[2575]2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1839);

[2576]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1840);

[2577]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1841);

[2578]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylmethyl-amide, trans-isomer, (Compound A1842);

[2579]2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1843);

[2580]2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1844);

[2581]2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1845);

[2582]2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1846);

[2583]2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1847);

[2584]2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1848);

[2585]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1849);

[2586]2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1850);

[2587]2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1851);

[2588]2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1852);

[2589]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1853);

[2590]2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1854);

[2591]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, R-isomer, trans-isomer, (Compound A1855);

[2592]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, S-isomer, trans-isomer, (Compound A1856);

[2593]2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1857);

[2594]2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1858);

[2595]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1859);

[2596]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1860);

[2597]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A861);

[2598]2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1862);

[2599]2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1863);

[2600]2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1864);

[2601]2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1865);

[2602]2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1866);

[2603]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1867);

[2604]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1868);

[2605]2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1869);

[2606]2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1870);

[2607]{4-[2-[5-(cyanomethyl-carbamoyl)-5-methyl-[1,3]dioxan-2-yl]-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-aceticacid, trans-isomer, (Compound A1871);

[2608]3-{4-[2-[5-(cyanomethyl-carbamoyl)-5-methyl-[1,3]dioxan-2-yl]-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionicacid, trans-isomer, (Compound A1872);

[2609]2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1873);

[2610]2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1874);

[2611]2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1875);

[2612]2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1876);

[2613]2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1877);

[2614]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1878);

[2615]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1879);

[2616]2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1880);

[2617]2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1881);

[2618]2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1882);

[2619]2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1883);

[2620]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1884);

[2621]2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1885);

[2622]2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1886);

[2623]2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1887);

[2624]2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1888);

[2625]2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1889);

[2626]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1890);

[2627]2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1891);

[2628]2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1892);

[2629]2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1893);

[2630]2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1894);

[2631]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1895);

[2632]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1896);

[2633]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyanomethyl-amide, trans-isomer, (Compound A1897);

[2634]2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1898);

[2635]2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1899);

[2636]2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1900);

[2637]2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1901);

[2638]2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1902);

[2639]2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1903);

[2640]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1904);

[2641]2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1905);

[2642]2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1906);

[2643]2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1907);

[2644]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1908);

[2645]2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1909);

[2646]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, R-isomer, trans-isomer, (Compound A1910);

[2647]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, S-isomer, trans-isomer, (Compound A1911);

[2648]2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1912);

[2649]2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1913);

[2650]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1914);

[2651]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1915);

[2652]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1916);

[2653]2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1917);

[2654]2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl)}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1918);

[2655]2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1919);

[2656]2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl)-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1920);

[2657]2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1921);

[2658]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1922);

[2659]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1923);

[2660]2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1924);

[2661]2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl[-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1925);

[2662]{4-[2-[5-(2-cyano-ethylcarbamoyl)-5-methyl-[1,3]dioxan-2-yl]-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-aceticacid, trans-isomer, (Compound A1926);

[2663]3-{4-[2-[5-(2-cyano-ethylcarbamoyl)-5-methyl-[1,3]dioxan-2-yl]-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propionicacid, trans-isomer, (Compound A1927);

[2664]2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1928);

[2665]2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid 2-cyano-ethyl)-amide, trans-isomer, (Compound A1929);

[2666]2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1930);

[2667]2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1931);

[2668]2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1932);

[2669]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1933);

[2670]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1934);

[2671]2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1935);

[2672]2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1936);

[2673]2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1937);

[2674]2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1938);

[2675]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1939);

[2676]2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1940);

[2677]2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1941);

[2678]2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1942);

[2679]2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1943);

[2680]2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1944);

[2681]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1945);

[2682]2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1946);

[2683]2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1947);

[2684]2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1948);

[2685]2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1949);

[2686]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1950);

[2687]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1951);

[2688]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-cyano-ethyl)-amide, trans-isomer, (Compound A1952);

[2689]2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1953);

[2690]2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1954);

[2691]2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1955);

[2692]2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1956);2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1957);

[2693]2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1958);

[2694]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1959);

[2695]2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1960);

[2696]2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1961);

[2697]2-{4-(4-fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2yl-}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1962);

[2698]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1963);

[2699]2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1964);

[2700]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, R-isomer, trans-isomer, (Compound A1965);

[2701]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, S-isomer, trans-isomer, (Compound A1966);

[2702]2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1967);

[2703]2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1968);

[2704]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1969);

[2705]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1970);

[2706]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1971);

[2707]2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1972);

[2708]2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1973);

[2709]2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1974);2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1975);

[2710]2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1976);

[2711]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1977);

[2712]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1978);

[2713]2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1979);

[2714]2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1980);

[2715](4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(pyridin-3-ylcarbamoyl)-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-aceticacid, trans-isomer, (Compound A1981);

[2716]3-(4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(pyridin-3-ylcarbamoyl)-[1,3]dioxane-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-propionicacid, trans-isomer, (Compound A1982);

[2717]2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1983);

[2718]2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylic acid pyridin-3-ylamide, trans-isomer, (Compound A1984);

[2719]2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1985);

[2720]2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1986);

[2721]2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1987);

[2722]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1988);

[2723]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1989);

[2724]2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1990);

[2725]2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1991);

[2726]2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1992);

[2727]2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1993);

[2728]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1994);

[2729]2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1995);

[2730]2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1996);

[2731]2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1997);

[2732]2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1998);

[2733]2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A1999);

[2734]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A2000);

[2735]2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A2001);

[2736]2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A2002);

[2737]2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A2003);

[2738]2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A2004);

[2739]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A2005);

[2740]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A2006);

[2741]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-3-ylamide, trans-isomer, (Compound A2007);

[2742]2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2008);

[2743]2-[4-(4-fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2009);

[2744]2-[5-(2-dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2010);

[2745]2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2011);

[2746]2-{4-(4-fluoro-phenyl)-5-[2-(piperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2012);

[2747]2-[5-(2-cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2013);

[2748]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2014);

[2749]2-[5-[2-(2-amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2015);

[2750]2-(4-(4-fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2016);

[2751]2-{4-(4-fluoro-phenyl)-5-[2{-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2017);

[2752]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2018);

[2753]2-[5-(2-benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2019);

[2754]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, R-isomer, trans-isomer, (Compound A2020);

[2755]2-{4-(4-fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, S-isomer, trans-isomer, (Compound A2021);

[2756]2-[4-(4-fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, R-isomer, trans-isomer, (Compound A2022);

[2757]2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, S-isomer, trans-isomer, (Compound A2023);

[2758]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2024);

[2759]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2025);

[2760]2-(4-(4-fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2026);

[2761]2-(4-(4-fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide 2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide , trans-isomer, (Compound A2027);

[2762]2-(4-(4-fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2yl)-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2028);

[2763]2-(4-(4-fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2029);

[2764]2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2030);

[2765]2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2031);

[2766]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylic acid pyridin-4-ylamide,trans-isomer, (Compound A2032);

[2767]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2033);

[2768]2-[5-[2-(3-dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2034);

[2769]2-[5-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2035);

[2770](4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(pyridin-4-ylcarbamoyl)-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-aceticacid, trans-isomer, (Compound A2036);

[2771]3-(4-{5-(4-fluoro-phenyl)-2-[5-methyl-5-(pyridin-4-ylcarbamoyl)-[1,3]dioxane-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-propionicacid, trans-isomer, (Compound A2037);

[2772]2-[4-(4-fluoro-phenyl)-5-(2-isopropylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2038);

[2773]2-[5-(2-allylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2039);

[2774]2-[5-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2040);

[2775]2-[5-[2-(cyanomethyl-amino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2041);

[2776]2-[5-[2-(2-cyano-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2042);

[2777]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-3-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2043);

[2778]2-{4-(4-fluoro-phenyl)-5-[2-(pyridin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2044);

[2779]2-[4-(4-fluoro-phenyl)-5-(2-propylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-81,3]dioxane-5-carboxylic acid pyridin-4-ylamide, trans-isomer, (CompoundA2045);

[2780]2-[4-(4-fluoro-phenyl)-5-(2-pyrrolidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2046);

[2781]2-{4-(4-fluoro-phenyl)-5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2047);

[2782]2-[5-[2-(3,4-difluoro-phenylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2048);

[2783]2-{4-(4-fluoro-phenyl)-5-[2-(3-methoxy-phenylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2049);

[2784]2-[5-[2-(4-fluoro-benzylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2050);

[2785]2-{4-(4-fluoro-phenyl)-5-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2051);

[2786]2-[4-(4-fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2052);

[2787]2-[5-(2-benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2053);

[2788]2-[4-(4-fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2054);

[2789]2-{4-(4-fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2055);

[2790]2-[5-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2056);

[2791]2-[5-(2-cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2057);

[2792]2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2058);

[2793]2-[4-(4-fluoro-phenyl)-5-(2-propoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2059);

[2794]2-{4-(4-fluoro-phenyl)-5-[2-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2060);

[2795]2-{4-(4-fluoro-phenyl)-5-[2-(3-hydroxy-propoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2061);

[2796]2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid pyridin-4-ylamide, trans-isomer, (Compound A2062);

[2797] (c) By proceeding in a similar manner to Example 40(b) but using2-[4-(4-fluorophenyl)-5-(2-methylylsulphonylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-carboxylicacid methyl ester, cis isomer (Compound LN) there is prepared thecorresponding cis-isomers of Compound GT and Compounds A557 to A2062.

Reference Example 1

[2798]4-[5-(4-Fluoro-phenyl)-2-formyl-1-[(2-(trimethylsilyl)ethoxy)methyl]-1H-imidazol-4-yl]-pyridine

[2799] A solution of4-[5-(4-fluoro-phenyl)-1-[(2-(trimethylsilyl)ethoxy)methyl]-1H-imidazol-4-yl]-pyridine(8.15 g, reference Example 2) in tetrahydrofuran (100 ml) was treatedwith a solution of n-butyllithium in hexane (10.6 ml, 2.1 M) to give adark green solution. The solution was stirred at −78° C. for 15 minutesthen treated with a solution of N-formylmorpholine (2.45ml) intetrahydrofuran (10 ml). After stirring for 15 minutes at −78° C., themixture was allowed to warm to room temperature then stirred at thistemperature for a further 1 hour. The reaction mixture was quenched withwater (50 ml) and then extracted four times with ethyl acetate (50 ml).The combined extracts were dried over magnesium sulphate and evaporated.The residual oil was subjected to flash chromatography on silica,eluting with ethyl acetate, to give the title compound (7.86 g) as ayellow oil.

Reference Example 2

[2800]4-[5-(4-Fluoro-phenyl)-1-[(2-(trimethylsilyl)ethoxy)methyl]-1H-imidazol-4-yl]-pyridine

[2801] A stirred solution of 5-(4-fluoro-phenyl)-4-(4-pyridyl)-imidazole[BOEHM ET AL.,] (12.86 g, prepared according to the procedure of Boehmet. al., J.Med.Chem., 1996, 39, page 3829-3937) in dry dimethylformamide(150 ml) was treated portionwise with sodium hydride (2.58 g, 60%dispersion in mineral oil). The mixture was stirred at room temperatureuntil the evolution of hydrogen stopped, then treated dropwise with2-(trimethylsilyl)ethoxymethyl chloride (10.66ml). After stirring atroom temperature for 1.5 hours, the reaction mixture was treated withwater (10 ml) then evaporated. The residual oil was then partitionedbetween ethyl acetate and water (100 ml). The aqueous phase wasextracted three times with ethyl acetate (100 ml). The combined organicphases were washed with brine (50 ml), then dried over magnesiumsulphate, then evaporated. The residual yellow oil was subjected toflash chromatography on silica eluting with a mixture of methanol anddichloromethane (98:2, v/v) to give the title compound.

Reference Example 3

[2802]4-[2-Dimethoxymethyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-pyridine

[2803] Method A: A solution of4-[2-formyl-5-(4-fluoro-phenyl)-1-{(2-(trimethylsilyl)ethoxy)-methyl}-1H-imidazol-4-yl]-pyridine(0.525 g, Reference Example 1) in methanol (10 ml) was treated withtrimethylorthoformate (5 ml) then with 4-toluenesulphonic acid (0.39 g).The reaction mixture was refluxed for 5 hours, then cooled to roomtemperature, then evaporated. The residue was partitioned between ethylacetate and saturated aqueous sodium bicarbonate solution (30 ml). Theaqueous phase was extracted four times with ethyl acetate (20 ml). Thecombined organic phases were washed with water (15 ml), then with brine(15 ml), then dried over magnesium sulphate and then evaporated. Theresidual oil was subjected to flash chromatography on silica elutingwith a mixture of dichloromethane and methanol (8:1, v/v) to give thetitle compound (0.344 g) as a white solid, m.p. 186-189° C.

[2804] Method B: A stirred suspension of1-(4-fluorophenyl)-2-(4-pyridyl)-1,2-ethandione (162.74 g, ReferenceExample 10) in tert-butylmethyl ether (735 ml), at 20-25° C., wastreated with a solution of glyoxal 1,1-dimethylacetal intert-butylmethyl ether (244.4 ml, 45%) followed by a solution ofammonium acetate (140.75 g) in methanol (260 ml) over a period of 30minutes, during which time the suspension dissolved to form an orangesolution. After stirring for 1 hour at 20-25° C., the resultingsuspension was cooled to 5-10° C., then stirred for a further 1 hour,then filtered. The damp filter cake was slurry washed three times withwater (350 ml) and then the pressed cake washed twice withtert-butylmethyl ether (350 ml). The air-dry cake was then dried invacuo at 60-65° C. for 16 hours, to afford the title compound, as acream coloured, free-flowing solid, m.p. 204-206° C. ¹H NMR [δ,(CD₃)₂SO[: 8.35 (d, 2H); 7.43 (dt, 2H); 7.36 (d, 2H); 7.19 (dt, 2H);5.39 (s, 1H); 3.34 (s, 6H).

Reference Example 4

[2805] 2-methyl-2-trifluoroacetamido-1,3-propanediol

[2806] A stirred solution of 2-amino-2-methyl-1,3-propanediol (1.05 g)in dry dimethylformamide (20 ml), at room temperature, was treated withpotassium carbonate (1.52g). After stirring at room temperature for 15minutes the mixture was treated dropwise with trifluoroacetic anhydride(1.55 ml) and stirring was then continued for a further 18 hours. Thereaction mixture was evaporated and the residue was subjected to flashchromatography on silica eluting with a mixture of dichloromethane andmethanol (95:5, v/v) to give the title compound (1 g) as a white solid.

Reference Example 5

[2807] 2-azidomethyl-2-methyl-1,3-propanediol

[2808] A mixture of 5-azidomethyl-2-dimethyl-5-methyl-1,3-dioxane [1.48g, prepared according to the procedure in J.Org.Chem., 1992, page 6080]concentrated hydrochloric acid (0.3 ml), water (0.8 ml) andtetrahydrofuran (10 ml) was heated at reflux for 1 hour. After coolingto room temperature the reaction mixture was evaporated. The residue wasdried under vacuum to give the title compound (1.3 g) as a colourlessoil.

Reference Example 6

[2809] 3-hydroxy-2-hydroxymethyl-2-methyl-1-morpholino-1-propanone

[2810] A stirred mixture of diisopropylethylamine (339.67 ml) andmorpholine (141.71 ml) in acetonitrile 1-hydroxybenzotriazole (43.92 g).The resulting suspension was warmed to 55-60° C. then treated dropwisewith a solution of 1,3-dicyclohexylcarbodiimide (147.62 g) inacetonitrile (232.2 ml) over 30 minutes. The resulting solution was thenstirred at 55-60° C. for a further 2 hours then filtered to remove thedicyclohexylurea (131.88 g) by-product. The filter cake was washed twicewith acetonitrile (250 ml). The filtrate was evaporated and the residuewas treated with warm ethyl acetate (500 ml). The resultant solution wasallowed to cool for 16 hours then the 1-hydroxybenzotriazole (42.04 g)which crystallised was removed by filtration. Further cooling of thefiltrate over 5 hours and filtration gave the title compound (44.82 g),m.p. 95-97° C.

[2811]¹H NMR (d, CDCl₃): 4.02 (d, 2H); 3.70 (m, 10H); 3.30 (bs, 2H);1.08 (s, 3H).

[2812] A further quantity of the title compound (41.33 g) was obtainedfollowing evaporation of the filtrate from the first crop of product,then treating the residue with ethyl acetate (1000 ml), then passing thesolution through a silica gel pad (4 cm high×11 cm diameter), thenevaporating the filtrate and then crystallising the residue from n-butylacetate (1000 ml) over 16 hours.

Reference Example 7

[2813]4-[2-Dimethoxymethyl-5(4)-(4-fluoro-phenyl)-1H-imidazol-4(5)-yl]-2-methanesulphanyl-pyrimidine

[2814] A solution of1-(4-fluorophenyl)-2-(2-methylsulphanylpyrimidin-4-yl)-1,2-ethandione(18.7 g, Reference Example 8) in t-butyl methyl ether (75 ml) andglyoxal dimethylacetal in t-butylmethyl ether (36 ml, 40%), at roomtemperature, was treated dropwise over 30 minutes with a solution ofammonium acetate (21.7 g) in methanol (40 ml) to give an orangesolution. After stirring for 2 hours at room temperature the resultingsuspension was filtered to give the title compound (15.6 g) as acolourless solid, m.p. 180-182° C. MH⁺361.

Reference Example 8

[2815]1-(4-fluorophenyl)-2-(2-methylsulphanylpyrimidin-4-yl)-1,2-ethandione

[2816] A solution of1-(4-fluorophenyl)-2-(2-methylsulphanylpyrimidin-4-yl)-1-ethanone(65.5g, Reference Example 9) in dimethylsulphoxide, at 55-70° C., was treateddropwise with an aqueous solution of hydrogen bromide (48%). Afterstirring at 60° C. for 3 hours, the reaction mixture was cooled to roomtemperature, then poured into water and the pH of the mixture adjustedto pH8 by addition of sodium bicarbonate. The reaction mixture wasextracted with ethyl acetate and the extracts were evaporated to givethe title compound (40.87 g), m.p. 74-76° C. MH⁺277.

Reference Example 9

[2817] 1-(4-fluorophenyl)-2-(2-methylsulphanylpyrimidin-4-yl)-1-ethanone

[2818] A solution of lithium hexamethyldisilazane in tetrahydrofuran(1.221, 1M), at −40° C., was treated with a solution of4-methyl-2-methylsulphanylpyrimidine (76.03 g) in tetrahydrofuran (100ml). The solution was warmed to 0° C., then stirred for 15 minutes, thencooled to −40° C., then treated with a solution of ethyl4-fluorobenzoate (91.32 g) in tetrahydrofuran (200 ml). After stirringat −40° C. for 15 minutes the reaction mixture was allowed to warm toroom temperature over 2 hours, then treated with ammonium chloridesolution. The organic phase was separated and the aqueous phase wasextracted with ethyl acetate. The combined organic phases wereevaporated to give the title compound (136.19 g), m.p. 212-214° C.MH⁺263.

Reference Example 10

[2819] 1-(4-fluorophenyl)-2-(4-pyridyl)-1,2-ethandione

[2820] A mixture of 1-(4-fluorophenyl)-2-(4-pyridyl)-1-ethanone (247.69g, Reference Example 11) was mixed with dimethylsulfoxide (500 ml) thenwarmed on a rotary evaporator (no vacuum). The resulting solution wastransferred to a reaction vessel with two rinses of dimethylsulfoxide(500 ml and 240 ml) incorporated to ensure complete transfer. Theresulting solution was then warmed to 55-65° C. and hydrogen bromide(581.47 g) was added at such a rate so as to maintain the solutiontemperature in the range 55-65° C., without the need for any externalheating. The solution was stirred at 55-65° C. for a further 2 hours,when thin layer chromatography on silica indicated the reaction to becomplete. The reaction mixture was added to water (4000 ml) a separatevessel, with external cooling to maintain a solution temperature in therange 15-25° C. The residual contents of the reaction vessel weretransferred using a further aliquot of water (2000 ml). The aqueoussolution was then treated with a solution of sodium acetate (600 g) inwater (2000 ml), over 15 minutes, and the resulting suspension wasstirred for 2 hours at ambient temperature, then filtered. The filtercake was washed three times with water (500 ml), then air-dried for 1hour, then dried in vacuo for 16 hours at 15-25° C. to give the titlecompound (296.93 g) as a free-flowing yellow-orange powder, m.p. 84-86C.¹H NMR (CDCl₃): δ 8.81 (d, 2H); 7.98 (dd, 2H); 7.74 (d, 2H); 7.18 (t,2H).

Reference Example 11

[2821] 1-(4-fluorophenyl)-2-(4-pyridyl)-1-ethanone

[2822] A stirred solution of sodium bis(trimethylsilyl)amide intetrahydrofuran (720 ml, 2M), under nitrogen, was treated with4-picoline (64.7 ml). After 5 minutes a solution of ethyl4-fluorobenzoate (111.7 g) was added over 30 minutes whilst maintainingthe temperature at 18-20° C. by occasional cooling. After stirring at20-21° C. for 30 minutes, the resultant slurry was cooled in an ice-baththen treated with toluene (500 ml). When the temperature reached 15° C.a solution of acetic acid (82 ml) in water (300 ml) was added over 15minutes maintaining the temperature below 25° C. After a further 30minutes stirring at 20-25° C., the organic phase was separated and thenevaporated. The oily residue was triturated with heptane to give thetitle compound (133 g) as a yellow solid, m.p. 80-84° C. ¹H NMR (δ,CDCl₃): 8.42 (d, 2H); 7.88 (dd, 2H); 7.06 (d, 2H, ); 7.01 (t, 2H); 4.12(s, 2H).

[2823] In vitro and in vivo Test Procedures

[2824] 1. In Vitro Inhibitory Effects on TNF-alpha Release by HumanMonocytes

[2825] The effects of compounds on TNF-alpha production by humanperipheral blood monocytes (PBMs) are examined as follows.

[2826] 1.1. Preparation of Human Peripheral Blood Monocytes

[2827] Freshly drawn blood from normal healthy donors was mixed (4:1,v/v) with sodium citrate (3.8%, w/v). Mononuclear cells were prepared bycentrifugation of the blood on Histopaque-1077 (Sigma Diagnostics)according to manufacturers instructions. The fraction enriched withmononuclear cells was washed and resuspended in Hank's balanced saltssolution (HBSS) supplemented with deoxyribonuclease (37.5 U/ml) andhuman serum albumin (0.3%). Differential (cytospin) cell counts revealedthat the mononuclear cell fraction routinely comprised 70-80% monocytes.Cells from the mononuclear leukocyte fraction were centrifuged (200 g,10 min, 20° C.), resuspended, at a density of 10⁶ cells/ml, in RPMI 1640containing foetal calf serum (FCS) (1% ), penicillin (50 U/ml) andstreptomycin (50 μg/ml) and allowed to adhere in 96 well plates.Following incubation (5% CO₂, 37° C.) for 90 min, medium containingnon-adherent cells was removed, the cells were washed once with freshmedium and fresh medium was added.

[2828] 1.2. Measurement of Monocyte TNF-alpha Release

[2829] Adherent cells in culture medium were incubated for 1h (5% CO₂,37° C.) with fresh medium containing compounds or vehicle (0.1 %dimethylsulphoxide). Compounds were tested within the concentrationrange of 3×10⁻⁹M to 3×10⁻⁶M. LPS (10 ng/ml) was then added to the cellsand the incubation continued for a further 18 hours. Cell supernatantswere removed into 96 well, 0.22 μm filtration plates for storage at −20°C.

[2830] TNF-alpha concentrations in cell supernatants were quantified bysandwich ELISA. Briefly, ELISA plates were coated overnight with 2 μ/mlof mouse anti-human TNF-alpha antibody in bicarbonate buffer (pH 9.9).After washing the wells with wash buffer (0.05% (v/v) Tween in PBS), andblocking standards were vacuum filtered into the corresponding wells ofthe ELISA plate. Biotinylated rabbit polyclonal anti-human TNF-alphaantibody (3 μg/ml) was used as the second antibody andstreptavidin-horseradish peroxidase was used as the detection antibody.The peroxidase substrate was 3,3′,5,5′-tetramethylbenzidine (TMB), inthe presence of hydrogen peroxide.

[2831] TNFα concentrations in supernatants from control andLPS-stimulated monocyte incubations were calculated by interpolationfrom a standard (log/log) curve (0.125-16 ng/ml) fitted by linearregression using a Multicalc software program (Wallac U.K., Ltd).

[2832] 1.3. Results

[2833] Compounds within the scope of the invention produce 50%inhibition of LPS induced TNF-alpha release from human monocytes atconcentrations within the range of 10⁻⁹ M to 10⁻⁴ M, preferably withinthe range of 10⁻⁹ M to 10⁻⁷ M.

[2834] 2. Inhibitory Effects of Compounds on Serum TNF-Alpha Levels inLPS-challenged Mice

[2835] 2.1. Treatment of Animals and Measurement of Murine TNF-Alpha.

[2836] Female Balb/c mice (age 6-8 weeks, weight 20-22 g from CharlesRiver, U.K.) in groups of five or more animals were dosed p.o. withcompounds (1 to 100 mg/kg) suspended in 1.5% (w/v) carboxymethylcellulose then challenged after a minimum period of 30 minutes with 30mg of LPS i.p. After 90 minutes, the animals were killed by carbondioxide asphyxiation and bled by cardiac puncture. Blood was allowed toclot at 4° C., centrifuged (12,000 g for 5 minutes) and serum taken forTNF-alpha analysis. TNF-alpha levels are measured using a commerciallyavailable murine TNF-alpha ELISA kit, purchased from Genzyme (Cat. no.1509.00), as recommended by the manufacturer. Values for TNF-alpha werecalculated from a recombinant murine TNF-alpha standard curve as above.

[2837] 2.2. Results

[2838] Compounds within the scope of the invention inhibit TNF-alpharelease in LPS challenged mice up to 50% at doses of 0.1 mg/kg to 100mg/kg.

1. A compound of formula (I):

wherein:— R¹ is optionally substituted heteroaryl; R² is optionallysubstituted aryl or optionally substituted heteroaryl; R³ represents agroup -L¹-R⁷ or -L²-R⁸ where L¹ represents a straight- or branched-chainalkylene linkage containing from 1 to about 6 carbon atoms optionallysubstituted by halogen or oxo; R⁷ is hydrogen, aryl, cyano, cycloalkyl,heteroaryl, heterocycloalkyl, nitro, —S(O)_(n)R⁹, (where R⁹ is alkyl,aryl, arylalkyl, cycloalkyl, heteroaryl, heteroarylalkyl, orheterocycloalkyl and n is zero or an integer 1 or 2), —NHSO₂R⁹,—C(═Z)OR¹⁰ (where Z is an oxygen or sulphur atom and R¹⁰ is hydrogen orR⁹), —C(═Z)R¹⁰, —OR^(10,) —N(R¹¹)—C(═Z)R⁹ (where R¹¹ is hydrogen oralkyl), —NY¹Y² {where Y¹ and Y² are independently hydrogen, alkenyl,alkyl, alkynyl, aryl, arylalkyl, cycloalkenyl, cycloalkyl, heteroaryl orheteroarylalkyl, or the group —NY¹Y² may form a 5-7 membered cyclicamine which may optionally contain a further heteroatom selected from O,S, or NY³ (where Y³ is hydrogen, alkyl, aryl, arylalkyl, —CHO, —C(═Z)R⁹or —SO₂R⁹), or which may also be fused to additional aryl, heteroaryl,heterocycloalkyl or cycloalkyl rings to form a bicyclic or tricyclicring system}, —SO₂—NY¹Y², —C(═Z)—NY¹Y², —N(R¹¹)—C(═Z)—NY¹Y²,—N(OR¹⁰)—C(═Z)—NY¹Y², —N(OR¹⁰)—C(═Z)R¹⁰, —C(═NOR¹⁰)R¹⁰, —C(═Z)NR¹⁰OR¹²(where R¹² is hydrogen, alkyl, aryl or arylalkyl),—N(R¹¹)—C(═NR¹³)—NY¹Y² (where R¹³ is hydrogen, cyano, alkyl, cycloalkylor aryl), or —N(R¹¹)—C(═Z)OR¹¹; L² represents a direct bond or astraight- or branched-carbon chain comprising from 2 to about 6 carbonatoms and containing a double or triple carbon-carbon bond; and R⁸ ishydrogen, aryl, cycloalkenyl, cycloalkyl, heteroaryl orheterocycloalkyl; R⁴ represents a group -L³-R¹⁴ where L³ represents adirect bond or a straight- or branched-chain alkylene linkage containingfrom 1 to about 6 carbon atoms (optionally substituted by halogen,hydroxy, alkoxy or oxo); and R¹⁴ is hydrogen, alkyl, azido, hydroxy,alkoxy, aryl, arylalkyloxy, aryloxy, carboxy (or an acid bioisostere),cycloalkyloxy, heteroaryl, heteroarylalkyloxy, heteroaryloxy,heterocycloalkyl, heterocycloalkyloxy, nitro, —NY⁴Y⁵, {where Y⁴ and Y⁵are independently hydrogen, aryl, cycloalkyl, heterocycloalkyl,heteroaryl or alkyl optionally substituted by alkoxy, aryl, cyano,cycloalkyl, heteroaryl, heterocycloalkyl, hydroxy, oxo, —CO₂R¹⁰,—CONY¹Y² or —NY¹Y², or the group —NY⁴Y⁵ may form a 5-7 membered cyclicamine which (i) may be optionally substituted with one or moresubstituents selected from alkoxy, carboxamido, carboxy, hydroxy, oxo(or a 5, 6,or 7 membered cyclic acetal derivative thereof), R⁹ or alkylsubstituted by carboxy, carboxamido or hydroxy (ii) may also contain afurther heteroatom selected from O, S, SO₂ or NY⁶ (where Y⁶ is hydrogen,alkyl, aryl, arylalkyl, —C(═Z)R⁹, —C(═Z)OR⁹ or —SO₂R⁹) and (iii) mayalso be fused to additional aryl, heteroaryl, heterocycloalkyl orcycloalkyl rings to form a bicyclic or tricyclic ring system},—N(R¹⁰)—C(═Z)—R¹⁵ (where R¹⁵ is alkyl, alkoxy, aryl, arylalkyloxy,cycloalkyl, heteroaryl, heteroarylalkoxy or heterocycloalkyl);—N(R¹⁰)—C(═Z)-L⁴-R¹⁶ (where R¹⁶ is alkoxy, aryl, arylalkyloxy,arylalkyloxycarbonylamino, carboxy (or an acid bioisostere), cycloalkyl,cyano, halo, heteroaryl, heteroarylalkoxy, heterocycloalkyl, hydroxy or—NY¹Y², and L⁴ is a straight- or branched-chain alkylene linkagecontaining from 1 to about 6 carbon atoms), —NH—C(═Z)—NH—R¹⁵,—NH—C(═Z)—NH-L⁴-R¹⁶, —N(R¹⁰)—SO₂—R¹⁵, —N(R¹⁰)—SO₂-L⁴-R¹⁶, —S(O)_(n)R⁹,—C(═Z)—NY⁴Y⁵ or —C(═Z)—OR⁹; R⁵ represents hydrogen, alkyl orhydroxyalkyl; or R⁴ and R⁵, when attached to the same carbon atom, mayform with the said carbon atom a cycloalkyl, cycloalkenyl orheterocycloalkyl ring or a group C═CH₂; R⁶ represents hydrogen or alkyl;and m is zero or an integer 1 or 2; and N-oxides thereof, and theirprodrugs; and pharmaceutically acceptable salts and solvates ofcompounds of formula (I) and N-oxides thereof, and their prodrugs.
 2. Acompound according to claim 1 in which R¹ is optionally substituted4-pyridyl or optionally substituted 4-pyrimidinyl.
 3. A compoundaccording to claim 1 in which R¹ is unsubstituted 4-pyridyl.
 4. Acompound according to claim 1 in which R¹ is 2-substituted4-pyrimidinyl.
 5. A compound according to claim 4 in which the2-substituent is a group selected from R¹⁷Z³—, where R¹⁷ is alkyl, aryl,cycloalkyl, heteroaryl, heterocycloalkyl, or alkyl substituted byalkoxy, aryl, cyano, cycloalkyl, heteroaryl, heterocycloalkyl, hydroxy,oxo, —CO₂R¹⁰, —CONY¹Y² or —NY⁴Y⁵ and Z³ is O or S(O)_(n) and Y⁴Y⁵N—. 6.A compound according claim 5 in which the 2-substituent is —NY⁴Y⁵ (whereone of Y⁴ and Y⁵ is hydrogen and the other is hydrogen, aryl,cycloalkyl, heterocycloalkyl, heteroaryl or alkyl optionally substitutedby alkoxy, aryl, cyano, cycloalkyl, heteroaryl, heterocycloalkyl,hydroxy, oxo, —CO₂R¹⁰, —CONY¹Y² or —NY¹Y²) or —OR¹⁷.
 7. A compoundaccording to claim 1 in which R² is optionally substituted phenyl.
 8. Acompound according to claim 7 in which R² is phenyl substituted byhalogen.
 9. A compound according to claim 7 in which R² is4-fluorophenyl.
 10. A compound according to claim 1 in which R³ ishydrogen or C₁₋₄alkyl.
 11. A compound according to claim 10 in which R³is hydrogen.
 12. A compound according to claim 1 in which R⁶ is hydrogenor C₁₋₄alkyl.
 13. A compound according to claim 12 in which R⁶ ishydrogen.
 14. A compound according to claim 1 in which m is aninteger
 1. 15. A compound of formula (Ia):—

in which R⁴ and R⁵ are as defined in claim 1, and N-oxides thereof, andtheir prodrugs; and pharmaceutically acceptable salts and solvates ofcompounds of formula (Ia) and N-oxides thereof, and their prodrugs. 16.A compound of formula (Ib):—

in which R⁴ and R⁵ are as defined in claim 1, and R¹⁸ is R¹⁷Z³— orY⁴Y⁵N— (in which Y⁴ and Y⁵ are as defined in claim 1 and R¹⁷ and Z³ areas defined in claim 5), and N-oxides thereof, and their prodrugs; andpharmaceutically acceptable salts and solvates of compounds of formula(Ib) and N-oxides thereof, and their prodrugs.
 17. A compound accordingto claim 1 in which R⁴ is a group -L³-R¹⁴ [where L³ is a direct bond andR¹⁴ is selected from alkyl, —NY⁴Y⁵, —N(R¹⁰)—C(═Z)—R¹⁵,—N(R¹⁰)—C(═Z)-L⁴-R¹⁶, —C(═Z)—NY⁴Y⁵ and —C(═Z)OR⁹].
 18. A compoundaccording to claim 1 in which R⁴ is a group -L³-R¹⁴, where L³ is amethylene linkage and R¹⁴ is selected from aryl, heteroaryl, hydroxy,—N(R¹⁰)—C(═Z)—R¹⁵, —N(R¹⁰)—C(═Z)-L⁴-R¹⁶, —NH—C(═Z)—NH—R¹⁵,—NH—C(═Z)—NH-L⁴-R¹⁶, —NY⁴Y⁵ and —N(R¹⁰)—SO₂—R¹⁵.
 19. A compoundaccording to claim 1 in which R⁵ is hydrogen, C₁₋₄alkyl or hydroxyalkyl.20. A compound according to claim 19 in which R⁵ is methyl.
 21. Acompound according to claim 19 in which R⁵ is hydroxymethyl.
 22. Acompound according to claim 1 in which R⁴ and R⁵ together with thecarbon atom to which they are attached represent the group C═CH₂ or a5-7 membered cyclic ether.
 23. A compound according to claim 16 in whichR¹⁸ is —NY⁴Y⁵ where Y⁴ is hydrogen and Y⁵ is selected from aryl,arylalkyl, cycloalkyl, heteroarylalkyl, and C₂₋₆alkyl substituted byhydroxy, alkoxy or —NY¹Y².
 24. A compound according to claim 16 in whichR¹⁸ is —OR¹⁷ where R¹⁷ is alkyl, aryl or cycloalkyl.
 25. A compoundaccording to claim 1 selected from:{2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,cis-isomer, (Compound A);{2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}methanol,trans-isomer, (Compound B);4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-pyridine,(Compound C);C-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5yl]-methylamine,cis- and trans-isomers, (Compound D);2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5yl]-acetamide,cis- and trans-isomers, (Compound E);2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]-5yl]-acetamide, cis-isomer, (Compound F);2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-yl]-acetamide, trans-isomer, (Compound G);4-[2-(5-azidomethyl-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-pyridine,cis- and trans-isomers, (Compound H);4-[2-(5-benzyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-pyridine,cis- and trans-isomers, (Compound I);2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methyl ester, cis- and trans-isomers, (Compound J);4-[5-(4-fluoro-phenyl)-2-(1,8,10-trioxa-spiro[5.5]undec-9-yl)-1H-imidazol-4-yl]pyridine,(Compound K);4-[5-(4-fluoro-phenyl)-2-(1,7,9-trioxa-spiro[4.5]dec-8-yl)-1H-imidazol-4-yl]-pyridin,(Compound L);4-[2-(5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyridine,(Compound M);4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyridine,(Compound N);4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyridine,(Compound O);4-[5-(4-fluoro-phenyl)-2-(4-methyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyridine,(R/S)(R/S) isomers, (Compound P);4-[2-(4,6-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyridine,(R/S)(R/S)(R/S) isomers, (Compound Q);4-[2-(5-benzyloxy-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyridine,cis- and trans-isomers, (Compound R);4-[5-(4-fluoro-phenyl)-2-(5-phenyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyridine,cis- and trans-isomers, (Compound S);4-[5-(4-fluoro-phenyl)-2-(4-isopropyl-5,5-dimethyl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyridine,(R/S)(R/S) isomers, (Compound T);4-[2-(5,5-diethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyridine,(Compound U);4-[2-(2,4-dioxa-spiro[5.5]undec-8-en-3-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyridine,cis- and trans-isomers, (Compound V);N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-benzamide,cis- and trans-isomers, (Compound W);1-(4-fluoro-phenyl)-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2yl]-5-methyl-[1,3]dioxan-5-yl}-thiourea,cis- and trans-isomers, (Compound X);1-(2,6-dimethyl-phenyl)-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-thiourea,cis- and trans-isomers, (Compound Y);4-[5-(4-fluoro-phenyl)-2-(5-methyl-5-pyrrol-1-yl-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-pyridine,cis- and trans-isomer, (Compound Z);C-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-yl]-methylamine,trans-isomer, (Compound AA);C-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-yl]-methlamine,cis-isomer, (Compound AB);2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylmethyl]-acetamide,trans-isomer, (Compound AC);2,2,2-trifluoro-N-[5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylmethyl]-acetamide,cis-isomer, (Compound AD);5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylamine,cis-isomer, (Compound AE);5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylamin,trans-isomer, (Compound AF);5-methyl-2-{5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl}-[1,3]dioxan-5-ylamine,cis- and trans-isomers, (Compound AG);2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid, trans-isomer, (Compound AH);2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid, cis-isomer, (Compound AI);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, cis-isomer, (Compound AJ);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid benzylamide, trans-isomer, (Compound AK);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, trans-isomer, (Compound AL);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-methoxy-ethyl)-amide, trans-isomer, (Compound AM);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, trans-isomer, (Compound AN);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (pyridin-2-ylmethyl)-amide, trans-isomer, (Compound AO);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (pyridin-3-ylmethyl)-amide, trans-isomer, (Compound AP);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (pyridin-4-ylmethyl)-amide, trans-isomer, (Compound AQ);{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,trans-isomer, (Compound AR);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, trans-isomer, (Compound AS);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid [2(1H-indol-3-yl)-ethyl]-amide, trans-isomer, (Compound AT);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, trans-isomer, (Compound AU);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, trans-isomer, (Compound AV);{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound AW);{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-pyrrolidin-1-yl-methanone,trans-isomer, (Compound AX);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid butylamide, trans-isomer, (Compound AY);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dipropylamide, trans-isomer, (Compound AZ);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, trans-isomer, (Compound BA);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenethyl-amide, trans-isomer, (Compound BB);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-pyridin-2-yl-ethyl)-amide, trans-isomer, (Compound BC);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (furan-2-ylmethyl)-amide, trans-isomer, (Compound BD);{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound BE);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, trans-isomer, (Compound BF);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, trans-isomer, (Compound BG);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, trans-isomer, (Compound BH);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopentylamide, trans-isomer, Compound BI);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, trans-isomer, (Compound BJ);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methoxy-ethyl)-amide, cis-isomer, (Compound BK);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-hydroxy-ethyl)-amide, cis-isomer, (Compound BL);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, cis-isomer, (Compound BM);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (pyridin-2-ylmethyl)-amide, cis-isomer, (Compound BN);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (pyridin-3-ylmethyl)-amide, cis-isomer, (Compound BO);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (pyridin-4-ylmethyl)-amide, cis-isomer, (Compound BP);{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,cis-isomer, (Compound BQ);{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methyl-piperazin-1-yl)-methanone,cis-isomer, (Compound BR);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-dimethylamino-propyl)-amide, cis-isomer, (Compound BS);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid [2-(1H-indol-3-yl)-ethyl]-amide, cis-isomer, (Compound BT);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-hydroxy-propyl)-amide, cis-isomer, (Compound BU);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid phenethyl-amide, cis-isomer, (Compound BV);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (3-methoxy-propyl)-amide, cis-isomer, (Compound BW);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-pyridin-2-yl-ethyl)-amide, cis-isomer, (Compound BX);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (furan-2-ylmethyl)-amide, cis-isomer, (Compound BY);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (tetrahydro-furan-2-ylmethyl)-amide, cis-isomer, (Compound BZ);{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-pyrrolidin-1-yl-methanone,cis-isomer, (Compound CA);{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidin-1-yl-methanone,cis-isomer, (Compound CB);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid propylamide, cis-isomer, (Compound CC);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid butylamide, cis-isomer, (Compound CD);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopropylamide, cis-isomer, (Compound CE);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclopentylamide, cis-isomer, (Compound CF);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid cyclohexylamide, cis-isomer, (Compound CG);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, cis-isomer, (Compound CH);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, cis-isomer, (Compound CI);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dimethylamide, cis-isomer, (Compound CJ);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid dipropylamide, cis-isomer, (Compound CK);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid ethylamide, cis-isomer, (Compound CL);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid methylamide, trans-isomer, (Compound CM);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid (2-dimethylamino-ethyl)-amide, trans-isomer, (Compound CN);2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid ethylamide, trans-isomer, (Compound CO);1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-3-phenyl-urea,cis-isomer, (Compound CP);1-ethyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-urea,cis-isomer, (Compound CQ);1-(3,5-dimethyl-isoxazol-4-yl)-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-urea,cis-isomer, (Compound CR);1-benzyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5yl}-urea,cis-isomer, (Compound CS);1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-3-(2-thiophen-2-yl-ethyl)-urea,cis-isomer, (Compound CT);1-(3-acetyl-phenyl)-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-urea,cis-isomer, (Compound CU);1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5yl}-3-phenyl-urea,trans-isomer, (Compound CV);3-(3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5yl}-ureido)-benzoicacid, trans-isomer, (Compound CW);1-benzyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-urea,trans-isomer, (Compound CX);1-ethyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-urea,trans-isomer, (Compound CY);1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-3-(2-thiophen-2-yl-ethyl)-urea,trans-isomer, (Compound CZ);1-benzyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-urea,cis-isomer, (Compound DA);1-ethyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-urea,cis-isomer, (Compound DB);1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-3-phenyl-urea,cis-isomer, (Compound DC);1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-3-phenyl-urea,trans-isomer, (Compound DD);1-benzyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-urea,trans-isomer, (compound DE);1-ethyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-urea,trans-isomer, (Compound DF);1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-3-(2-morpholin-4-yl-ethyl)-thiourea,cis-isomer, (Compound DG);1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-3-ylmethyl-thiourea,cis-isomer, (Compound DH);1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-3-yl-thiourea,cis-isomer, (Compound DI);1-benzo[1,3]dioxol-5-yl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2yl]-5-methyl-[1,3]dioxan-5-yl}-thiourea,cis-isomer, (Compound DJ);1-benzo[1,3]dioxol-5-ylmethyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2yl]-5-methyl-[1,3]dioxan-5-yl}-thiourea,cis-isomer, (Compound DK);1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-3-pyridin-3-yl-thiourea,trans-isomer, (Compound DL);1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-3-(2-morpholin-4-yl-ethyl)-thiourea,trans-isomer, (Compound DM);1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-3-furan-2-ylmethyl-thiourea,trans-isomer, (Compound DN);1-benzo[1,3]dioxol-5-ylmethyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-thiourea, trans-isomer, (Compound DO);1-benzo[1,3]dioxol-5-yl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-thiourea,cis-isomer, (Compound DP);1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-3-furan-2-ylmethyl-thiourea,cis-isomer, (Compound DQ);3-(3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-thioureido)-benzoicacid, cis-isomer, (Compound DR);1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-5-ylmethyl}-3-pyridin-3-yl-thiourea,cis-isomer, (Compound DS);1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-3-(2-morpholin-4-yl-ethyl)-thiourea,cis-isomer, (Compound DT);1-benzo[1,3]dioxol-5-ylmethyl-3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-thiourea,cis-isomer, (Compound DU);N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-acetamide,cis-isomer, (Compound DV);N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-2-phenyl-acetamide,cis-isomer, (Compound DW); cyclohexanecarboxylicacid{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-amide,cis-isomer, (Compound DX);2-benzyloxy-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]-dioxan-5-yl}-acetamide,trans-isomer, (Compound DY);2-benzyloxy-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-acetamide,cis-isomer, (Compound DZ);N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-acetamide,trans-isomer, (Compound EA);N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-2phenyl-acetamide,trans-isomer, (Compound EB); cyclohexanecarboxylicacid{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-amide,trans-isomer, (Compound EC);N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3dioxan-5-yl}-phenyl-acetamide,cis-isomer, (Compound ED);2-benzyloxy-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound EE);N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound EF);N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis-isomer, (Compound EG);N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,cis-isomer, (Compound EH); cyclohexanecarboxylicacid{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-amide,cis-isomer, (Compound EI);N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,trans-isomer, (Compound EJ);N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,trans-isomer, (Compound EK); cyclohexanecarboxylicacid{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-amide,trans-isomer, (Compound EL);N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-2-phenyl-acetamide,trans-isomer, (Compound EM);4-{2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}-butyricacid, cis-isomer, (Compound EN);4-({2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-carbamoyl)-butyricacid, cis-isomer, (Compound EO);4-{2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}-propionicacid, cis-isomer, (Compound EP);4-({2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-carbamoyl)-propionicacid, cis-isomer, (Compound EQ);4-({2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-carbamoyl)-propionicacid, trans-isomer, (Compound ER);N-{2-[5-(4-fluoro-phenyl)-4-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanesulphonamide,cis-isomer, (Compound ES);N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulphonamide,cis-isomer, (Compound ET);N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzenesulphonamide,cis-isomer, (Compound EU);N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-C-phenyl-methanesulphonamide,cis-isomer, (Compound EV); thiophene-2-sulphonicacid{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-amide,cis-isomer, (Compound EW); 3,5-dimethyl-isoxazole-4-sulphonicacid{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-amide,cis-isomer, (Compound EX);N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-methanesulphonamide,trans-isomer, (Compound EY);N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-benzenesulphonamide,trans-isomer, (Compound EZ); thiophene-2-sulphonicacid{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-amide,trans-isomer, (Compound FA); 3,5-dimethyl-isoxazole-4-sulphonicacid{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-amide,trans-isomer, (Compound FB);3-amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-propionamide,trans-isomer, (Compound FC);3-amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-propionamide,cis-isomer, (Compound FD);4-amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-butyramide,trans-isomer, (Compound FE);4-amino-N-(2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-butyramide,cis-isomer, (Compound FF);2-amino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-acetamide,trans-isomer, (Compound FG);2-amino-N-2-[4-(4-fluoro-phenyl)-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-acetamide,cis-isomer, (Compound FH);(3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}-ethyl)-carbamicacid benzyl ester, trans-isomer, (Compound FI);(3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}-ethyl)-carbamicacid benzyl ester, cis-isomer, (Compound FJ);(3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}-propyl)-carbamicacid benzyl ester, trans-isomer, (Compound FK);(3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}-propyl)-carbamicacid benzyl ester, cis-isomer, (Compound FL);(3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}-methyl)-carbamicacid benzyl ester, trans-isomer, (Compound FM);(3-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylcarbamoyl}-methyl)-carbamicacid benzyl ester, cis-isomer, (Compound FN);4-dimethylamino-N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-butyramide,cis- and trans-isomers, (Compound FO);N-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-benzamide,trans-isomer, (Compound FR);{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-hydroxy-piperidin-1-yl)-methanone,trans isomer, (Compound FS);(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanone,trans isomer, (Compound FT);1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidine-4-carboxylicacid ethyl ester, trans isomer, (Compound FU);1-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-piperidine-4-carboxylicacid, trans isomer, (Compound FV);{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-thiomorpholin-4yl-methanone,trans isomer, (Compound FW);(1,1-dioxothiomorpholin-4-yl)-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanone,trans isomer, (Compound FX);{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxymethyl-piperidin-1-yl)-methanone,trans isomer, (Compound FY);{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-piperidin-1-yl)-methanone,trans isomer, (Compound FZ);(2,6-dimethyl-morpholin-4-yl)-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanone,trans isomer, (Compound GA);{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(3-hydroxy-pyrrolidin-1-yl)-methanone,trans isomer, (Compound GB);{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-(4-methoxy-piperidin-1-yl)-methanone,trans isomer, (Compound GC);{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-[4-(2-hydroxy-ethyl)-piperidin-1-yl]-methanone,trans isomer, (Compound GD);{5-Amino-2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,cis isomer, (Compound LE);{5-Amino-2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans isomer, (Compound LF);{2-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-nitro-[1,3]dioxan-5-yl}-methanol,cis isomer, (Compound LG);{2-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-nitro-[1,3]dioxan-5-yl}-methanol,trans isomer,(Compound LH);C-{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5,5-dimethyl-[1,3]dioxan-5-yl}-methylamine(Compound LI);4-[2-(5,5-dimethyl-4-nitromethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyridine(Compound LJ); and the corresponding N-oxides, and their prodrugs; andpharmaceutically acceptable salts and solvates of such compounds andtheir N-oxides and prodrugs.
 26. A compound according to claim 1selected from:{2-[5-(2-cyclopropylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans isomer, (Compound GE);2-[5-(2-Amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound GI);{2-[5-(2-Dimethylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound GJ);(2-{4-(4-Fluoro-phenyl)-5-[2-(3-hydroxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound GK);(2-{4-(4-Fluoro-phenyl)-5-[2-(2-methoxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound GL);{2-[4-(4-Fluoro-phenyl)-5-(2-methylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound GM);(2-{4-(4-Fluoro-phenyl)-5-[2-(1-ethoxycarbonylpiperidin-4-ylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound GN);{2-[5-(2-Cyclohexylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3[dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound GO);(2-{4-(4-Fluoro-phenyl)-5-[2-(2-hydroxy-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-ylγ-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound GP);{2-[5-[2-(2-Amino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound GQ);[2-(4-(4-Fluoro-phenyl)-5-{2-[3-(5H-imidazol-1-yl)-propylamino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone,trans-isomer, (Compound GR);(2-{4-(4-Fluoro-phenyl)-5-[2-(3-morpholin-4-yl-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound GS);2-[5-(2-Benzylamino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound GT);(2-{4-(4-Fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,R isomer, trans-isomer, (Compound GU);(2-{4-(4-Fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,S isomer, trans-isomer, (Compound GV);{2-[4-(4-Fluoro-phenyl)-5-(2-phenylamino-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound GW);{2-[4-(4-Fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound GX);[2-(4-(4-Fluoro-phenyl)-5-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone,trans-isomer, (Compound GY);[2-(4-(4-Fluoro-phenyl)-5-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone,trans-isomer, (Compound GZ);[2-(4-(4-Fluoro-phenyl)-5-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone,trans-isomer, (Compound HA);[2-(4-(4-Fluoro-phenyl)-5-{2-[(furan-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone,trans-isomer, (Compound HB);[2-(4-(4-Fluoro-phenyl)-5-{2-[(thiophen-2-ylmethyl)-amino]-pyrimidin-4-yl}-1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone,trans-isomer, (Compound HC);[2-(4-(4-Fluoro-phenyl)-5-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yl}1H-imidazol-2-yl)-5-methyl-[1,3]dioxan-5-yl]-morpholin-4-yl-methanone,trans-isomer, (Compound HD);(2-{4-(4-Fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound HE);{2-[4-(4-Fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound HF);(2-{4-(4-Fluoro-phenyl)-5-[2-(3-methoxy-propylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound FG);{2-[5-[2-(3-Dimethylamino-propylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound HH);{2-[5-[2-(2-Dimethylamino-ethylamino)-pyrimidin-4-yl]-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound HI);(4-{5-(4-Fluoro-phenyl)-2-[5-methyl-5-(morpholine-4-carbonyl)-[1,3]dioxan-2-yl}-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-aceticacid, trans-isomer, (Compound HJ);3-(4-{5-(4-Fluoro-phenyl)-2-[5-methyl-5-(morpholine-4-carbonyl)-[1,3]dioxan-2-yl]-3H-imidazol-4-yl}-pyrimidin-2-ylamino)-propionicacid, trans-isomer, (Compound HK);4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamine,(Compound HL);{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-methyl-amine,(Compound HM);{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-dimethyl-amine,(Compound HN);cyclopropyl-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-amine,(Compound HO);cyclohexyl-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-amine,(Compound HQ);2-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pryimidin-2-ylamino}-ethanol,(Compound HR);N1-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-ethane-1,2-diamine,(Compound HS);{4-[2-(5,5-dimethyl-[1,3]dioxan-2-y)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-[3-(5H-imidazol-1-yl)-propyl]-amine,(Compound HT);{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(3-morpholin-4-yl-propyl)-amine,(Compound HU);3-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-propan-1-ol,(Compound HV);benzyl-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-amine,(Compound HW);{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl}-(1-phenyl-ethyl)-amine,R-isomer, (Compound HX);{4-[2-(5,5-dimethyl-[1,3]dioxan-2-y)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(1phenyl-ethyl)-amine,S-isomer, (Compound HY);{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(1-phenyl-amine,(Compound HZ);4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-2-piperidin-1-yl-pyrimidine,(Compound IA);{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyridin-2-yl}-pyridin-4-ylmethyl-amine,(Compound IB);{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pryimidin-2-yl}-pyridin-2-ylmethyl-amine,(Compound IC);{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-pyridin-3-ylmethyl-amine,(Compound ID);{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(furan-2-ylmethyl)-amine,(Compound IE);{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(thiophen-2-ylmethyl)-amine,(Compound IF);{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(tetrahydro-2-ylmethyl)-amine,(Compound IG);4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-2-(4-methyl-piperazin-1-yl)-pyrimidine,(Compound IH);4-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-morpholine,(Compound IJ);{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(3-methoxy-propyl)-amine,(Compound IK);{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(2-methoxy-ethyl)-amine,(Compound IL);N-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-N′,N′-dimethyl-propane-1,3-diamine,(Compound IM);N-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-N′,N′-dimethyl-ethane-1,2-diamine,(Compound IN);{2-[5-(2-amino-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer, (Compound IO){2-[4-(4-Fluoro-phenyl)-5-(2-methoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound IP);{2-[5-(2-Benzyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound IQ);{2-[4-(4-Fluoro-phenyl)-5-(2-phenoxy-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound IR);(2-{4-(4-Fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound IR);(2-}4-(4-Fluoro-phenyl)-5-[2-(2-methoxy-ethoxy)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,trans-isomer, (Compound IS);{2-[5-[2-(2-Dimethylamino-ethoxy)-pyrimidin-4-yl]4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound IT);{2-[5-(2-Cyclohexyloxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound IU);{2-[5-(2-Isopropoxy-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer, (Compound IW);4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-2-methoxy-pyrimidine,(Compound IY);2-benzyloxy-4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidine,(Compound IZ);4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-2-phenoxy-pyrimidine,(Compound JA);4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-2-(2-methoxy-ethoxy)-pyrimidine,(Compound JB);(2-{4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yloxy}-ethyl)-dimethyl-amine,(Compound JC);2-cyclohexyloxy-4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidine,(Compound JD);2-isopropoxy-4-[2-(5,5-dimethyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidine,(Compound JE);4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamine,cis-isomer, (Compound JF);{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-methyl-amine,cis-isomer, (Compound JG);{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-dimethyl-amine,cis-isomer, (Compound JH);{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-cyclopropyl-amine,cis-isomer, (Compound JI);{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-piperidin-4-yl-amine,cis-isomer, (Compound JJ);{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-cyclohexyl-amine,cis-isomer, (Compound JK);2-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamino}-ethanol,cis-isomer, (Compound JL);N1-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-ethane-1,2-diamine,cis-isomer, (Compound JM);{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-[3-(5H-imidazol-1-yl)-propyl]-amine,cis-isomer, (Compound JN);{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(3-morpholin-4-yl-propyl)-amine,cis-isomer, (Compound JO);3-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3-H-imidazol-4-yl]-pyrimidin-2-ylamino}-propan-1-ol,cis-isomer, (Compound JP);{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-benzyl-amine,,cis-isomer, (Compound JQ);{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(1-phenyl-ethyl)-amine,R isomer, cis-isomer, (Compound JR);{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(1-phenyl-ethyl)-amine,S isomer, cis-isomer, (Compound JS);{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl[-pyrimidin-2-yl}-phenyl-amine,cis-isomer, (Compound JT);2-[4-(4-fluoro-phenyl)-5-(2-piperidin-1-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylamine,cis-isomer, (Compound JU);{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-pyridin-4-ylmethyl-amine,cis-isomer, (Compound JV);{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-pyridin-2-ylmethyl-amine,cis-isomer, (Compound JW);{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-pyridin-3-ylmethyl-amine,cis-isomer, (Compound JX);{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(furan-2-ylmethyl)-amine,cis-isomer, (Compound JY);{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(thiophen-2-ylmethyl)-amine,cis-isomer, (Compound JZ);{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidan-2-yl}-(tetrahydro-furan-2-ylmethyl)-amine,cis-isomer, (Compound KA);2-{4-(4-fluoro-phenyl)-5-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-ylamine,cis-isomer, (Compound KB);2-[4-(4-fluoro-phenyl)-5-(2-morpholin-4-yl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylamine,cis-isomer, (Compound KC);{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-(3-methoxy-propyl)-amine,cis-isomer, (Compound KD);{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2yl}-(2-methoxy-ethyl)-amine,cis-isomer, (Compound KE);N-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-N′,N′-dimethyl-propane-1,3-diamine,cis-isomer, (Compound KF);N-{4-[2-(5-amino-5-methyl-[1,3]dioxan-2-yl)-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-yl}-N′,N′-dimethyl-ethane-1,2-diamine,cis-isomer, (Compound KG);{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans isomer, (Compound KH);2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonylpyrimidin-4-yl)-1H-imidazol-2-yl]-5,5-dimethyl-[1,3]dioxane(Compound KI);{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans-isomer (Compound KJ);{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,cis-isomer (Compound KK);2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methylene-[1,3]dioxane(Compound KL).4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-2-methylsulphonyl-pyrimidine(Compound KM);{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer (Compound KN);{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphonyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,cis-isomer (Compound KO);2,2,2-trifluoro-N-[2-{4-(4-fluoro-phenyl)-5-(2-methanesulphonylpyrimidin-4-yl)-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl]acetamide,cis-isomer (Compound KP);{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans isomer, (Compound KQ);2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanylpyrimidin-4-yl)-1H-imidazol-2-yl]-5,5-dimethyl-[1,3]dioxane(Compound KR);2,2,2-trifluoro-N-[2-{4-(4-fluoro-phenyl)-5-(2-methylsulphanyl-pyrimidin-4-yl)-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl]acetamide,cis-isomer, (Compound KS);{2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,cis isomer (Compound KT);{2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methanol,trans isomer (Compound KU);4-[5-(4-fluoro-phenyl)-2-(5-methylene-[1,3]dioxan-2-yl)-3H-imidazol-4-yl]-2-methylsulfanyl-pyrimidine(Compound KV);4-[2-[1,3]dioxan-2-yl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-2-methylsulphanyl-pyrimidine(Compound KW);{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,trans-isomer (Compound KX);{2-[4-(4-fluoro-phenyl)-5-(2-methylsulphanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-[1,3]dioxan-5-yl}-methanol,cis-isomer (Compound KY);C-{2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-methylamine,cis isomer (Compound KZ);2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid amide, cis isomer Compound LA);2-[4-(4-fluoro-phenyl)-5-(2-methylsulfanyl-pyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxane-5-carboxylicacid, cis isomer (Compound LB);2-[4-(4-fluorophenyl)-5-(2-methylsulphanylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,2]dioxan-5-carboxylicacid methyl ester, trans isomer, (Compound LC);2-[4-(4-fluorophenyl)-5-(2-methylsulphanylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[5-methyl-[1,3]dioxan-5-carboxylicacid methyl ester, cis isomer, (Compound LD);2,2,2-trifluoro-N-{2-[5-(2-methylsulphonyl-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,cis isomer, (Compound LK);2,2,2-trifluoro-N-{2-[5-(2-methylsulphonyl-pyrimidin-4-yl)-4-(4-fluoro-phenyl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-ylmethyl}-acetamide,trans isomer,(Compound LL);2-[4-(4-fluorophenyl)-5-(2-methylsulphonylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-carboxylicacid methyl ester, trans isomer, (Compound LM);2-[4-(4-fluorophenyl)-5-(2-methylenesulphonylpyrimidin-4-yl)-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-carboxylicacid methyl ester, cis isomer (Compound LN); and the correspondingN-oxides, and their prodrugs; and pharmaceutically acceptable salts andsolvates of such compounds and their N-oxides and prodrugs. 27.{2-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-y}-morpholin-4-yl-methanone,trans-isomer, (Compound AW); and the corresponding N-oxide, and itsprodrugs; and pharmaceutically acceptable salts and solvates of thiscompound and its N-oxide and prodrugs.
 28. The mesylate salt of{2-[4-(4-fluoro-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl]-5-methyl-[1,3]dioxan-5-yl}-morpholin-4-yl-methanone,trans-isomer. 29.(2-{4-(4-Fluoro-phenyl)-5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1H-imidazol-2-yl}-5-methyl-[1,3]dioxan-5-yl)-morpholin-4-yl-methanone,S isomer, trans-isomer, (Compound GV); and the corresponding N-oxide,and its prodrugs; and pharmaceutically acceptable salts and solvates ofthis compound and its N-oxide and prodrugs.
 30. A pharmaceuticalcomposition comprising a compound according to claim 1 together with apharmaceutically acceptable carrier or excipient.
 31. A pharmaceuticalcomposition for use in the treatment of a condition which can beameliorated by the administration of an inhibitor of TNF-alphacomprising an effective amount of the compound according to claim
 1. 32.Method for the treatment of a human or animal patient suffering from, orsubject to, conditions which can be ameliorated by the administration ofan inhibitor of TNF-alpha, which comprises the administration to saidpatient of an effective amount of a compound of claim
 1. 33. Methodaccording to claim 32 for the treatment of asthma.
 34. Method accordingto claim 32 for the treatment of joint inflammation.
 35. A compound offormula (II)

wherein R¹ represents optionally substituted heteroaryl, R² representsoptionally substituted aryl or optionally substituted heteroaryl, R¹⁹ ishydrogen or a protecting group and R²⁰ is —CHO or —CH(OMe)₂.
 36. Acompound of formula (V)

wherein R², R³, R⁴, R⁵, R⁶ and m are as defined in claim
 1. 37. Acompound of formula Resin C:

wherein R², R³, R⁴, R⁵, R⁶ and m are as defined in claim
 1. 38. Acompound of formula Resin D.:

wherein R², R³, R⁴, R⁵, R⁶ and m are as defined in claim
 1. 39. Processfor the preparation of a compound of formula (I), wherein R¹, R², R⁴,R⁵, R⁶ and m are as defined in claim 1 and R³ is hydrogen, comprisingreacting a compound of formula (II)

wherein R¹ and R² are as defined in claim 1, R¹⁹ is hydrogen or aprotecting group and R²⁰ is —CHO or —CH(OMe)₂, with a compound offormula (III)

wherein R⁴, R⁵, R⁶ and m are as defined in claim 1, under acidicconditions.
 40. Process for the preparation of a compound of formula(II)

wherein R¹ and R² are as defined in claim 1, R¹⁹ is hydrogen and R²⁰ is—CH(OMe)₂, this process comprising reacting a compound of formula (2)

wherein R¹ and R² are as defined in claim 1, with glyoxal1,1-dimethylacetal and ammonium acetate.